Annotation Cluster 1	Enrichment Score: 5.88389131629278
Category	Term	Count	%	PValue	CASRNs	List Total	Pop Hits	Pop Total	Fold Enrichment	Bonferroni	Benjamini	FDR
TOXINS_TARGETS	BE0000372	10	90.9090909090909	2.31782253766193e-19	56-55-3, 85-01-8, 83-32-9, 129-00-0, 53-70-3, 120-12-7, 50-32-8, 206-44-0, 191-24-2, 218-01-9	10	34	3520	103.529411764706	1	1.05692707717384e-16	2.31782253766193e-19
TOXINS_TARGETS	GNMT	9	81.8181818181818	1.21716670159572e-16	56-55-3, 85-01-8, 83-32-9, 53-70-3, 120-12-7, 50-32-8, 206-44-0, 191-24-2, 218-01-9	10	31	3520	102.193548387097	1	5.53810849226053e-14	1.21716670159572e-16
TOXPRINT_STRUCTURE	ring:fused_[6_6]_naphthalene	10	90.9090909090909	1.91625676072693e-15	56-55-3, 85-01-8, 83-32-9, 129-00-0, 53-70-3, 120-12-7, 50-32-8, 206-44-0, 191-24-2, 218-01-9	10	197	8337	42.3197969543147	1	8.69980569370027e-13	1.91625676072693e-15
TOXPRINT_STRUCTURE	ring:fused_PAH_phenanthrene	7	63.6363636363636	3.17689979568195e-14	56-55-3, 85-01-8, 129-00-0, 53-70-3, 50-32-8, 191-24-2, 218-01-9	10	25	8337	233.436	1	1.43913560744393e-11	3.17689979568195e-14
MESH	Polycyclic Hydrocarbons, Aromatic	10	90.9090909090909	1.69173929937112e-12	56-55-3, 85-01-8, 83-32-9, 129-00-0, 53-70-3, 120-12-7, 50-32-8, 206-44-0, 191-24-2, 218-01-9	10	272	5450	20.0367647058824	1	7.64666163315745e-10	1.69173929937112e-12
MESH	Polycyclic Compounds	10	90.9090909090909	1.57998739059328e-09	56-55-3, 85-01-8, 83-32-9, 129-00-0, 53-70-3, 120-12-7, 50-32-8, 206-44-0, 191-24-2, 218-01-9	10	577	5450	9.44540727902946	1	7.12574313157571e-07	1.57998739059328e-09
TOXINS_TARGETS	BE0004796	10	90.9090909090909	2.9156463321686e-09	56-55-3, 85-01-8, 83-32-9, 129-00-0, 53-70-3, 120-12-7, 50-32-8, 206-44-0, 191-24-2, 218-01-9	10	400	3520	8.8	1	1.31204084947587e-06	2.9156463321686e-09
LEADSCOPE_TOXICITY	Genetic Toxicity -microbial	10	90.9090909090909	1.63691281627976e-08	56-55-3, 85-01-8, 83-32-9, 129-00-0, 53-70-3, 120-12-7, 50-32-8, 206-44-0, 191-24-2, 218-01-9	10	1019	7444	7.30520117762512	1	7.31700028877052e-06	1.63691281627976e-08
LEADSCOPE_TOXICITY	Genetic Toxicity -salmonella	10	90.9090909090909	5.40237889169358e-08	56-55-3, 85-01-8, 83-32-9, 129-00-0, 53-70-3, 120-12-7, 50-32-8, 206-44-0, 191-24-2, 218-01-9	10	1163	7444	6.40068787618229	1	2.40946098569533e-05	5.40237889169358e-08
CTD_CHEMICALS_DISEASES	Hyperoxia	8	72.7272727272727	7.01311864136831e-08	56-55-3, 85-01-8, 83-32-9, 129-00-0, 53-70-3, 206-44-0, 191-24-2, 218-01-9	10	496	8530	13.758064516129	1	3.1208377954089e-05	7.01311864136831e-08
MESH	Hydrocarbons, Aromatic	10	90.9090909090909	1.87205491567512e-07	56-55-3, 85-01-8, 83-32-9, 129-00-0, 53-70-3, 120-12-7, 50-32-8, 206-44-0, 191-24-2, 218-01-9	10	978	5450	5.57259713701432	1	8.31192382559755e-05	1.87205491567512e-07
MULTICASE_TOX_PREDICTION	BCRP inhibition at 10uM	10	90.9090909090909	2.16284518591505e-07	56-55-3, 85-01-8, 83-32-9, 129-00-0, 53-70-3, 120-12-7, 50-32-8, 206-44-0, 191-24-2, 218-01-9	10	1463	8032	5.49008885850991	1	9.58140417360366e-05	2.16284518591505e-07
TOXINS_TARGETS	BE0003721	10	90.9090909090909	3.44880046351008e-07	56-55-3, 85-01-8, 83-32-9, 129-00-0, 53-70-3, 120-12-7, 50-32-8, 206-44-0, 191-24-2, 218-01-9	10	677	3520	5.19940915805022	1	0.000152436980487146	3.44880046351008e-07
MESH	Hydrocarbons, Cyclic	10	90.9090909090909	5.64126925479837e-07	56-55-3, 85-01-8, 83-32-9, 129-00-0, 53-70-3, 120-12-7, 50-32-8, 206-44-0, 191-24-2, 218-01-9	10	1105	5450	4.93212669683258	1	0.000248215847211128	5.64126925479837e-07
MULTICASE_TOX_PREDICTION	MRP1 inhibition at 10uM	10	90.9090909090909	1.63748356851382e-06	56-55-3, 85-01-8, 83-32-9, 129-00-0, 53-70-3, 120-12-7, 50-32-8, 206-44-0, 191-24-2, 218-01-9	10	1831	8032	4.38667394866193	1	0.000717217803009052	1.63748356851382e-06
LEADSCOPE_TOXICITY	Genetic Toxicity -UDS human lymphocytes	7	63.6363636363636	5.32875123886235e-06	56-55-3, 83-32-9, 53-70-3, 120-12-7, 50-32-8, 206-44-0, 191-24-2	10	486	7444	10.7218106995885	1	0.00232866429138285	5.32875123886235e-06
MESH	Hydrocarbons	10	90.9090909090909	7.4673529107998e-06	56-55-3, 85-01-8, 83-32-9, 129-00-0, 53-70-3, 120-12-7, 50-32-8, 206-44-0, 191-24-2, 218-01-9	10	1471	5450	3.70496261046907	1	0.00325576586910871	7.4673529107998e-06
MULTICASE_TOX_PREDICTION	OCT1 inhibition at 100uM	10	90.9090909090909	8.68077096172879e-06	56-55-3, 85-01-8, 83-32-9, 129-00-0, 53-70-3, 120-12-7, 50-32-8, 206-44-0, 191-24-2, 218-01-9	10	2203	8032	3.64593735814798	1	0.00377613536835202	8.68077096172879e-06
TOXINS_TARGETS	AHR	9	81.8181818181818	8.8175249359466e-06	56-55-3, 85-01-8, 83-32-9, 53-70-3, 120-12-7, 50-32-8, 206-44-0, 191-24-2, 218-01-9	10	641	3520	4.94227769110764	1	0.00382680582220082	8.8175249359466e-06
MULTICASE_TOX_PREDICTION	Local lymph node assay, mouse, extreme sensitizers (EC3 < 1%)	9	81.8181818181818	1.16512758585476e-05	56-55-3, 85-01-8, 83-32-9, 129-00-0, 53-70-3, 50-32-8, 206-44-0, 191-24-2, 218-01-9	10	1512	8032	4.78095238095238	1	0.00504500244675113	1.16512758585476e-05
LEADSCOPE_TOXICITY	Reproductive Toxicity- sperm mouse	10	90.9090909090909	3.26366340540017e-05	56-55-3, 85-01-8, 83-32-9, 129-00-0, 53-70-3, 120-12-7, 50-32-8, 206-44-0, 191-24-2, 218-01-9	10	2365	7444	3.14756871035941	1	0.0140011160091667	3.26366340540017e-05
LEADSCOPE_TOXICITY	Genetic Toxicity -In vitro chrom. ab. CHL	8	72.7272727272727	5.98083809723057e-05	56-55-3, 85-01-8, 83-32-9, 129-00-0, 53-70-3, 50-32-8, 191-24-2, 218-01-9	10	1162	7444	5.1249569707401	1	0.0254185619132299	5.98083809723057e-05
MULTICASE_TOX_PREDICTION	Local lymph node assay, mouse, moderate sensitizers (EC3 < 10%)	10	90.9090909090909	0.000102168488320366	56-55-3, 85-01-8, 83-32-9, 129-00-0, 53-70-3, 120-12-7, 50-32-8, 206-44-0, 191-24-2, 218-01-9	10	2896	8032	2.77348066298343	1	0.0431151020711944	0.000102168488320366
LEADSCOPE_TOXICITY	Reproductive Toxicity-cell transformation	10	90.9090909090909	0.000251251011070883	56-55-3, 85-01-8, 83-32-9, 129-00-0, 53-70-3, 120-12-7, 50-32-8, 206-44-0, 191-24-2, 218-01-9	10	2966	7444	2.50977747808496	1	0.105022922627629	0.000251251011070883
LEADSCOPE_TOXICITY	Reproductive Toxicity-SHE	10	90.9090909090909	0.000286908331489587	56-55-3, 85-01-8, 83-32-9, 129-00-0, 53-70-3, 120-12-7, 50-32-8, 206-44-0, 191-24-2, 218-01-9	10	3010	7444	2.47308970099668	1	0.119640774231158	0.000286908331489587
LEADSCOPE_TOXICITY	Genetic Toxicity -E. coli	7	63.6363636363636	0.000747210705574584	56-55-3, 83-32-9, 53-70-3, 120-12-7, 50-32-8, 206-44-0, 191-24-2	10	1152	7444	4.52326388888889	1	0.309345232107878	0.000747210705574584
MULTICASE_TOX_PREDICTION	Human plasma protein binding, %bound	10	90.9090909090909	0.000766919879218519	56-55-3, 85-01-8, 83-32-9, 129-00-0, 53-70-3, 120-12-7, 50-32-8, 206-44-0, 191-24-2, 218-01-9	10	3622	8032	2.21755935946991	1	0.316737910117248	0.000766919879218519
MULTICASE_TOX_PREDICTION	Extent of human metabolism, %	10	90.9090909090909	0.00141566512105422	56-55-3, 85-01-8, 83-32-9, 129-00-0, 53-70-3, 120-12-7, 50-32-8, 206-44-0, 191-24-2, 218-01-9	10	3877	8032	2.07170492648955	1	0.574760039148012	0.00141566512105422
LEADSCOPE_TOXICITY	Genetic Toxicity -SCE in vitro other cells	9	81.8181818181818	0.00412115768321787	56-55-3, 85-01-8, 83-32-9, 129-00-0, 53-70-3, 50-32-8, 206-44-0, 191-24-2, 218-01-9	10	3012	7444	2.22430278884462	1	1	0.00412115768321787
LEADSCOPE_TOXICITY	Genetic Toxicity -SCE in vitro CHO	10	90.9090909090909	0.00416152811538436	56-55-3, 85-01-8, 83-32-9, 129-00-0, 53-70-3, 120-12-7, 50-32-8, 206-44-0, 191-24-2, 218-01-9	10	3886	7444	1.91559444158518	1	1	0.00416152811538436
MULTICASE_TOX_PREDICTION	Local lymph node assay, mouse, weak sensitizers (EC3 < 100%)	10	90.9090909090909	0.00519138534061582	56-55-3, 85-01-8, 83-32-9, 129-00-0, 53-70-3, 120-12-7, 50-32-8, 206-44-0, 191-24-2, 218-01-9	10	4397	8032	1.82670002274278	1	1	0.00519138534061582
TOXPRINT_STRUCTURE	ring:aromatic_benzene	10	90.9090909090909	0.0055331746630284	56-55-3, 85-01-8, 83-32-9, 129-00-0, 53-70-3, 120-12-7, 50-32-8, 206-44-0, 191-24-2, 218-01-9	10	4611	8337	1.80806766428107	1	1	0.0055331746630284
MESH	Organic Chemicals	10	90.9090909090909	0.0649933426194292	56-55-3, 85-01-8, 83-32-9, 129-00-0, 53-70-3, 120-12-7, 50-32-8, 206-44-0, 191-24-2, 218-01-9	10	3766	5450	1.44715878916622	1	1	0.0649933426194292
MULTICASE_TOX_PREDICTION	ARE activation in keratinocytes at 100uM	7	63.6363636363636	0.174729825180559	56-55-3, 85-01-8, 53-70-3, 120-12-7, 50-32-8, 206-44-0, 218-01-9	10	3313	8032	1.69707214005433	1	1	0.174729825180559
MULTICASE_TOX_PREDICTION	MCT1 inhibition at 10uM	10	90.9090909090909	0.610366112475254	56-55-3, 85-01-8, 83-32-9, 129-00-0, 53-70-3, 120-12-7, 50-32-8, 206-44-0, 191-24-2, 218-01-9	10	7105	8032	1.13047149894441	1	1	0.610366112475254
MULTICASE_TOX_PREDICTION	MRP5 inhibition at 50uM	10	90.9090909090909	1	56-55-3, 85-01-8, 83-32-9, 129-00-0, 53-70-3, 120-12-7, 50-32-8, 206-44-0, 191-24-2, 218-01-9	10	7642	8032	1.0510337607956	1	1	1

Annotation Cluster 2	Enrichment Score: 5.35020455047152
Category	Term	Count	%	PValue	CASRNs	List Total	Pop Hits	Pop Total	Fold Enrichment	Bonferroni	Benjamini	FDR
TOXINS_TARGETS	GNMT	9	81.8181818181818	1.21716670159572e-16	56-55-3, 85-01-8, 83-32-9, 53-70-3, 120-12-7, 50-32-8, 206-44-0, 191-24-2, 218-01-9	10	31	3520	102.193548387097	1	5.53810849226053e-14	1.21716670159572e-16
TOXPRINT_STRUCTURE	ring:fused_PAH_anthracene	5	45.4545454545455	3.71853803497062e-09	56-55-3, 53-70-3, 120-12-7, 50-32-8, 191-24-2	10	21	8337	198.5	1	1.66590503966684e-06	3.71853803497062e-09
LEADSCOPE_TOXICITY	Genetic Toxicity -UDS human lymphocytes	7	63.6363636363636	5.32875123886235e-06	56-55-3, 83-32-9, 53-70-3, 120-12-7, 50-32-8, 206-44-0, 191-24-2	10	486	7444	10.7218106995885	1	0.00232866429138285	5.32875123886235e-06
TOXINS_TARGETS	AHR	9	81.8181818181818	8.8175249359466e-06	56-55-3, 85-01-8, 83-32-9, 53-70-3, 120-12-7, 50-32-8, 206-44-0, 191-24-2, 218-01-9	10	641	3520	4.94227769110764	1	0.00382680582220082	8.8175249359466e-06
LEADSCOPE_TOXICITY	Genetic Toxicity -UDS rat hepatocytes	5	45.4545454545455	0.000224560809570683	56-55-3, 83-32-9, 53-70-3, 120-12-7, 50-32-8	10	284	7444	13.1056338028169	1	0.0940909792101163	0.000224560809570683
LEADSCOPE_TOXICITY	Genetic Toxicity -E. coli	7	63.6363636363636	0.000747210705574584	56-55-3, 83-32-9, 53-70-3, 120-12-7, 50-32-8, 206-44-0, 191-24-2	10	1152	7444	4.52326388888889	1	0.309345232107878	0.000747210705574584
LEADSCOPE_TOXICITY	Genetic Toxicity -drosophila SLRL	5	45.4545454545455	0.00393193441471615	56-55-3, 83-32-9, 53-70-3, 50-32-8, 206-44-0	10	606	7444	6.14191419141914	1	1	0.00393193441471615
LEADSCOPE_TOXICITY	Genetic Toxicity -UDS	5	45.4545454545455	0.00539865920821757	56-55-3, 83-32-9, 53-70-3, 50-32-8, 206-44-0	10	661	7444	5.63086232980333	1	1	0.00539865920821757
CTD_CHEMICALS_DISEASES	Silicosis	5	45.4545454545455	0.00930669288019021	56-55-3, 83-32-9, 50-32-8, 206-44-0, 191-24-2	10	881	8530	4.8410896708286	1	1	0.00930669288019021

Annotation Cluster 3	Enrichment Score: 4.67398351283267
Category	Term	Count	%	PValue	CASRNs	List Total	Pop Hits	Pop Total	Fold Enrichment	Bonferroni	Benjamini	FDR
CTD_CHEMICALS_DISEASES	Hyperoxia	8	72.7272727272727	7.01311864136831e-08	56-55-3, 85-01-8, 83-32-9, 129-00-0, 53-70-3, 206-44-0, 191-24-2, 218-01-9	10	496	8530	13.758064516129	1	3.1208377954089e-05	7.01311864136831e-08
MULTICASE_TOX_PREDICTION	Local lymph node assay, mouse, extreme sensitizers (EC3 < 1%)	9	81.8181818181818	1.16512758585476e-05	56-55-3, 85-01-8, 83-32-9, 129-00-0, 53-70-3, 50-32-8, 206-44-0, 191-24-2, 218-01-9	10	1512	8032	4.78095238095238	1	0.00504500244675113	1.16512758585476e-05
LEADSCOPE_TOXICITY	Genetic Toxicity -In vitro chrom. ab. CHL	8	72.7272727272727	5.98083809723057e-05	56-55-3, 85-01-8, 83-32-9, 129-00-0, 53-70-3, 50-32-8, 191-24-2, 218-01-9	10	1162	7444	5.1249569707401	1	0.0254185619132299	5.98083809723057e-05
LEADSCOPE_TOXICITY	Genetic Toxicity -SCE in vitro other cells	9	81.8181818181818	0.00412115768321787	56-55-3, 85-01-8, 83-32-9, 129-00-0, 53-70-3, 50-32-8, 206-44-0, 191-24-2, 218-01-9	10	3012	7444	2.22430278884462	1	1	0.00412115768321787

Annotation Cluster 4	Enrichment Score: 3.94879554588163
Category	Term	Count	%	PValue	CASRNs	List Total	Pop Hits	Pop Total	Fold Enrichment	Bonferroni	Benjamini	FDR
TOXPRINT_STRUCTURE	ring:fused_PAH_phenanthrene	7	63.6363636363636	3.17689979568195e-14	56-55-3, 85-01-8, 129-00-0, 53-70-3, 50-32-8, 191-24-2, 218-01-9	10	25	8337	233.436	1	1.43913560744393e-11	3.17689979568195e-14
CTD_PATHWAY	KEGG:00380|Tryptophan metabolism	8	72.7272727272727	5.44857192505085e-07	56-55-3, 85-01-8, 129-00-0, 53-70-3, 120-12-7, 50-32-8, 206-44-0, 218-01-9	8	493	3849	7.80730223123732	1	0.000240282021894742	5.44857192505085e-07
LEADSCOPE_TOXICITY	Genetic Toxicity -In vitro composite	8	72.7272727272727	2.83726817211726e-05	56-55-3, 85-01-8, 129-00-0, 53-70-3, 120-12-7, 50-32-8, 191-24-2, 218-01-9	10	1040	7444	5.72615384615385	1	0.0122002531401042	2.83726817211726e-05
LEADSCOPE_TOXICITY	Genetic Toxicity -In vitro chrom. ab. CHL	8	72.7272727272727	5.98083809723057e-05	56-55-3, 85-01-8, 83-32-9, 129-00-0, 53-70-3, 50-32-8, 191-24-2, 218-01-9	10	1162	7444	5.1249569707401	1	0.0254185619132299	5.98083809723057e-05
CTD_PATHWAY	KEGG:00980|Metabolism of xenobiotics by cytochrome P450	8	72.7272727272727	6.68100413885258e-05	56-55-3, 85-01-8, 129-00-0, 53-70-3, 120-12-7, 50-32-8, 206-44-0, 218-01-9	8	977	3849	3.9396110542477	1	0.028327457548735	6.68100413885258e-05
CTD_PATHWAY	KEGG:00140|Steroid hormone biosynthesis	7	63.6363636363636	8.87027128244181e-05	56-55-3, 85-01-8, 129-00-0, 53-70-3, 120-12-7, 50-32-8, 218-01-9	8	604	3849	5.57595198675497	1	0.0375212475247289	8.87027128244181e-05
LEADSCOPE_TOXICITY	Human Adverse Cardiological Effects -bradycardia	6	54.5454545454545	0.000896481315838951	56-55-3, 85-01-8, 53-70-3, 120-12-7, 50-32-8, 218-01-9	10	747	7444	5.97911646586345	1	0.369350302125648	0.000896481315838951
CTD_PATHWAY	KEGG:00830|Retinol metabolism	6	54.5454545454545	0.00188957841821907	85-01-8, 129-00-0, 53-70-3, 120-12-7, 50-32-8, 218-01-9	8	635	3849	4.54606299212598	1	0.763389680960506	0.00188957841821907
MULTICASE_TOX_PREDICTION	Haptenation (DPRA, SH test)	6	54.5454545454545	0.331464461255224	56-55-3, 85-01-8, 53-70-3, 120-12-7, 50-32-8, 218-01-9	10	3178	8032	1.51642542479547	1	1	0.331464461255224
MULTICASE_TOX_PREDICTION	ARE activation in keratinocytes at 1mM	6	54.5454545454545	0.505614224428372	56-55-3, 85-01-8, 53-70-3, 120-12-7, 50-32-8, 218-01-9	10	3375	8032	1.42791111111111	1	1	0.505614224428372
MULTICASE_TOX_PREDICTION	Dendritic cell activation at 1mM (CD86, CD54)	6	54.5454545454545	0.740217413481032	56-55-3, 85-01-8, 53-70-3, 120-12-7, 50-32-8, 218-01-9	10	3656	8032	1.31816192560175	1	1	0.740217413481032

Annotation Cluster 5	Enrichment Score: 3.57338737003502
Category	Term	Count	%	PValue	CASRNs	List Total	Pop Hits	Pop Total	Fold Enrichment	Bonferroni	Benjamini	FDR
TOXPRINT_STRUCTURE	ring:fused_PAH_phenanthrene	7	63.6363636363636	3.17689979568195e-14	56-55-3, 85-01-8, 129-00-0, 53-70-3, 50-32-8, 191-24-2, 218-01-9	10	25	8337	233.436	1	1.43913560744393e-11	3.17689979568195e-14
CTD_CHEMICALS_DISEASES	Hyperoxia	8	72.7272727272727	7.01311864136831e-08	56-55-3, 85-01-8, 83-32-9, 129-00-0, 53-70-3, 206-44-0, 191-24-2, 218-01-9	10	496	8530	13.758064516129	1	3.1208377954089e-05	7.01311864136831e-08
MULTICASE_TOX_PREDICTION	Local lymph node assay, mouse, extreme sensitizers (EC3 < 1%)	9	81.8181818181818	1.16512758585476e-05	56-55-3, 85-01-8, 83-32-9, 129-00-0, 53-70-3, 50-32-8, 206-44-0, 191-24-2, 218-01-9	10	1512	8032	4.78095238095238	1	0.00504500244675113	1.16512758585476e-05
LEADSCOPE_TOXICITY	Genetic Toxicity -In vitro composite	8	72.7272727272727	2.83726817211726e-05	56-55-3, 85-01-8, 129-00-0, 53-70-3, 120-12-7, 50-32-8, 191-24-2, 218-01-9	10	1040	7444	5.72615384615385	1	0.0122002531401042	2.83726817211726e-05
LEADSCOPE_TOXICITY	Genetic Toxicity -In vitro chrom. ab. CHL	8	72.7272727272727	5.98083809723057e-05	56-55-3, 85-01-8, 83-32-9, 129-00-0, 53-70-3, 50-32-8, 191-24-2, 218-01-9	10	1162	7444	5.1249569707401	1	0.0254185619132299	5.98083809723057e-05
CTD_PATHWAY	KEGG:00140|Steroid hormone biosynthesis	7	63.6363636363636	8.87027128244181e-05	56-55-3, 85-01-8, 129-00-0, 53-70-3, 120-12-7, 50-32-8, 218-01-9	8	604	3849	5.57595198675497	1	0.0375212475247289	8.87027128244181e-05
LEADSCOPE_TOXICITY	Genetic Toxicity -SCE in vitro other cells	9	81.8181818181818	0.00412115768321787	56-55-3, 85-01-8, 83-32-9, 129-00-0, 53-70-3, 50-32-8, 206-44-0, 191-24-2, 218-01-9	10	3012	7444	2.22430278884462	1	1	0.00412115768321787
LEADSCOPE_TOXICITY	Genetic Toxicity -mouse lymphoma	6	54.5454545454545	0.00801170543450712	56-55-3, 83-32-9, 129-00-0, 53-70-3, 50-32-8, 191-24-2	10	1211	7444	3.68819157720892	1	1	0.00801170543450712
MULTICASE_TOX_PREDICTION	RCA survival post-implantation, rodent	5	45.4545454545455	0.0146851948293235	56-55-3, 85-01-8, 53-70-3, 50-32-8, 218-01-9	10	944	8032	4.25423728813559	1	1	0.0146851948293235
MULTICASE_TOX_PREDICTION	RCA fetal death, rat	5	45.4545454545455	0.226572127515184	56-55-3, 85-01-8, 53-70-3, 50-32-8, 218-01-9	10	1865	8032	2.15335120643432	1	1	0.226572127515184
MULTICASE_TOX_PREDICTION	Tox21 ARE activation assay, only strong actives by NIEHS calls, research only	5	45.4545454545455	0.235252813850228	56-55-3, 53-70-3, 50-32-8, 191-24-2, 218-01-9	10	1961	8032	2.04793472718001	1	1	0.235252813850228
MULTICASE_TOX_PREDICTION	Tox21 ARE activation assay, strong and weak actives by NIEHS calls, research only	5	45.4545454545455	0.478018371225875	56-55-3, 53-70-3, 50-32-8, 191-24-2, 218-01-9	10	2553	8032	1.57305131218175	1	1	0.478018371225875
MULTICASE_TOX_PREDICTION	RCA fetal death, rodent	5	45.4545454545455	0.728227126747906	56-55-3, 85-01-8, 53-70-3, 50-32-8, 218-01-9	10	2811	8032	1.42867307008182	1	1	0.728227126747906

Annotation Cluster 6	Enrichment Score: 2.65162738460715
Category	Term	Count	%	PValue	CASRNs	List Total	Pop Hits	Pop Total	Fold Enrichment	Bonferroni	Benjamini	FDR
TOXINS_TARGETS	GNMT	9	81.8181818181818	1.21716670159572e-16	56-55-3, 85-01-8, 83-32-9, 53-70-3, 120-12-7, 50-32-8, 206-44-0, 191-24-2, 218-01-9	10	31	3520	102.193548387097	1	5.53810849226053e-14	1.21716670159572e-16
TOXPRINT_STRUCTURE	ring:fused_PAH_phenanthrene	7	63.6363636363636	3.17689979568195e-14	56-55-3, 85-01-8, 129-00-0, 53-70-3, 50-32-8, 191-24-2, 218-01-9	10	25	8337	233.436	1	1.43913560744393e-11	3.17689979568195e-14
CTD_PATHWAY	KEGG:00380|Tryptophan metabolism	8	72.7272727272727	5.44857192505085e-07	56-55-3, 85-01-8, 129-00-0, 53-70-3, 120-12-7, 50-32-8, 206-44-0, 218-01-9	8	493	3849	7.80730223123732	1	0.000240282021894742	5.44857192505085e-07
CTD_CHEM2DISEASE	Immunologic Deficiency Syndromes	4	36.3636363636364	5.89598544801171e-07	56-55-3, 53-70-3, 50-32-8, 218-01-9	8	15	5441	181.366666666667	1	0.000258833761167714	5.89598544801171e-07
TOXINS_TARGETS	AHR	9	81.8181818181818	8.8175249359466e-06	56-55-3, 85-01-8, 83-32-9, 53-70-3, 120-12-7, 50-32-8, 206-44-0, 191-24-2, 218-01-9	10	641	3520	4.94227769110764	1	0.00382680582220082	8.8175249359466e-06
LEADSCOPE_TOXICITY	Genetic Toxicity -In vitro composite	8	72.7272727272727	2.83726817211726e-05	56-55-3, 85-01-8, 129-00-0, 53-70-3, 120-12-7, 50-32-8, 191-24-2, 218-01-9	10	1040	7444	5.72615384615385	1	0.0122002531401042	2.83726817211726e-05
CTD_PATHWAY	KEGG:00980|Metabolism of xenobiotics by cytochrome P450	8	72.7272727272727	6.68100413885258e-05	56-55-3, 85-01-8, 129-00-0, 53-70-3, 120-12-7, 50-32-8, 206-44-0, 218-01-9	8	977	3849	3.9396110542477	1	0.028327457548735	6.68100413885258e-05
CTD_PATHWAY	KEGG:00140|Steroid hormone biosynthesis	7	63.6363636363636	8.87027128244181e-05	56-55-3, 85-01-8, 129-00-0, 53-70-3, 120-12-7, 50-32-8, 218-01-9	8	604	3849	5.57595198675497	1	0.0375212475247289	8.87027128244181e-05
TOXINS_TARGETS	BE0000132	5	45.4545454545455	0.000695315762108111	56-55-3, 53-70-3, 50-32-8, 206-44-0, 218-01-9	10	181	3520	9.72375690607735	1	0.288556041274866	0.000695315762108111
LEADSCOPE_TOXICITY	Human Adverse Cardiological Effects -bradycardia	6	54.5454545454545	0.000896481315838951	56-55-3, 85-01-8, 53-70-3, 120-12-7, 50-32-8, 218-01-9	10	747	7444	5.97911646586345	1	0.369350302125648	0.000896481315838951
CTD_PATHWAY	KEGG:00830|Retinol metabolism	6	54.5454545454545	0.00188957841821907	85-01-8, 129-00-0, 53-70-3, 120-12-7, 50-32-8, 218-01-9	8	635	3849	4.54606299212598	1	0.763389680960506	0.00188957841821907
CTD_PATHWAY	KEGG:00982|Drug metabolism - cytochrome P450	6	54.5454545454545	0.00575728005005298	85-01-8, 129-00-0, 53-70-3, 50-32-8, 206-44-0, 218-01-9	8	807	3849	3.5771375464684	1	1	0.00575728005005298
HTS_ACTIVE	agonism_RSP	5	45.4545454545455	0.0136585978987229	56-55-3, 53-70-3, 120-12-7, 50-32-8, 218-01-9	9	552	4173	4.19987922705314	1	1	0.0136585978987229
MULTICASE_TOX_PREDICTION	RCA survival post-implantation, rodent	5	45.4545454545455	0.0146851948293235	56-55-3, 85-01-8, 53-70-3, 50-32-8, 218-01-9	10	944	8032	4.25423728813559	1	1	0.0146851948293235
CTD_PATHWAY	KEGG:01100|Metabolic pathways	6	54.5454545454545	0.0169048015194375	85-01-8, 129-00-0, 53-70-3, 50-32-8, 206-44-0, 218-01-9	8	1024	3849	2.819091796875	1	1	0.0169048015194375
CTD_CHEMICALS_DISEASES	Uterine Cervical Neoplasms	4	36.3636363636364	0.0176261147308594	56-55-3, 85-01-8, 206-44-0, 218-01-9	10	561	8530	6.08199643493761	1	1	0.0176261147308594
CTD_PATHWAY	KEGG:05323|Rheumatoid arthritis	6	54.5454545454545	0.0213970724873281	56-55-3, 129-00-0, 120-12-7, 50-32-8, 206-44-0, 218-01-9	8	1080	3849	2.67291666666667	1	1	0.0213970724873281
MULTICASE_TOX_PREDICTION	RCA fetal death, mouse	6	54.5454545454545	0.0222411753102739	56-55-3, 85-01-8, 53-70-3, 50-32-8, 206-44-0, 218-01-9	10	1657	8032	2.90838865419433	1	1	0.0222411753102739
HTS_ACTIVE	antagonism_AR/full/run2	6	54.5454545454545	0.0229860025478882	56-55-3, 85-01-8, 129-00-0, 120-12-7, 50-32-8, 206-44-0	9	1003	4173	2.77367896311067	1	1	0.0229860025478882
CTD_CHEM2DISEASE	Kidney Diseases	4	36.3636363636364	0.0236141489826933	85-01-8, 120-12-7, 50-32-8, 218-01-9	8	528	5441	5.15246212121212	1	1	0.0236141489826933
CTD_CHEM2DISEASE	Necrosis	4	36.3636363636364	0.0313619372463322	129-00-0, 53-70-3, 50-32-8, 218-01-9	8	587	5441	4.63458262350937	1	1	0.0313619372463322
CTD_CHEMICALS_DISEASES	Status Epilepticus	5	45.4545454545455	0.0315607300258116	56-55-3, 85-01-8, 120-12-7, 206-44-0, 218-01-9	10	1253	8530	3.40383080606544	1	1	0.0315607300258116
CTD_CHEMICALS_DISEASES	Neoplasm Recurrence, Local	4	36.3636363636364	0.0520963047169056	85-01-8, 129-00-0, 53-70-3, 218-01-9	10	848	8530	4.02358490566038	1	1	0.0520963047169056
CTD_CHEMICALS_DISEASES	Subarachnoid Hemorrhage	4	36.3636363636364	0.0742009573531017	85-01-8, 129-00-0, 120-12-7, 218-01-9	10	977	8530	3.49232343909928	1	1	0.0742009573531017
HTS_ACTIVE	agonism_AhR	4	36.3636363636364	0.0910445529556652	56-55-3, 53-70-3, 50-32-8, 218-01-9	9	590	4173	3.14350282485876	1	1	0.0910445529556652
MULTICASE_TOX_PREDICTION	ARE activation in keratinocytes at 100uM	7	63.6363636363636	0.174729825180559	56-55-3, 85-01-8, 53-70-3, 120-12-7, 50-32-8, 206-44-0, 218-01-9	10	3313	8032	1.69707214005433	1	1	0.174729825180559
CTD_CHEMICALS_DISEASES	Schizophrenia	4	36.3636363636364	0.182956008427525	85-01-8, 53-70-3, 120-12-7, 218-01-9	10	1439	8530	2.37109103544128	1	1	0.182956008427525
MULTICASE_TOX_PREDICTION	RCA fetal death, rat	5	45.4545454545455	0.226572127515184	56-55-3, 85-01-8, 53-70-3, 50-32-8, 218-01-9	10	1865	8032	2.15335120643432	1	1	0.226572127515184
CTD_PATHWAY	KEGG:05200|Pathways in cancer	6	54.5454545454545	0.261432115085288	56-55-3, 129-00-0, 53-70-3, 50-32-8, 206-44-0, 218-01-9	8	1788	3849	1.61451342281879	1	1	0.261432115085288
MULTICASE_TOX_PREDICTION	Haptenation (DPRA, SH test)	6	54.5454545454545	0.331464461255224	56-55-3, 85-01-8, 53-70-3, 120-12-7, 50-32-8, 218-01-9	10	3178	8032	1.51642542479547	1	1	0.331464461255224
TOXINS_TARGETS	BE0000123	4	36.3636363636364	0.436518670567954	56-55-3, 85-01-8, 53-70-3, 50-32-8	10	806	3520	1.7468982630273	1	1	0.436518670567954
MULTICASE_TOX_PREDICTION	ARE activation in keratinocytes at 1mM	6	54.5454545454545	0.505614224428372	56-55-3, 85-01-8, 53-70-3, 120-12-7, 50-32-8, 218-01-9	10	3375	8032	1.42791111111111	1	1	0.505614224428372
CTD_PATHWAY	KEGG:05215|Prostate cancer	4	36.3636363636364	0.69359369890391	56-55-3, 53-70-3, 50-32-8, 206-44-0	8	1292	3849	1.48955108359133	1	1	0.69359369890391
MULTICASE_TOX_PREDICTION	RCA fetal death, rodent	5	45.4545454545455	0.728227126747906	56-55-3, 85-01-8, 53-70-3, 50-32-8, 218-01-9	10	2811	8032	1.42867307008182	1	1	0.728227126747906
MULTICASE_TOX_PREDICTION	Dendritic cell activation at 1mM (CD86, CD54)	6	54.5454545454545	0.740217413481032	56-55-3, 85-01-8, 53-70-3, 120-12-7, 50-32-8, 218-01-9	10	3656	8032	1.31816192560175	1	1	0.740217413481032
CTD_CHEMICALS_DISEASES	Prostatic Neoplasms	4	36.3636363636364	1	56-55-3, 85-01-8, 53-70-3, 206-44-0	10	2979	8530	1.14535078885532	1	1	1

Annotation Cluster 7	Enrichment Score: 1.98113607477152
Category	Term	Count	%	PValue	CASRNs	List Total	Pop Hits	Pop Total	Fold Enrichment	Bonferroni	Benjamini	FDR
CTD_PATHWAY	KEGG:00380|Tryptophan metabolism	8	72.7272727272727	5.44857192505085e-07	56-55-3, 85-01-8, 129-00-0, 53-70-3, 120-12-7, 50-32-8, 206-44-0, 218-01-9	8	493	3849	7.80730223123732	1	0.000240282021894742	5.44857192505085e-07
CTD_PATHWAY	KEGG:00980|Metabolism of xenobiotics by cytochrome P450	8	72.7272727272727	6.68100413885258e-05	56-55-3, 85-01-8, 129-00-0, 53-70-3, 120-12-7, 50-32-8, 206-44-0, 218-01-9	8	977	3849	3.9396110542477	1	0.028327457548735	6.68100413885258e-05
CTD_PATHWAY	KEGG:00830|Retinol metabolism	6	54.5454545454545	0.00188957841821907	85-01-8, 129-00-0, 53-70-3, 120-12-7, 50-32-8, 218-01-9	8	635	3849	4.54606299212598	1	0.763389680960506	0.00188957841821907
CTD_PATHWAY	KEGG:00982|Drug metabolism - cytochrome P450	6	54.5454545454545	0.00575728005005298	85-01-8, 129-00-0, 53-70-3, 50-32-8, 206-44-0, 218-01-9	8	807	3849	3.5771375464684	1	1	0.00575728005005298
CTD_PATHWAY	KEGG:01100|Metabolic pathways	6	54.5454545454545	0.0169048015194375	85-01-8, 129-00-0, 53-70-3, 50-32-8, 206-44-0, 218-01-9	8	1024	3849	2.819091796875	1	1	0.0169048015194375
MULTICASE_TOX_PREDICTION	RCA fetal death, mouse	6	54.5454545454545	0.0222411753102739	56-55-3, 85-01-8, 53-70-3, 50-32-8, 206-44-0, 218-01-9	10	1657	8032	2.90838865419433	1	1	0.0222411753102739
CTD_CHEM2DISEASE	Necrosis	4	36.3636363636364	0.0313619372463322	129-00-0, 53-70-3, 50-32-8, 218-01-9	8	587	5441	4.63458262350937	1	1	0.0313619372463322
CTD_CHEMICALS_DISEASES	Neoplasm Recurrence, Local	4	36.3636363636364	0.0520963047169056	85-01-8, 129-00-0, 53-70-3, 218-01-9	10	848	8530	4.02358490566038	1	1	0.0520963047169056
CTD_CHEMICALS_DISEASES	Psoriasis	4	36.3636363636364	0.0991187969560934	85-01-8, 129-00-0, 206-44-0, 218-01-9	10	1101	8530	3.09900090826521	1	1	0.0991187969560934
CTD_PATHWAY	KEGG:05200|Pathways in cancer	6	54.5454545454545	0.261432115085288	56-55-3, 129-00-0, 53-70-3, 50-32-8, 206-44-0, 218-01-9	8	1788	3849	1.61451342281879	1	1	0.261432115085288
CTD_CHEMICALS_DISEASES	Parkinson Disease	4	36.3636363636364	0.382515735612742	129-00-0, 53-70-3, 206-44-0, 218-01-9	10	1590	8530	2.14591194968554	1	1	0.382515735612742
HTS_ACTIVE	cytotoxicity_RXR/agonism	4	36.3636363636364	0.698422986144893	85-01-8, 129-00-0, 50-32-8, 206-44-0	9	1213	4173	1.52899148117615	1	1	0.698422986144893

Annotation Cluster 8	Enrichment Score: 1.90679079803579
Category	Term	Count	%	PValue	CASRNs	List Total	Pop Hits	Pop Total	Fold Enrichment	Bonferroni	Benjamini	FDR
CTD_CHEMICALS_DISEASES	Dermatitis, Atopic	6	54.5454545454545	0.00124765560105704	56-55-3, 85-01-8, 83-32-9, 129-00-0, 120-12-7, 191-24-2	10	919	8530	5.56909684439608	1	0.507795829630216	0.00124765560105704
CTD_CHEMICALS_DISEASES	Hepatitis, Alcoholic	4	36.3636363636364	0.0242576204028539	56-55-3, 85-01-8, 83-32-9, 129-00-0	10	632	8530	5.39873417721519	1	1	0.0242576204028539
CTD_CHEMICALS_DISEASES	Diabetes Mellitus	4	36.3636363636364	0.062904930898229	85-01-8, 83-32-9, 129-00-0, 120-12-7	10	914	8530	3.73304157549234	1	1	0.062904930898229

Annotation Cluster 9	Enrichment Score: 1.89699887814972
Category	Term	Count	%	PValue	CASRNs	List Total	Pop Hits	Pop Total	Fold Enrichment	Bonferroni	Benjamini	FDR
TOXPRINT_STRUCTURE	ring:fused_PAH_pyrene	3	27.2727272727273	3.71505131915305e-05	129-00-0, 50-32-8, 191-24-2	10	9	8337	277.9	1	0.015826118619592	3.71505131915305e-05
CTD_CHEMICALS_DISEASES	Spherocytosis, Hereditary	3	27.2727272727273	0.00104378054269197	53-70-3, 50-32-8, 191-24-2	10	47	8530	54.4468085106383	1	0.427950022503709	0.00104378054269197
CTD_CHEMICALS_DISEASES	Neurodevelopmental Disorders	4	36.3636363636364	0.0016295343407518	50-32-8, 206-44-0, 191-24-2, 218-01-9	10	240	8530	14.2166666666667	1	0.659961408004478	0.0016295343407518
CTD_CHEMICALS_DISEASES	Loeys-Dietz Syndrome	2	18.1818181818182	0.0901192365103538	50-32-8, 191-24-2	10	89	8530	19.1685393258427	1	1	0.0901192365103538
CTD_CHEMICALS_DISEASES	Melanoma	4	36.3636363636364	0.135405138270814	83-32-9, 50-32-8, 191-24-2, 218-01-9	10	1258	8530	2.71224165341812	1	1	0.135405138270814
CTD_CHEMICALS_DISEASES	Adenocarcinoma of Lung	3	27.2727272727273	0.171032253904042	83-32-9, 50-32-8, 191-24-2	10	716	8530	3.57402234636872	1	1	0.171032253904042
HTS_ACTIVE	agonism_AR/partial	2	18.1818181818182	0.398877605240494	50-32-8, 191-24-2	9	257	4173	3.6083009079118	1	1	0.398877605240494

Annotation Cluster 10	Enrichment Score: 1.78115710416054
Category	Term	Count	%	PValue	CASRNs	List Total	Pop Hits	Pop Total	Fold Enrichment	Bonferroni	Benjamini	FDR
TOXPRINT_STRUCTURE	ring:fused_PAH_phenanthrene	7	63.6363636363636	3.17689979568195e-14	56-55-3, 85-01-8, 129-00-0, 53-70-3, 50-32-8, 191-24-2, 218-01-9	10	25	8337	233.436	1	1.43913560744393e-11	3.17689979568195e-14
TOXPRINT_STRUCTURE	ring:fused_PAH_anthracene	5	45.4545454545455	3.71853803497062e-09	56-55-3, 53-70-3, 120-12-7, 50-32-8, 191-24-2	10	21	8337	198.5	1	1.66590503966684e-06	3.71853803497062e-09
CTD_CHEM2DISEASE	Immunologic Deficiency Syndromes	4	36.3636363636364	5.89598544801171e-07	56-55-3, 53-70-3, 50-32-8, 218-01-9	8	15	5441	181.366666666667	1	0.000258833761167714	5.89598544801171e-07
LEADSCOPE_TOXICITY	Genetic Toxicity -UDS human lymphocytes	7	63.6363636363636	5.32875123886235e-06	56-55-3, 83-32-9, 53-70-3, 120-12-7, 50-32-8, 206-44-0, 191-24-2	10	486	7444	10.7218106995885	1	0.00232866429138285	5.32875123886235e-06
TOXPRINT_STRUCTURE	ring:fused_PAH_benz(a)anthracene	3	27.2727272727273	2.16954225653909e-05	56-55-3, 53-70-3, 50-32-8	10	7	8337	357.3	1	0.00935072712568346	2.16954225653909e-05
MESH	Benz(a)Anthracenes	3	27.2727272727273	3.62427966031961e-05	56-55-3, 53-70-3, 191-24-2	10	6	5450	272.5	1	0.0154756741495647	3.62427966031961e-05
CTD_PATHWAY	KEGG:00140|Steroid hormone biosynthesis	7	63.6363636363636	8.87027128244181e-05	56-55-3, 85-01-8, 129-00-0, 53-70-3, 120-12-7, 50-32-8, 218-01-9	8	604	3849	5.57595198675497	1	0.0375212475247289	8.87027128244181e-05
CTD_CHEMICALS_DISEASES	Varicose Veins	4	36.3636363636364	0.000161229112732324	56-55-3, 53-70-3, 191-24-2, 218-01-9	10	109	8530	31.302752293578	1	0.0677162273475759	0.000161229112732324
LEADSCOPE_TOXICITY	Genetic Toxicity -UDS rat hepatocytes	5	45.4545454545455	0.000224560809570683	56-55-3, 83-32-9, 53-70-3, 120-12-7, 50-32-8	10	284	7444	13.1056338028169	1	0.0940909792101163	0.000224560809570683
TOXINS_TARGETS	BE0000132	5	45.4545454545455	0.000695315762108111	56-55-3, 53-70-3, 50-32-8, 206-44-0, 218-01-9	10	181	3520	9.72375690607735	1	0.288556041274866	0.000695315762108111
LEADSCOPE_TOXICITY	Genetic Toxicity -E. coli	7	63.6363636363636	0.000747210705574584	56-55-3, 83-32-9, 53-70-3, 120-12-7, 50-32-8, 206-44-0, 191-24-2	10	1152	7444	4.52326388888889	1	0.309345232107878	0.000747210705574584
LEADSCOPE_TOXICITY	Human Adverse Cardiological Effects -bradycardia	6	54.5454545454545	0.000896481315838951	56-55-3, 85-01-8, 53-70-3, 120-12-7, 50-32-8, 218-01-9	10	747	7444	5.97911646586345	1	0.369350302125648	0.000896481315838951
CTD_CHEMICALS_DISEASES	Spherocytosis, Hereditary	3	27.2727272727273	0.00104378054269197	53-70-3, 50-32-8, 191-24-2	10	47	8530	54.4468085106383	1	0.427950022503709	0.00104378054269197
CTD_CHEMICALS_DISEASES	Sleep Disorders, Circadian Rhythm	3	27.2727272727273	0.00108856578631984	56-55-3, 53-70-3, 218-01-9	10	48	8530	53.3125	1	0.445223406604813	0.00108856578631984
CTD_CHEM2DISEASE	Sarcoma	3	27.2727272727273	0.00119209936666582	56-55-3, 53-70-3, 50-32-8	8	42	5441	48.5803571428571	1	0.486376541599653	0.00119209936666582
LEADSCOPE_TOXICITY	Genetic Toxicity -drosophila SLRL	5	45.4545454545455	0.00393193441471615	56-55-3, 83-32-9, 53-70-3, 50-32-8, 206-44-0	10	606	7444	6.14191419141914	1	1	0.00393193441471615
CTD_CHEMICALS_DISEASES	Prostatic Intraepithelial Neoplasia	5	45.4545454545455	0.00394778910211831	56-55-3, 129-00-0, 53-70-3, 206-44-0, 218-01-9	10	695	8530	6.13669064748201	1	1	0.00394778910211831
CTD_CHEM2DISEASE	Hypertrophy	3	27.2727272727273	0.00470341717948041	56-55-3, 50-32-8, 206-44-0	8	84	5441	24.2901785714286	1	1	0.00470341717948041
LEADSCOPE_TOXICITY	Genetic Toxicity -UDS	5	45.4545454545455	0.00539865920821757	56-55-3, 83-32-9, 53-70-3, 50-32-8, 206-44-0	10	661	7444	5.63086232980333	1	1	0.00539865920821757
CTD_CHEMICALS_DISEASES	Osteogenesis Imperfecta, Type IV	3	27.2727272727273	0.00559210288190369	56-55-3, 191-24-2, 218-01-9	10	110	8530	23.2636363636364	1	1	0.00559210288190369
CTD_CHEM2DISEASE	Adenoma	3	27.2727272727273	0.00754375979623929	56-55-3, 53-70-3, 50-32-8	8	107	5441	19.0689252336449	1	1	0.00754375979623929
CTD_CHEMICALS_DISEASES	Silicosis	5	45.4545454545455	0.00930669288019021	56-55-3, 83-32-9, 50-32-8, 206-44-0, 191-24-2	10	881	8530	4.8410896708286	1	1	0.00930669288019021
CTD_CHEM2DISEASE	Skin Neoplasms	3	27.2727272727273	0.011160363438817	56-55-3, 53-70-3, 50-32-8	8	131	5441	15.5753816793893	1	1	0.011160363438817
HTS_ACTIVE	agonism_RSP	5	45.4545454545455	0.0136585978987229	56-55-3, 53-70-3, 120-12-7, 50-32-8, 218-01-9	9	552	4173	4.19987922705314	1	1	0.0136585978987229
MULTICASE_TOX_PREDICTION	RCA survival post-implantation, rodent	5	45.4545454545455	0.0146851948293235	56-55-3, 85-01-8, 53-70-3, 50-32-8, 218-01-9	10	944	8032	4.25423728813559	1	1	0.0146851948293235
MULTICASE_TOX_PREDICTION	RCA fetal death, mouse	6	54.5454545454545	0.0222411753102739	56-55-3, 85-01-8, 53-70-3, 50-32-8, 206-44-0, 218-01-9	10	1657	8032	2.90838865419433	1	1	0.0222411753102739
CTD_CHEMICALS_DISEASES	Infertility, Male	5	45.4545454545455	0.028531244554579	56-55-3, 83-32-9, 129-00-0, 53-70-3, 218-01-9	10	1216	8530	3.50740131578947	1	1	0.028531244554579
CTD_CHEMICALS_DISEASES	Precancerous Conditions	5	45.4545454545455	0.0336313442300668	83-32-9, 53-70-3, 120-12-7, 50-32-8, 218-01-9	10	1277	8530	3.33985904463587	1	1	0.0336313442300668
CTD_CHEM2DISEASE	Lung Neoplasms	3	27.2727272727273	0.0348636919615052	53-70-3, 50-32-8, 218-01-9	8	239	5441	8.53713389121339	1	1	0.0348636919615052
CTD_CHEM2DISEASE	Liver Neoplasms	3	27.2727272727273	0.0378937552950221	56-55-3, 53-70-3, 50-32-8	8	250	5441	8.1615	1	1	0.0378937552950221
CTD_CHEMICALS_DISEASES	Hernias, Diaphragmatic, Congenital	3	27.2727272727273	0.0507089139436357	56-55-3, 53-70-3, 218-01-9	10	353	8530	7.24929178470255	1	1	0.0507089139436357
CTD_CHEMICALS_DISEASES	Nasopharyngeal Carcinoma	3	27.2727272727273	0.0565471056732694	56-55-3, 85-01-8, 53-70-3	10	375	8530	6.824	1	1	0.0565471056732694
CTD_CHEMICALS_DISEASES	Intellectual Disability	3	27.2727272727273	0.0748408646402691	56-55-3, 50-32-8, 218-01-9	10	439	8530	5.82915717539863	1	1	0.0748408646402691
CTD_CHEMICALS_DISEASES	Seizures	5	45.4545454545455	0.0808093523513679	56-55-3, 83-32-9, 53-70-3, 50-32-8, 218-01-9	10	1675	8530	2.54626865671642	1	1	0.0808093523513679
HTS_ACTIVE	agonism_AhR	4	36.3636363636364	0.0910445529556652	56-55-3, 53-70-3, 50-32-8, 218-01-9	9	590	4173	3.14350282485876	1	1	0.0910445529556652
CTD_PATHWAY	KEGG:03320|PPAR signaling pathway	3	27.2727272727273	0.125702003437735	53-70-3, 50-32-8, 206-44-0	8	347	3849	4.15958213256484	1	1	0.125702003437735
CTD_CHEMICALS_DISEASES	Arthritis, Rheumatoid	4	36.3636363636364	0.134912068564149	56-55-3, 83-32-9, 53-70-3, 50-32-8	10	1256	8530	2.71656050955414	1	1	0.134912068564149
CTD_CHEMICALS_DISEASES	Barrett Esophagus	3	27.2727272727273	0.166823403160389	56-55-3, 85-01-8, 218-01-9	10	705	8530	3.62978723404255	1	1	0.166823403160389
MULTICASE_TOX_PREDICTION	ARE activation in keratinocytes at 100uM	7	63.6363636363636	0.174729825180559	56-55-3, 85-01-8, 53-70-3, 120-12-7, 50-32-8, 206-44-0, 218-01-9	10	3313	8032	1.69707214005433	1	1	0.174729825180559
CTD_CHEMICALS_DISEASES	Leukemia	3	27.2727272727273	0.176808931941653	85-01-8, 53-70-3, 218-01-9	10	731	8530	3.50068399452804	1	1	0.176808931941653
CTD_CHEMICALS_DISEASES	Vitiligo	3	27.2727272727273	0.185354843152422	56-55-3, 53-70-3, 50-32-8	10	753	8530	3.39840637450199	1	1	0.185354843152422
CTD_CHEMICALS_DISEASES	Respiratory Hypersensitivity	3	27.2727272727273	0.192014313684733	56-55-3, 206-44-0, 218-01-9	10	770	8530	3.32337662337662	1	1	0.192014313684733
CTD_CHEMICALS_DISEASES	Lupus Erythematosus, Systemic	3	27.2727272727273	0.199906507181389	56-55-3, 85-01-8, 218-01-9	10	790	8530	3.23924050632911	1	1	0.199906507181389
MULTICASE_TOX_PREDICTION	RCA fetal death, rat	5	45.4545454545455	0.226572127515184	56-55-3, 85-01-8, 53-70-3, 50-32-8, 218-01-9	10	1865	8032	2.15335120643432	1	1	0.226572127515184
MULTICASE_TOX_PREDICTION	Tox21 ARE activation assay, only strong actives by NIEHS calls, research only	5	45.4545454545455	0.235252813850228	56-55-3, 53-70-3, 50-32-8, 191-24-2, 218-01-9	10	1961	8032	2.04793472718001	1	1	0.235252813850228
CTD_PATHWAY	KEGG:05200|Pathways in cancer	6	54.5454545454545	0.261432115085288	56-55-3, 129-00-0, 53-70-3, 50-32-8, 206-44-0, 218-01-9	8	1788	3849	1.61451342281879	1	1	0.261432115085288
CTD_CHEMICALS_DISEASES	Mesothelioma	3	27.2727272727273	0.262239529814586	56-55-3, 53-70-3, 218-01-9	10	944	8530	2.71080508474576	1	1	0.262239529814586
CTD_CHEMICALS_DISEASES	Esophageal Neoplasms	3	27.2727272727273	0.299001685160361	53-70-3, 206-44-0, 218-01-9	10	1033	8530	2.47725072604066	1	1	0.299001685160361
MULTICASE_TOX_PREDICTION	Haptenation (DPRA, SH test)	6	54.5454545454545	0.331464461255224	56-55-3, 85-01-8, 53-70-3, 120-12-7, 50-32-8, 218-01-9	10	3178	8032	1.51642542479547	1	1	0.331464461255224
TOXINS_TARGETS	BE0000123	4	36.3636363636364	0.436518670567954	56-55-3, 85-01-8, 53-70-3, 50-32-8	10	806	3520	1.7468982630273	1	1	0.436518670567954
HTS_ACTIVE	activation_Nrf2	4	36.3636363636364	0.457975100052759	56-55-3, 53-70-3, 191-24-2, 218-01-9	9	1141	4173	1.62547472976921	1	1	0.457975100052759
MULTICASE_TOX_PREDICTION	Tox21 ARE activation assay, strong and weak actives by NIEHS calls, research only	5	45.4545454545455	0.478018371225875	56-55-3, 53-70-3, 50-32-8, 191-24-2, 218-01-9	10	2553	8032	1.57305131218175	1	1	0.478018371225875
MULTICASE_TOX_PREDICTION	ARE activation in keratinocytes at 1mM	6	54.5454545454545	0.505614224428372	56-55-3, 85-01-8, 53-70-3, 120-12-7, 50-32-8, 218-01-9	10	3375	8032	1.42791111111111	1	1	0.505614224428372
CTD_PATHWAY	KEGG:04350|TGF-beta signaling pathway	3	27.2727272727273	0.62140532293499	53-70-3, 50-32-8, 206-44-0	8	718	3849	2.01027158774373	1	1	0.62140532293499
CTD_CHEMICALS_DISEASES	Pulmonary Disease, Chronic Obstructive	3	27.2727272727273	0.634859175577902	83-32-9, 53-70-3, 50-32-8	10	1303	8530	1.96392939370683	1	1	0.634859175577902
CTD_CHEMICALS_DISEASES	Liver Neoplasms, Experimental	3	27.2727272727273	0.656360013201798	56-55-3, 83-32-9, 218-01-9	10	1457	8530	1.75634866163349	1	1	0.656360013201798
CTD_PATHWAY	KEGG:05214|Glioma	3	27.2727272727273	0.674665603494797	56-55-3, 50-32-8, 206-44-0	8	919	3849	1.5705930359086	1	1	0.674665603494797
CTD_PATHWAY	KEGG:05215|Prostate cancer	4	36.3636363636364	0.69359369890391	56-55-3, 53-70-3, 50-32-8, 206-44-0	8	1292	3849	1.48955108359133	1	1	0.69359369890391
CTD_PATHWAY	KEGG:05152|Tuberculosis	3	27.2727272727273	0.709344124047658	56-55-3, 50-32-8, 206-44-0	8	1541	3849	0.936648280337443	1	1	0.709344124047658
MULTICASE_TOX_PREDICTION	RCA fetal death, rodent	5	45.4545454545455	0.728227126747906	56-55-3, 85-01-8, 53-70-3, 50-32-8, 218-01-9	10	2811	8032	1.42867307008182	1	1	0.728227126747906
MULTICASE_TOX_PREDICTION	Dendritic cell activation at 1mM (CD86, CD54)	6	54.5454545454545	0.740217413481032	56-55-3, 85-01-8, 53-70-3, 120-12-7, 50-32-8, 218-01-9	10	3656	8032	1.31816192560175	1	1	0.740217413481032
CTD_PATHWAY	KEGG:04621|NOD-like receptor signaling pathway	3	27.2727272727273	1	56-55-3, 120-12-7, 50-32-8	8	1293	3849	1.11629930394432	1	1	1
CTD_PATHWAY	KEGG:05020|Prion diseases	3	27.2727272727273	1	56-55-3, 50-32-8, 206-44-0	8	994	3849	1.45208752515091	1	1	1
CTD_PATHWAY	KEGG:05140|Leishmaniasis	3	27.2727272727273	1	56-55-3, 120-12-7, 50-32-8	8	1374	3849	1.05049126637555	1	1	1
CTD_PATHWAY	KEGG:05210|Colorectal cancer	3	27.2727272727273	1	50-32-8, 206-44-0, 218-01-9	8	1345	3849	1.07314126394052	1	1	1
CTD_PATHWAY	KEGG:05219|Bladder cancer	3	27.2727272727273	1	56-55-3, 50-32-8, 206-44-0	8	1098	3849	1.31454918032787	1	1	1
CTD_PATHWAY	KEGG:04380|Osteoclast differentiation	3	27.2727272727273	1	56-55-3, 50-32-8, 218-01-9	8	1221	3849	1.18212530712531	1	1	1

Annotation Cluster 11	Enrichment Score: 1.74840562114031
Category	Term	Count	%	PValue	CASRNs	List Total	Pop Hits	Pop Total	Fold Enrichment	Bonferroni	Benjamini	FDR
CTD_CHEM2DISEASE	Liver Neoplasms, Experimental	4	36.3636363636364	0.00213090951793363	56-55-3, 129-00-0, 50-32-8, 218-01-9	8	224	5441	12.1450892857143	1	0.856625626209318	0.00213090951793363
CTD_CHEMICALS_DISEASES	Disease Progression	6	54.5454545454545	0.00574870132668383	56-55-3, 83-32-9, 129-00-0, 120-12-7, 50-32-8, 218-01-9	10	1287	8530	3.97668997668998	1	1	0.00574870132668383
CTD_PATHWAY	KEGG:05323|Rheumatoid arthritis	6	54.5454545454545	0.0213970724873281	56-55-3, 129-00-0, 120-12-7, 50-32-8, 206-44-0, 218-01-9	8	1080	3849	2.67291666666667	1	1	0.0213970724873281
CTD_CHEMICALS_DISEASES	Inflammatory Bowel Diseases	4	36.3636363636364	0.0365965470545591	56-55-3, 129-00-0, 120-12-7, 218-01-9	10	739	8530	4.617050067659	1	1	0.0365965470545591
CTD_CHEMICALS_DISEASES	Heart Failure	4	36.3636363636364	0.188817685894531	83-32-9, 129-00-0, 120-12-7, 218-01-9	10	1460	8530	2.33698630136986	1	1	0.188817685894531

Annotation Cluster 12	Enrichment Score: 1.68682023675604
Category	Term	Count	%	PValue	CASRNs	List Total	Pop Hits	Pop Total	Fold Enrichment	Bonferroni	Benjamini	FDR
HTS_ACTIVE	activation_EndoRS	4	36.3636363636364	0.000328932112757107	53-70-3, 120-12-7, 206-44-0, 191-24-2	9	78	4173	23.7777777777778	1	0.136835758906957	0.000328932112757107
CTD_CHEMICALS_DISEASES	Neurodevelopmental Disorders	4	36.3636363636364	0.0016295343407518	50-32-8, 206-44-0, 191-24-2, 218-01-9	10	240	8530	14.2166666666667	1	0.659961408004478	0.0016295343407518
CTD_CHEMICALS_DISEASES	Spinal Cord Injuries	4	36.3636363636364	0.0460657166304461	53-70-3, 206-44-0, 191-24-2, 218-01-9	10	808	8530	4.22277227722772	1	1	0.0460657166304461
CTD_CHEMICALS_DISEASES	Calcinosis	3	27.2727272727273	0.214654502836388	53-70-3, 206-44-0, 191-24-2	10	827	8530	3.09431680773882	1	1	0.214654502836388
CTD_CHEMICALS_DISEASES	Stomach Neoplasms	2	18.1818181818182	0.69440236222211	206-44-0, 191-24-2	10	1974	8530	0.864235055724418	1	1	0.69440236222211

Annotation Cluster 13	Enrichment Score: 1.68352789473595
Category	Term	Count	%	PValue	CASRNs	List Total	Pop Hits	Pop Total	Fold Enrichment	Bonferroni	Benjamini	FDR
LEADSCOPE_TOXICITY	Genetic Toxicity -UDS human lymphocytes	7	63.6363636363636	5.32875123886235e-06	56-55-3, 83-32-9, 53-70-3, 120-12-7, 50-32-8, 206-44-0, 191-24-2	10	486	7444	10.7218106995885	1	0.00232866429138285	5.32875123886235e-06
LEADSCOPE_TOXICITY	Genetic Toxicity -E. coli	7	63.6363636363636	0.000747210705574584	56-55-3, 83-32-9, 53-70-3, 120-12-7, 50-32-8, 206-44-0, 191-24-2	10	1152	7444	4.52326388888889	1	0.309345232107878	0.000747210705574584
LEADSCOPE_TOXICITY	Genetic Toxicity -drosophila SLRL	5	45.4545454545455	0.00393193441471615	56-55-3, 83-32-9, 53-70-3, 50-32-8, 206-44-0	10	606	7444	6.14191419141914	1	1	0.00393193441471615
CTD_CHEM2DISEASE	Hypertrophy	3	27.2727272727273	0.00470341717948041	56-55-3, 50-32-8, 206-44-0	8	84	5441	24.2901785714286	1	1	0.00470341717948041
LEADSCOPE_TOXICITY	Genetic Toxicity -UDS	5	45.4545454545455	0.00539865920821757	56-55-3, 83-32-9, 53-70-3, 50-32-8, 206-44-0	10	661	7444	5.63086232980333	1	1	0.00539865920821757
CTD_CHEMICALS_DISEASES	Silicosis	5	45.4545454545455	0.00930669288019021	56-55-3, 83-32-9, 50-32-8, 206-44-0, 191-24-2	10	881	8530	4.8410896708286	1	1	0.00930669288019021
CTD_CHEMICALS_DISEASES	Adenocarcinoma of Lung	3	27.2727272727273	0.171032253904042	83-32-9, 50-32-8, 191-24-2	10	716	8530	3.57402234636872	1	1	0.171032253904042
CTD_PATHWAY	KEGG:05214|Glioma	3	27.2727272727273	0.674665603494797	56-55-3, 50-32-8, 206-44-0	8	919	3849	1.5705930359086	1	1	0.674665603494797
CTD_PATHWAY	KEGG:05152|Tuberculosis	3	27.2727272727273	0.709344124047658	56-55-3, 50-32-8, 206-44-0	8	1541	3849	0.936648280337443	1	1	0.709344124047658
CTD_PATHWAY	KEGG:05219|Bladder cancer	3	27.2727272727273	1	56-55-3, 50-32-8, 206-44-0	8	1098	3849	1.31454918032787	1	1	1
CTD_PATHWAY	KEGG:05020|Prion diseases	3	27.2727272727273	1	56-55-3, 50-32-8, 206-44-0	8	994	3849	1.45208752515091	1	1	1

Annotation Cluster 14	Enrichment Score: 1.64130290100454
Category	Term	Count	%	PValue	CASRNs	List Total	Pop Hits	Pop Total	Fold Enrichment	Bonferroni	Benjamini	FDR
MESH	Benz(a)Anthracenes	3	27.2727272727273	3.62427966031961e-05	56-55-3, 53-70-3, 191-24-2	10	6	5450	272.5	1	0.0154756741495647	3.62427966031961e-05
CTD_CHEMICALS_DISEASES	Varicose Veins	4	36.3636363636364	0.000161229112732324	56-55-3, 53-70-3, 191-24-2, 218-01-9	10	109	8530	31.302752293578	1	0.0677162273475759	0.000161229112732324
HTS_ACTIVE	activation_EndoRS	4	36.3636363636364	0.000328932112757107	53-70-3, 120-12-7, 206-44-0, 191-24-2	9	78	4173	23.7777777777778	1	0.136835758906957	0.000328932112757107
CTD_CHEMICALS_DISEASES	Spherocytosis, Hereditary	3	27.2727272727273	0.00104378054269197	53-70-3, 50-32-8, 191-24-2	10	47	8530	54.4468085106383	1	0.427950022503709	0.00104378054269197
CTD_CHEMICALS_DISEASES	HIV Infections	4	36.3636363636364	0.0411143263159188	56-55-3, 129-00-0, 53-70-3, 191-24-2	10	773	8530	4.41397153945666	1	1	0.0411143263159188
CTD_CHEMICALS_DISEASES	Spinal Cord Injuries	4	36.3636363636364	0.0460657166304461	53-70-3, 206-44-0, 191-24-2, 218-01-9	10	808	8530	4.22277227722772	1	1	0.0460657166304461
CTD_CHEMICALS_DISEASES	Mouth Neoplasms	4	36.3636363636364	0.0608609592342952	83-32-9, 53-70-3, 120-12-7, 191-24-2	10	902	8530	3.78270509977827	1	1	0.0608609592342952
CTD_CHEMICALS_DISEASES	Heart Valve Diseases	3	27.2727272727273	0.15697318292029	85-01-8, 53-70-3, 191-24-2	10	679	8530	3.76877761413844	1	1	0.15697318292029
CTD_CHEMICALS_DISEASES	Calcinosis	3	27.2727272727273	0.214654502836388	53-70-3, 206-44-0, 191-24-2	10	827	8530	3.09431680773882	1	1	0.214654502836388
CTD_CHEMICALS_DISEASES	Mouth Diseases	2	18.1818181818182	0.237465929474481	53-70-3, 191-24-2	10	253	8530	6.74308300395257	1	1	0.237465929474481
HTS_ACTIVE	activation_Nrf2	4	36.3636363636364	0.457975100052759	56-55-3, 53-70-3, 191-24-2, 218-01-9	9	1141	4173	1.62547472976921	1	1	0.457975100052759
HTS_ACTIVE	activation_p53	2	18.1818181818182	0.543204307132219	53-70-3, 191-24-2	9	389	4173	2.38389031705227	1	1	0.543204307132219
CTD_CHEMICALS_DISEASES	Reperfusion Injury	3	27.2727272727273	1	83-32-9, 53-70-3, 191-24-2	10	1799	8530	1.4224569205114	1	1	1

Annotation Cluster 15	Enrichment Score: 1.638317208984
Category	Term	Count	%	PValue	CASRNs	List Total	Pop Hits	Pop Total	Fold Enrichment	Bonferroni	Benjamini	FDR
CTD_CHEM2DISEASE	Immunologic Deficiency Syndromes	4	36.3636363636364	5.89598544801171e-07	56-55-3, 53-70-3, 50-32-8, 218-01-9	8	15	5441	181.366666666667	1	0.000258833761167714	5.89598544801171e-07
CTD_CHEM2DISEASE	Immune System Diseases	3	27.2727272727273	0.00097573533203122	129-00-0, 50-32-8, 218-01-9	8	38	5441	53.6940789473684	1	0.401027221464831	0.00097573533203122
CTD_CHEMICALS_DISEASES	Neurodevelopmental Disorders	4	36.3636363636364	0.0016295343407518	50-32-8, 206-44-0, 191-24-2, 218-01-9	10	240	8530	14.2166666666667	1	0.659961408004478	0.0016295343407518
CTD_CHEM2DISEASE	Liver Neoplasms, Experimental	4	36.3636363636364	0.00213090951793363	56-55-3, 129-00-0, 50-32-8, 218-01-9	8	224	5441	12.1450892857143	1	0.856625626209318	0.00213090951793363
TOXPRINT_STRUCTURE	ring:fused_PAH_benzophenanthrene	2	18.1818181818182	0.00323546785961068	50-32-8, 218-01-9	10	3	8337	555.8	1	1	0.00323546785961068
CTD_CHEM2DISEASE	Kidney Diseases	4	36.3636363636364	0.0236141489826933	85-01-8, 120-12-7, 50-32-8, 218-01-9	8	528	5441	5.15246212121212	1	1	0.0236141489826933
CTD_CHEM2DISEASE	Necrosis	4	36.3636363636364	0.0313619372463322	129-00-0, 53-70-3, 50-32-8, 218-01-9	8	587	5441	4.63458262350937	1	1	0.0313619372463322
CTD_CHEM2DISEASE	Lung Neoplasms	3	27.2727272727273	0.0348636919615052	53-70-3, 50-32-8, 218-01-9	8	239	5441	8.53713389121339	1	1	0.0348636919615052
CTD_CHEMICALS_DISEASES	Facies	2	18.1818181818182	0.048532933254587	50-32-8, 218-01-9	10	47	8530	36.2978723404255	1	1	0.048532933254587
CTD_CHEMICALS_DISEASES	Intellectual Disability	3	27.2727272727273	0.0748408646402691	56-55-3, 50-32-8, 218-01-9	10	439	8530	5.82915717539863	1	1	0.0748408646402691
HTS_ACTIVE	agonism_AhR	4	36.3636363636364	0.0910445529556652	56-55-3, 53-70-3, 50-32-8, 218-01-9	9	590	4173	3.14350282485876	1	1	0.0910445529556652
CTD_CHEM2DISEASE	Carcinoma, Squamous Cell	2	18.1818181818182	0.114903310821507	50-32-8, 218-01-9	8	94	5441	14.4707446808511	1	1	0.114903310821507
CTD_CHEMICALS_DISEASES	Melanoma	4	36.3636363636364	0.135405138270814	83-32-9, 50-32-8, 191-24-2, 218-01-9	10	1258	8530	2.71224165341812	1	1	0.135405138270814
CTD_CHEMICALS_DISEASES	Methylmalonic acidemia	2	18.1818181818182	0.163986406291866	50-32-8, 218-01-9	10	168	8530	10.1547619047619	1	1	0.163986406291866
CTD_CHEMICALS_DISEASES	Asthma	2	18.1818181818182	1	50-32-8, 218-01-9	10	1225	8530	1.39265306122449	1	1	1
CTD_PATHWAY	KEGG:05210|Colorectal cancer	3	27.2727272727273	1	50-32-8, 206-44-0, 218-01-9	8	1345	3849	1.07314126394052	1	1	1
CTD_PATHWAY	KEGG:04380|Osteoclast differentiation	3	27.2727272727273	1	56-55-3, 50-32-8, 218-01-9	8	1221	3849	1.18212530712531	1	1	1

Annotation Cluster 16	Enrichment Score: 1.63329680240591
Category	Term	Count	%	PValue	CASRNs	List Total	Pop Hits	Pop Total	Fold Enrichment	Bonferroni	Benjamini	FDR
MESH	Benz(a)Anthracenes	3	27.2727272727273	3.62427966031961e-05	56-55-3, 53-70-3, 191-24-2	10	6	5450	272.5	1	0.0154756741495647	3.62427966031961e-05
CTD_CHEMICALS_DISEASES	Varicose Veins	4	36.3636363636364	0.000161229112732324	56-55-3, 53-70-3, 191-24-2, 218-01-9	10	109	8530	31.302752293578	1	0.0677162273475759	0.000161229112732324
CTD_CHEMICALS_DISEASES	Neurodevelopmental Disorders	4	36.3636363636364	0.0016295343407518	50-32-8, 206-44-0, 191-24-2, 218-01-9	10	240	8530	14.2166666666667	1	0.659961408004478	0.0016295343407518
CTD_CHEMICALS_DISEASES	Osteogenesis Imperfecta, Type IV	3	27.2727272727273	0.00559210288190369	56-55-3, 191-24-2, 218-01-9	10	110	8530	23.2636363636364	1	1	0.00559210288190369
CTD_CHEMICALS_DISEASES	MACULAR DEGENERATION, AGE-RELATED, 14	2	18.1818181818182	0.0240183419136186	56-55-3, 191-24-2	10	23	8530	74.1739130434783	1	1	0.0240183419136186
CTD_CHEMICALS_DISEASES	HIV Infections	4	36.3636363636364	0.0411143263159188	56-55-3, 129-00-0, 53-70-3, 191-24-2	10	773	8530	4.41397153945666	1	1	0.0411143263159188
CTD_CHEMICALS_DISEASES	Spinal Cord Injuries	4	36.3636363636364	0.0460657166304461	53-70-3, 206-44-0, 191-24-2, 218-01-9	10	808	8530	4.22277227722772	1	1	0.0460657166304461
CTD_CHEMICALS_DISEASES	Polycystic Ovary Syndrome	4	36.3636363636364	0.0590179253583112	56-55-3, 120-12-7, 191-24-2, 218-01-9	10	891	8530	3.8294051627385	1	1	0.0590179253583112
CTD_CHEMICALS_DISEASES	Melanoma	4	36.3636363636364	0.135405138270814	83-32-9, 50-32-8, 191-24-2, 218-01-9	10	1258	8530	2.71224165341812	1	1	0.135405138270814
CTD_CHEMICALS_DISEASES	Dermatitis, Contact	3	27.2727272727273	0.371765050144617	83-32-9, 191-24-2, 218-01-9	10	1209	8530	2.1166253101737	1	1	0.371765050144617
CTD_CHEMICALS_DISEASES	Urinary Bladder Neoplasms	4	36.3636363636364	0.401659256023774	56-55-3, 83-32-9, 191-24-2, 218-01-9	10	1748	8530	1.95194508009153	1	1	0.401659256023774
CTD_CHEMICALS_DISEASES	Cholangiocarcinoma	2	18.1818181818182	0.441912627136784	191-24-2, 218-01-9	10	535	8530	3.18878504672897	1	1	0.441912627136784
HTS_ACTIVE	activation_Nrf2	4	36.3636363636364	0.457975100052759	56-55-3, 53-70-3, 191-24-2, 218-01-9	9	1141	4173	1.62547472976921	1	1	0.457975100052759

Annotation Cluster 17	Enrichment Score: 1.57354686677334
Category	Term	Count	%	PValue	CASRNs	List Total	Pop Hits	Pop Total	Fold Enrichment	Bonferroni	Benjamini	FDR
CTD_CHEMICALS_DISEASES	Acid Phosphatase Deficiency	3	27.2727272727273	1.48124094549888e-05	85-01-8, 129-00-0, 120-12-7	10	6	8530	426.5	1	0.00639896088455515	1.48124094549888e-05
CTD_CHEMICALS_DISEASES	Cecal Neoplasms	5	45.4545454545455	3.30427679482527e-05	85-01-8, 129-00-0, 120-12-7, 206-44-0, 218-01-9	10	199	8530	21.4321608040201	1	0.0141423046818521	3.30427679482527e-05
CTD_CHEMICALS_DISEASES	Hepatolenticular Degeneration	5	45.4545454545455	0.00313940745083899	129-00-0, 53-70-3, 120-12-7, 206-44-0, 218-01-9	10	653	8530	6.53139356814701	1	1	0.00313940745083899
CTD_CHEMICALS_DISEASES	Common Variable Immunodeficiency	3	27.2727272727273	0.00446284445366068	129-00-0, 120-12-7, 218-01-9	10	98	8530	26.1122448979592	1	1	0.00446284445366068
CTD_CHEMICALS_DISEASES	Bronchiectasis	3	27.2727272727273	0.0155509940314743	85-01-8, 129-00-0, 218-01-9	10	187	8530	13.6844919786096	1	1	0.0155509940314743
CTD_CHEMICALS_DISEASES	Status Epilepticus	5	45.4545454545455	0.0315607300258116	56-55-3, 85-01-8, 120-12-7, 206-44-0, 218-01-9	10	1253	8530	3.40383080606544	1	1	0.0315607300258116
CTD_CHEMICALS_DISEASES	Myocardial Reperfusion Injury	5	45.4545454545455	0.0324133082386259	85-01-8, 129-00-0, 120-12-7, 206-44-0, 218-01-9	10	1263	8530	3.37688044338876	1	1	0.0324133082386259
CTD_CHEMICALS_DISEASES	Subarachnoid Hemorrhage	4	36.3636363636364	0.0742009573531017	85-01-8, 129-00-0, 120-12-7, 218-01-9	10	977	8530	3.49232343909928	1	1	0.0742009573531017
CTD_CHEMICALS_DISEASES	Psoriasis	4	36.3636363636364	0.0991187969560934	85-01-8, 129-00-0, 206-44-0, 218-01-9	10	1101	8530	3.09900090826521	1	1	0.0991187969560934
CTD_CHEMICALS_DISEASES	Pleural Diseases	3	27.2727272727273	0.12233991496354	85-01-8, 129-00-0, 218-01-9	10	584	8530	4.38184931506849	1	1	0.12233991496354
TOXCAST_ACTIVE	BSK_3C_TissueFactor_down	3	27.2727272727273	0.154424933343467	85-01-8, 120-12-7, 206-44-0	7	206	1723	3.58460471567268	1	1	0.154424933343467
CTD_CHEMICALS_DISEASES	Shock, Hemorrhagic	3	27.2727272727273	0.166441966912268	129-00-0, 206-44-0, 218-01-9	10	704	8530	3.63494318181818	1	1	0.166441966912268
TOXCAST_ACTIVE	OT_ER_ERaERb_0480	3	27.2727272727273	0.177390641717901	85-01-8, 129-00-0, 206-44-0	7	224	1723	3.29655612244898	1	1	0.177390641717901
TOXCAST_ACTIVE	APR_HepG2_OxidativeStress_72h_up	3	27.2727272727273	0.189166768409049	129-00-0, 120-12-7, 206-44-0	7	233	1723	3.16922133660331	1	1	0.189166768409049
CTD_CHEMICALS_DISEASES	Tobacco Use Disorder	3	27.2727272727273	0.228353107168394	85-01-8, 120-12-7, 206-44-0	10	861	8530	2.97212543554007	1	1	0.228353107168394
CTD_CHEMICALS_DISEASES	Amphetamine-Related Disorders	3	27.2727272727273	0.293203180204688	85-01-8, 129-00-0, 218-01-9	10	1019	8530	2.51128557409225	1	1	0.293203180204688
CTD_CHEMICALS_DISEASES	Sepsis	3	27.2727272727273	0.313507567321241	129-00-0, 120-12-7, 206-44-0	10	1068	8530	2.39606741573034	1	1	0.313507567321241

Annotation Cluster 18	Enrichment Score: 1.52034558221227
Category	Term	Count	%	PValue	CASRNs	List Total	Pop Hits	Pop Total	Fold Enrichment	Bonferroni	Benjamini	FDR
CTD_CHEM2DISEASE	Immunologic Deficiency Syndromes	4	36.3636363636364	5.89598544801171e-07	56-55-3, 53-70-3, 50-32-8, 218-01-9	8	15	5441	181.366666666667	1	0.000258833761167714	5.89598544801171e-07
CTD_CHEMICALS_DISEASES	Varicose Veins	4	36.3636363636364	0.000161229112732324	56-55-3, 53-70-3, 191-24-2, 218-01-9	10	109	8530	31.302752293578	1	0.0677162273475759	0.000161229112732324
CTD_CHEMICALS_DISEASES	Sleep Disorders, Circadian Rhythm	3	27.2727272727273	0.00108856578631984	56-55-3, 53-70-3, 218-01-9	10	48	8530	53.3125	1	0.445223406604813	0.00108856578631984
CTD_CHEMICALS_DISEASES	Carcinoma, Pancreatic Ductal	4	36.3636363636364	0.00625214424581279	56-55-3, 129-00-0, 53-70-3, 218-01-9	10	385	8530	8.86233766233766	1	1	0.00625214424581279
CTD_CHEM2DISEASE	Necrosis	4	36.3636363636364	0.0313619372463322	129-00-0, 53-70-3, 50-32-8, 218-01-9	8	587	5441	4.63458262350937	1	1	0.0313619372463322
CTD_CHEM2DISEASE	Lung Neoplasms	3	27.2727272727273	0.0348636919615052	53-70-3, 50-32-8, 218-01-9	8	239	5441	8.53713389121339	1	1	0.0348636919615052
CTD_CHEMICALS_DISEASES	Spinal Cord Injuries	4	36.3636363636364	0.0460657166304461	53-70-3, 206-44-0, 191-24-2, 218-01-9	10	808	8530	4.22277227722772	1	1	0.0460657166304461
CTD_CHEMICALS_DISEASES	Hernias, Diaphragmatic, Congenital	3	27.2727272727273	0.0507089139436357	56-55-3, 53-70-3, 218-01-9	10	353	8530	7.24929178470255	1	1	0.0507089139436357
CTD_CHEMICALS_DISEASES	Neoplasm Recurrence, Local	4	36.3636363636364	0.0520963047169056	85-01-8, 129-00-0, 53-70-3, 218-01-9	10	848	8530	4.02358490566038	1	1	0.0520963047169056
HTS_ACTIVE	agonism_AhR	4	36.3636363636364	0.0910445529556652	56-55-3, 53-70-3, 50-32-8, 218-01-9	9	590	4173	3.14350282485876	1	1	0.0910445529556652
CTD_CHEMICALS_DISEASES	Leukemia	3	27.2727272727273	0.176808931941653	85-01-8, 53-70-3, 218-01-9	10	731	8530	3.50068399452804	1	1	0.176808931941653
CTD_CHEMICALS_DISEASES	Schizophrenia	4	36.3636363636364	0.182956008427525	85-01-8, 53-70-3, 120-12-7, 218-01-9	10	1439	8530	2.37109103544128	1	1	0.182956008427525
CTD_CHEMICALS_DISEASES	Wilms Tumor	2	18.1818181818182	0.244076660035014	53-70-3, 218-01-9	10	261	8530	6.53639846743295	1	1	0.244076660035014
CTD_CHEMICALS_DISEASES	Mesothelioma	3	27.2727272727273	0.262239529814586	56-55-3, 53-70-3, 218-01-9	10	944	8530	2.71080508474576	1	1	0.262239529814586
CTD_CHEMICALS_DISEASES	Esophageal Neoplasms	3	27.2727272727273	0.299001685160361	53-70-3, 206-44-0, 218-01-9	10	1033	8530	2.47725072604066	1	1	0.299001685160361
CTD_CHEMICALS_DISEASES	Parkinson Disease	4	36.3636363636364	0.382515735612742	129-00-0, 53-70-3, 206-44-0, 218-01-9	10	1590	8530	2.14591194968554	1	1	0.382515735612742
HTS_ACTIVE	activation_Nrf2	4	36.3636363636364	0.457975100052759	56-55-3, 53-70-3, 191-24-2, 218-01-9	9	1141	4173	1.62547472976921	1	1	0.457975100052759
CTD_CHEMICALS_DISEASES	Brain Neoplasms	2	18.1818181818182	0.506240171162502	53-70-3, 218-01-9	10	643	8530	2.65318818040435	1	1	0.506240171162502

Annotation Cluster 19	Enrichment Score: 1.51739085546063
Category	Term	Count	%	PValue	CASRNs	List Total	Pop Hits	Pop Total	Fold Enrichment	Bonferroni	Benjamini	FDR
CTD_PATHWAY	KEGG:00380|Tryptophan metabolism	8	72.7272727272727	5.44857192505085e-07	56-55-3, 85-01-8, 129-00-0, 53-70-3, 120-12-7, 50-32-8, 206-44-0, 218-01-9	8	493	3849	7.80730223123732	1	0.000240282021894742	5.44857192505085e-07
CTD_PATHWAY	KEGG:00980|Metabolism of xenobiotics by cytochrome P450	8	72.7272727272727	6.68100413885258e-05	56-55-3, 85-01-8, 129-00-0, 53-70-3, 120-12-7, 50-32-8, 206-44-0, 218-01-9	8	977	3849	3.9396110542477	1	0.028327457548735	6.68100413885258e-05
CTD_CHEMICALS_DISEASES	MELAS Syndrome	4	36.3636363636364	0.0124726155525753	56-55-3, 85-01-8, 129-00-0, 206-44-0	10	494	8530	6.90688259109312	1	1	0.0124726155525753
CTD_PATHWAY	KEGG:05323|Rheumatoid arthritis	6	54.5454545454545	0.0213970724873281	56-55-3, 129-00-0, 120-12-7, 50-32-8, 206-44-0, 218-01-9	8	1080	3849	2.67291666666667	1	1	0.0213970724873281
HTS_ACTIVE	antagonism_AR/full/run2	6	54.5454545454545	0.0229860025478882	56-55-3, 85-01-8, 129-00-0, 120-12-7, 50-32-8, 206-44-0	9	1003	4173	2.77367896311067	1	1	0.0229860025478882
HTS_ACTIVE	inhibition_MMP	5	45.4545454545455	0.0898736098692622	56-55-3, 129-00-0, 120-12-7, 50-32-8, 206-44-0	9	967	4173	2.39744915546363	1	1	0.0898736098692622
TOXCAST_ACTIVE	BSK_3C_Proliferation_down	4	36.3636363636364	0.144440962418179	56-55-3, 85-01-8, 129-00-0, 206-44-0	7	403	1723	2.44310528181496	1	1	0.144440962418179
HTS_ACTIVE	cytotoxicity_MMP/inhibition	4	36.3636363636364	0.162512486661459	56-55-3, 129-00-0, 50-32-8, 206-44-0	9	755	4173	2.45651214128035	1	1	0.162512486661459
CTD_PATHWAY	KEGG:05146|Amoebiasis	5	45.4545454545455	0.210981893745681	56-55-3, 129-00-0, 120-12-7, 50-32-8, 206-44-0	8	1177	3849	2.04386151231946	1	1	0.210981893745681
CTD_PATHWAY	KEGG:05144|Malaria	4	36.3636363636364	0.387133481369952	129-00-0, 120-12-7, 50-32-8, 206-44-0	8	1006	3849	1.91302186878728	1	1	0.387133481369952
HTS_ACTIVE	cytotoxicity_RXR/agonism	4	36.3636363636364	0.698422986144893	85-01-8, 129-00-0, 50-32-8, 206-44-0	9	1213	4173	1.52899148117615	1	1	0.698422986144893
CTD_PATHWAY	KEGG:04620|Toll-like receptor signaling pathway	4	36.3636363636364	0.699174155964701	56-55-3, 120-12-7, 50-32-8, 206-44-0	8	1333	3849	1.4437359339835	1	1	0.699174155964701
CTD_PATHWAY	KEGG:05142|Chagas disease (American trypanosomiasis)	4	36.3636363636364	1	56-55-3, 120-12-7, 50-32-8, 206-44-0	8	1545	3849	1.24563106796117	1	1	1

Annotation Cluster 20	Enrichment Score: 1.47515636268792
Category	Term	Count	%	PValue	CASRNs	List Total	Pop Hits	Pop Total	Fold Enrichment	Bonferroni	Benjamini	FDR
TOXPRINT_STRUCTURE	ring:fused_PAH_anthracene	5	45.4545454545455	3.71853803497062e-09	56-55-3, 53-70-3, 120-12-7, 50-32-8, 191-24-2	10	21	8337	198.5	1	1.66590503966684e-06	3.71853803497062e-09
CTD_CHEM2DISEASE	Immunologic Deficiency Syndromes	4	36.3636363636364	5.89598544801171e-07	56-55-3, 53-70-3, 50-32-8, 218-01-9	8	15	5441	181.366666666667	1	0.000258833761167714	5.89598544801171e-07
TOXPRINT_STRUCTURE	ring:fused_PAH_benz(a)anthracene	3	27.2727272727273	2.16954225653909e-05	56-55-3, 53-70-3, 50-32-8	10	7	8337	357.3	1	0.00935072712568346	2.16954225653909e-05
MESH	Benz(a)Anthracenes	3	27.2727272727273	3.62427966031961e-05	56-55-3, 53-70-3, 191-24-2	10	6	5450	272.5	1	0.0154756741495647	3.62427966031961e-05
CTD_CHEMICALS_DISEASES	Varicose Veins	4	36.3636363636364	0.000161229112732324	56-55-3, 53-70-3, 191-24-2, 218-01-9	10	109	8530	31.302752293578	1	0.0677162273475759	0.000161229112732324
CTD_CHEMICALS_DISEASES	Spherocytosis, Hereditary	3	27.2727272727273	0.00104378054269197	53-70-3, 50-32-8, 191-24-2	10	47	8530	54.4468085106383	1	0.427950022503709	0.00104378054269197
CTD_CHEMICALS_DISEASES	Sleep Disorders, Circadian Rhythm	3	27.2727272727273	0.00108856578631984	56-55-3, 53-70-3, 218-01-9	10	48	8530	53.3125	1	0.445223406604813	0.00108856578631984
CTD_CHEM2DISEASE	Sarcoma	3	27.2727272727273	0.00119209936666582	56-55-3, 53-70-3, 50-32-8	8	42	5441	48.5803571428571	1	0.486376541599653	0.00119209936666582
CTD_CHEMICALS_DISEASES	Osteogenesis Imperfecta, Type IV	3	27.2727272727273	0.00559210288190369	56-55-3, 191-24-2, 218-01-9	10	110	8530	23.2636363636364	1	1	0.00559210288190369
CTD_CHEMICALS_DISEASES	Carcinoma, Pancreatic Ductal	4	36.3636363636364	0.00625214424581279	56-55-3, 129-00-0, 53-70-3, 218-01-9	10	385	8530	8.86233766233766	1	1	0.00625214424581279
CTD_CHEM2DISEASE	Adenoma	3	27.2727272727273	0.00754375979623929	56-55-3, 53-70-3, 50-32-8	8	107	5441	19.0689252336449	1	1	0.00754375979623929
CTD_CHEM2DISEASE	Skin Neoplasms	3	27.2727272727273	0.011160363438817	56-55-3, 53-70-3, 50-32-8	8	131	5441	15.5753816793893	1	1	0.011160363438817
CTD_CHEMICALS_DISEASES	MACULAR DEGENERATION, AGE-RELATED, 14	2	18.1818181818182	0.0240183419136186	56-55-3, 191-24-2	10	23	8530	74.1739130434783	1	1	0.0240183419136186
CTD_CHEMICALS_DISEASES	Advanced Sleep-Phase Syndrome, Familial	2	18.1818181818182	0.0291713487916958	56-55-3, 53-70-3	10	28	8530	60.9285714285714	1	1	0.0291713487916958
CTD_CHEM2DISEASE	Liver Neoplasms	3	27.2727272727273	0.0378937552950221	56-55-3, 53-70-3, 50-32-8	8	250	5441	8.1615	1	1	0.0378937552950221
CTD_CHEMICALS_DISEASES	HIV Infections	4	36.3636363636364	0.0411143263159188	56-55-3, 129-00-0, 53-70-3, 191-24-2	10	773	8530	4.41397153945666	1	1	0.0411143263159188
CTD_CHEMICALS_DISEASES	Hypophosphatasia	2	18.1818181818182	0.0444855780991777	56-55-3, 53-70-3	10	43	8530	39.6744186046512	1	1	0.0444855780991777
CTD_CHEMICALS_DISEASES	Hernias, Diaphragmatic, Congenital	3	27.2727272727273	0.0507089139436357	56-55-3, 53-70-3, 218-01-9	10	353	8530	7.24929178470255	1	1	0.0507089139436357
CTD_CHEMICALS_DISEASES	Hypersensitivity	4	36.3636363636364	0.0560654991308512	56-55-3, 129-00-0, 53-70-3, 120-12-7	10	873	8530	3.90836197021764	1	1	0.0560654991308512
CTD_CHEMICALS_DISEASES	Nasopharyngeal Carcinoma	3	27.2727272727273	0.0565471056732694	56-55-3, 85-01-8, 53-70-3	10	375	8530	6.824	1	1	0.0565471056732694
CTD_CHEMICALS_DISEASES	Osteoarthritis	4	36.3636363636364	0.0670967823321621	56-55-3, 85-01-8, 129-00-0, 53-70-3	10	938	8530	3.63752665245203	1	1	0.0670967823321621
HTS_ACTIVE	agonism_AhR	4	36.3636363636364	0.0910445529556652	56-55-3, 53-70-3, 50-32-8, 218-01-9	9	590	4173	3.14350282485876	1	1	0.0910445529556652
TOXCAST_ACTIVE	Tox21_AR_LUC_MDAKB2_Agonist	2	18.1818181818182	0.119158080380958	56-55-3, 53-70-3	7	36	1723	13.6746031746032	1	1	0.119158080380958
CTD_CHEMICALS_DISEASES	Arthritis, Rheumatoid	4	36.3636363636364	0.134912068564149	56-55-3, 83-32-9, 53-70-3, 50-32-8	10	1256	8530	2.71656050955414	1	1	0.134912068564149
CTD_CHEMICALS_DISEASES	Heart Valve Diseases	3	27.2727272727273	0.15697318292029	85-01-8, 53-70-3, 191-24-2	10	679	8530	3.76877761413844	1	1	0.15697318292029
CTD_CHEMICALS_DISEASES	Vitiligo	3	27.2727272727273	0.185354843152422	56-55-3, 53-70-3, 50-32-8	10	753	8530	3.39840637450199	1	1	0.185354843152422
CTD_CHEMICALS_DISEASES	Calcinosis	3	27.2727272727273	0.214654502836388	53-70-3, 206-44-0, 191-24-2	10	827	8530	3.09431680773882	1	1	0.214654502836388
MULTICASE_TOX_PREDICTION	Tox21 ARE activation assay, only strong actives by NIEHS calls, research only	5	45.4545454545455	0.235252813850228	56-55-3, 53-70-3, 50-32-8, 191-24-2, 218-01-9	10	1961	8032	2.04793472718001	1	1	0.235252813850228
CTD_CHEMICALS_DISEASES	Mouth Diseases	2	18.1818181818182	0.237465929474481	53-70-3, 191-24-2	10	253	8530	6.74308300395257	1	1	0.237465929474481
TOXCAST_ACTIVE	ATG_NRF2_ARE_CIS_up	2	18.1818181818182	0.24266961584836	56-55-3, 53-70-3	7	747	1723	0.659017020462804	1	1	0.24266961584836
CTD_CHEMICALS_DISEASES	Mesothelioma	3	27.2727272727273	0.262239529814586	56-55-3, 53-70-3, 218-01-9	10	944	8530	2.71080508474576	1	1	0.262239529814586
HTS_ACTIVE	activation_ATAD5	2	18.1818181818182	0.380191314679718	56-55-3, 53-70-3	9	242	4173	3.83195592286501	1	1	0.380191314679718
TOXINS_TARGETS	BE0000123	4	36.3636363636364	0.436518670567954	56-55-3, 85-01-8, 53-70-3, 50-32-8	10	806	3520	1.7468982630273	1	1	0.436518670567954
HTS_ACTIVE	activation_Nrf2	4	36.3636363636364	0.457975100052759	56-55-3, 53-70-3, 191-24-2, 218-01-9	9	1141	4173	1.62547472976921	1	1	0.457975100052759
MULTICASE_TOX_PREDICTION	Tox21 ARE activation assay, strong and weak actives by NIEHS calls, research only	5	45.4545454545455	0.478018371225875	56-55-3, 53-70-3, 50-32-8, 191-24-2, 218-01-9	10	2553	8032	1.57305131218175	1	1	0.478018371225875
TOXCAST_ACTIVE	Tox21_AhR	2	18.1818181818182	0.496646648326119	56-55-3, 53-70-3	7	186	1723	2.64669738863287	1	1	0.496646648326119
HTS_ACTIVE	agonism_AR/full	2	18.1818181818182	0.513386897178324	56-55-3, 53-70-3	9	359	4173	2.58310120705664	1	1	0.513386897178324
HTS_ACTIVE	activation_p53	2	18.1818181818182	0.543204307132219	53-70-3, 191-24-2	9	389	4173	2.38389031705227	1	1	0.543204307132219
CTD_CHEMICALS_DISEASES	Arsenic Poisoning	2	18.1818181818182	0.556771840788753	56-55-3, 53-70-3	10	737	8530	2.31478968792402	1	1	0.556771840788753
TOXCAST_ACTIVE	ATG_Ahr_CIS_up	2	18.1818181818182	0.565217041077115	56-55-3, 53-70-3	7	223	1723	2.20755925688661	1	1	0.565217041077115
TOXCAST_ACTIVE	ATG_ERE_CIS_up	2	18.1818181818182	0.670556054339584	56-55-3, 53-70-3	7	559	1723	0.880654229491439	1	1	0.670556054339584
CTD_PATHWAY	KEGG:05215|Prostate cancer	4	36.3636363636364	0.69359369890391	56-55-3, 53-70-3, 50-32-8, 206-44-0	8	1292	3849	1.48955108359133	1	1	0.69359369890391
CTD_CHEMICALS_DISEASES	Prostatic Neoplasms	4	36.3636363636364	1	56-55-3, 85-01-8, 53-70-3, 206-44-0	10	2979	8530	1.14535078885532	1	1	1
CTD_CHEMICALS_DISEASES	Reperfusion Injury	3	27.2727272727273	1	83-32-9, 53-70-3, 191-24-2	10	1799	8530	1.4224569205114	1	1	1
CTD_CHEMICALS_DISEASES	Liver Cirrhosis, Biliary	2	18.1818181818182	1	56-55-3, 53-70-3	10	861	8530	1.98141695702671	1	1	1
TOXCAST_ACTIVE	Tox21_ARE_BLA_agonist_ratio	2	18.1818181818182	1	56-55-3, 53-70-3	7	470	1723	1.04741641337386	1	1	1

Annotation Cluster 21	Enrichment Score: 1.43821046068406
Category	Term	Count	%	PValue	CASRNs	List Total	Pop Hits	Pop Total	Fold Enrichment	Bonferroni	Benjamini	FDR
TOXPRINT_STRUCTURE	ring:fused_PAH_anthracene	5	45.4545454545455	3.71853803497062e-09	56-55-3, 53-70-3, 120-12-7, 50-32-8, 191-24-2	10	21	8337	198.5	1	1.66590503966684e-06	3.71853803497062e-09
CTD_CHEM2DISEASE	Immunologic Deficiency Syndromes	4	36.3636363636364	5.89598544801171e-07	56-55-3, 53-70-3, 50-32-8, 218-01-9	8	15	5441	181.366666666667	1	0.000258833761167714	5.89598544801171e-07
TOXPRINT_STRUCTURE	ring:fused_PAH_benz(a)anthracene	3	27.2727272727273	2.16954225653909e-05	56-55-3, 53-70-3, 50-32-8	10	7	8337	357.3	1	0.00935072712568346	2.16954225653909e-05
MESH	Benz(a)Anthracenes	3	27.2727272727273	3.62427966031961e-05	56-55-3, 53-70-3, 191-24-2	10	6	5450	272.5	1	0.0154756741495647	3.62427966031961e-05
TOXPRINT_STRUCTURE	ring:fused_PAH_pyrene	3	27.2727272727273	3.71505131915305e-05	129-00-0, 50-32-8, 191-24-2	10	9	8337	277.9	1	0.015826118619592	3.71505131915305e-05
CTD_CHEMICALS_DISEASES	Spherocytosis, Hereditary	3	27.2727272727273	0.00104378054269197	53-70-3, 50-32-8, 191-24-2	10	47	8530	54.4468085106383	1	0.427950022503709	0.00104378054269197
CTD_CHEM2DISEASE	Sarcoma	3	27.2727272727273	0.00119209936666582	56-55-3, 53-70-3, 50-32-8	8	42	5441	48.5803571428571	1	0.486376541599653	0.00119209936666582
CTD_CHEM2DISEASE	Adenoma	3	27.2727272727273	0.00754375979623929	56-55-3, 53-70-3, 50-32-8	8	107	5441	19.0689252336449	1	1	0.00754375979623929
CTD_CHEM2DISEASE	Skin Neoplasms	3	27.2727272727273	0.011160363438817	56-55-3, 53-70-3, 50-32-8	8	131	5441	15.5753816793893	1	1	0.011160363438817
CTD_CHEM2DISEASE	Necrosis	4	36.3636363636364	0.0313619372463322	129-00-0, 53-70-3, 50-32-8, 218-01-9	8	587	5441	4.63458262350937	1	1	0.0313619372463322
CTD_CHEM2DISEASE	Lung Neoplasms	3	27.2727272727273	0.0348636919615052	53-70-3, 50-32-8, 218-01-9	8	239	5441	8.53713389121339	1	1	0.0348636919615052
CTD_CHEM2DISEASE	Liver Neoplasms	3	27.2727272727273	0.0378937552950221	56-55-3, 53-70-3, 50-32-8	8	250	5441	8.1615	1	1	0.0378937552950221
CTD_CHEM2DISEASE	Arteriosclerosis	2	18.1818181818182	0.0404715317683153	53-70-3, 50-32-8	8	32	5441	42.5078125	1	1	0.0404715317683153
CTD_CHEM2DISEASE	Mammary Neoplasms, Animal	2	18.1818181818182	0.0601751374329586	53-70-3, 50-32-8	8	48	5441	28.3385416666667	1	1	0.0601751374329586
CTD_CHEMICALS_DISEASES	Loeys-Dietz Syndrome	2	18.1818181818182	0.0901192365103538	50-32-8, 191-24-2	10	89	8530	19.1685393258427	1	1	0.0901192365103538
HTS_ACTIVE	agonism_AhR	4	36.3636363636364	0.0910445529556652	56-55-3, 53-70-3, 50-32-8, 218-01-9	9	590	4173	3.14350282485876	1	1	0.0910445529556652
CTD_CHEM2DISEASE	Papilloma	2	18.1818181818182	0.0961859275138748	53-70-3, 50-32-8	8	78	5441	17.4391025641026	1	1	0.0961859275138748
CTD_PATHWAY	KEGG:03320|PPAR signaling pathway	3	27.2727272727273	0.125702003437735	53-70-3, 50-32-8, 206-44-0	8	347	3849	4.15958213256484	1	1	0.125702003437735
CTD_CHEMICALS_DISEASES	Arthritis, Rheumatoid	4	36.3636363636364	0.134912068564149	56-55-3, 83-32-9, 53-70-3, 50-32-8	10	1256	8530	2.71656050955414	1	1	0.134912068564149
CTD_CHEM2DISEASE	Carcinoma	2	18.1818181818182	0.136697788972581	53-70-3, 50-32-8	8	113	5441	12.037610619469	1	1	0.136697788972581
CTD_CHEM2DISEASE	Stomach Neoplasms	2	18.1818181818182	0.138964948200555	53-70-3, 50-32-8	8	115	5441	11.8282608695652	1	1	0.138964948200555
CTD_CHEMICALS_DISEASES	Heart Valve Diseases	3	27.2727272727273	0.15697318292029	85-01-8, 53-70-3, 191-24-2	10	679	8530	3.76877761413844	1	1	0.15697318292029
CTD_CHEMICALS_DISEASES	Peritoneal Neoplasms	2	18.1818181818182	0.162184221815844	53-70-3, 50-32-8	10	166	8530	10.2771084337349	1	1	0.162184221815844
CTD_CHEMICALS_DISEASES	Adenocarcinoma of Lung	3	27.2727272727273	0.171032253904042	83-32-9, 50-32-8, 191-24-2	10	716	8530	3.57402234636872	1	1	0.171032253904042
CTD_CHEM2DISEASE	Adenocarcinoma	2	18.1818181818182	0.176733327544551	53-70-3, 50-32-8	8	149	5441	9.12919463087248	1	1	0.176733327544551
CTD_CHEMICALS_DISEASES	Vitiligo	3	27.2727272727273	0.185354843152422	56-55-3, 53-70-3, 50-32-8	10	753	8530	3.39840637450199	1	1	0.185354843152422
CTD_CHEM2DISEASE	Neoplasms, Experimental	2	18.1818181818182	0.205705656985529	53-70-3, 50-32-8	8	176	5441	7.72869318181818	1	1	0.205705656985529
CTD_CHEMICALS_DISEASES	Calcinosis	3	27.2727272727273	0.214654502836388	53-70-3, 206-44-0, 191-24-2	10	827	8530	3.09431680773882	1	1	0.214654502836388
MULTICASE_TOX_PREDICTION	Tox21 ARE activation assay, only strong actives by NIEHS calls, research only	5	45.4545454545455	0.235252813850228	56-55-3, 53-70-3, 50-32-8, 191-24-2, 218-01-9	10	1961	8032	2.04793472718001	1	1	0.235252813850228
CTD_CHEMICALS_DISEASES	Mouth Diseases	2	18.1818181818182	0.237465929474481	53-70-3, 191-24-2	10	253	8530	6.74308300395257	1	1	0.237465929474481
CTD_CHEMICALS_DISEASES	Myelodysplastic Syndromes	2	18.1818181818182	0.32846880903088	53-70-3, 50-32-8	10	369	8530	4.62330623306233	1	1	0.32846880903088
CTD_PATHWAY	KEGG:04610|Complement and coagulation cascades	2	18.1818181818182	0.359317060713413	53-70-3, 50-32-8	8	237	3849	4.06012658227848	1	1	0.359317060713413
CTD_PATHWAY	KEGG:04146|Peroxisome	2	18.1818181818182	0.396861112746981	53-70-3, 50-32-8	8	268	3849	3.59048507462687	1	1	0.396861112746981
HTS_ACTIVE	agonism_AR/partial	2	18.1818181818182	0.398877605240494	50-32-8, 191-24-2	9	257	4173	3.6083009079118	1	1	0.398877605240494
CTD_CHEMICALS_DISEASES	Adrenocortical Carcinoma	2	18.1818181818182	0.409025636081733	53-70-3, 50-32-8	10	484	8530	3.52479338842975	1	1	0.409025636081733
TOXINS_TARGETS	BE0000123	4	36.3636363636364	0.436518670567954	56-55-3, 85-01-8, 53-70-3, 50-32-8	10	806	3520	1.7468982630273	1	1	0.436518670567954
MULTICASE_TOX_PREDICTION	Tox21 ARE activation assay, strong and weak actives by NIEHS calls, research only	5	45.4545454545455	0.478018371225875	56-55-3, 53-70-3, 50-32-8, 191-24-2, 218-01-9	10	2553	8032	1.57305131218175	1	1	0.478018371225875
HTS_ACTIVE	activation_p53	2	18.1818181818182	0.543204307132219	53-70-3, 191-24-2	9	389	4173	2.38389031705227	1	1	0.543204307132219
CTD_PATHWAY	KEGG:04350|TGF-beta signaling pathway	3	27.2727272727273	0.62140532293499	53-70-3, 50-32-8, 206-44-0	8	718	3849	2.01027158774373	1	1	0.62140532293499
CTD_CHEMICALS_DISEASES	Pulmonary Disease, Chronic Obstructive	3	27.2727272727273	0.634859175577902	83-32-9, 53-70-3, 50-32-8	10	1303	8530	1.96392939370683	1	1	0.634859175577902
CTD_PATHWAY	KEGG:05215|Prostate cancer	4	36.3636363636364	0.69359369890391	56-55-3, 53-70-3, 50-32-8, 206-44-0	8	1292	3849	1.48955108359133	1	1	0.69359369890391
CTD_CHEMICALS_DISEASES	Reperfusion Injury	3	27.2727272727273	1	83-32-9, 53-70-3, 191-24-2	10	1799	8530	1.4224569205114	1	1	1
CTD_CHEMICALS_DISEASES	Brain Ischemia	2	18.1818181818182	1	53-70-3, 50-32-8	10	1338	8530	1.27503736920777	1	1	1

Annotation Cluster 22	Enrichment Score: 1.3755557175773
Category	Term	Count	%	PValue	CASRNs	List Total	Pop Hits	Pop Total	Fold Enrichment	Bonferroni	Benjamini	FDR
TOXPRINT_STRUCTURE	ring:fused_PAH_pyrene	3	27.2727272727273	3.71505131915305e-05	129-00-0, 50-32-8, 191-24-2	10	9	8337	277.9	1	0.015826118619592	3.71505131915305e-05
CTD_CHEMICALS_DISEASES	HIV Infections	4	36.3636363636364	0.0411143263159188	56-55-3, 129-00-0, 53-70-3, 191-24-2	10	773	8530	4.41397153945666	1	1	0.0411143263159188
CTD_CHEMICALS_DISEASES	Aortic Valve Insufficiency	2	18.1818181818182	0.248182450112441	129-00-0, 191-24-2	10	266	8530	6.41353383458647	1	1	0.248182450112441
CTD_CHEMICALS_DISEASES	Abortion, Spontaneous	2	18.1818181818182	0.577332830179072	129-00-0, 191-24-2	10	778	8530	2.19280205655527	1	1	0.577332830179072
CTD_CHEMICALS_DISEASES	Occupational Diseases	2	18.1818181818182	0.605433006902818	129-00-0, 191-24-2	10	837	8530	2.03823178016726	1	1	0.605433006902818

Annotation Cluster 23	Enrichment Score: 1.27764800693731
Category	Term	Count	%	PValue	CASRNs	List Total	Pop Hits	Pop Total	Fold Enrichment	Bonferroni	Benjamini	FDR
CTD_CHEM2DISEASE	Immunologic Deficiency Syndromes	4	36.3636363636364	5.89598544801171e-07	56-55-3, 53-70-3, 50-32-8, 218-01-9	8	15	5441	181.366666666667	1	0.000258833761167714	5.89598544801171e-07
MESH	Benz(a)Anthracenes	3	27.2727272727273	3.62427966031961e-05	56-55-3, 53-70-3, 191-24-2	10	6	5450	272.5	1	0.0154756741495647	3.62427966031961e-05
CTD_CHEMICALS_DISEASES	Varicose Veins	4	36.3636363636364	0.000161229112732324	56-55-3, 53-70-3, 191-24-2, 218-01-9	10	109	8530	31.302752293578	1	0.0677162273475759	0.000161229112732324
CTD_CHEMICALS_DISEASES	Sleep Disorders, Circadian Rhythm	3	27.2727272727273	0.00108856578631984	56-55-3, 53-70-3, 218-01-9	10	48	8530	53.3125	1	0.445223406604813	0.00108856578631984
CTD_CHEM2DISEASE	Liver Neoplasms, Experimental	4	36.3636363636364	0.00213090951793363	56-55-3, 129-00-0, 50-32-8, 218-01-9	8	224	5441	12.1450892857143	1	0.856625626209318	0.00213090951793363
CTD_CHEMICALS_DISEASES	SPERMATOGENIC FAILURE, X-LINKED, 2	2	18.1818181818182	0.00421446389108924	56-55-3, 218-01-9	10	4	8530	426.5	1	1	0.00421446389108924
CTD_CHEMICALS_DISEASES	Osteogenesis Imperfecta, Type IV	3	27.2727272727273	0.00559210288190369	56-55-3, 191-24-2, 218-01-9	10	110	8530	23.2636363636364	1	1	0.00559210288190369
CTD_CHEMICALS_DISEASES	Carcinoma, Pancreatic Ductal	4	36.3636363636364	0.00625214424581279	56-55-3, 129-00-0, 53-70-3, 218-01-9	10	385	8530	8.86233766233766	1	1	0.00625214424581279
CTD_CHEMICALS_DISEASES	Neuronopathy, Distal Hereditary Motor, Type V	2	18.1818181818182	0.011551798761955	56-55-3, 218-01-9	10	11	8530	155.090909090909	1	1	0.011551798761955
CTD_CHEMICALS_DISEASES	Uterine Cervical Neoplasms	4	36.3636363636364	0.0176261147308594	56-55-3, 85-01-8, 206-44-0, 218-01-9	10	561	8530	6.08199643493761	1	1	0.0176261147308594
CTD_CHEMICALS_DISEASES	MACULAR DEGENERATION, AGE-RELATED, 14	2	18.1818181818182	0.0240183419136186	56-55-3, 191-24-2	10	23	8530	74.1739130434783	1	1	0.0240183419136186
CTD_CHEMICALS_DISEASES	Inflammatory Bowel Diseases	4	36.3636363636364	0.0365965470545591	56-55-3, 129-00-0, 120-12-7, 218-01-9	10	739	8530	4.617050067659	1	1	0.0365965470545591
CTD_CHEMICALS_DISEASES	MIGRAINE WITH OR WITHOUT AURA, SUSCEPTIBILITY TO, 1	4	36.3636363636364	0.0429178509269492	56-55-3, 129-00-0, 206-44-0, 218-01-9	10	786	8530	4.34096692111959	1	1	0.0429178509269492
CTD_CHEMICALS_DISEASES	Musculoskeletal Pain	3	27.2727272727273	0.0476286689937421	56-55-3, 129-00-0, 218-01-9	10	341	8530	7.50439882697947	1	1	0.0476286689937421
CTD_CHEMICALS_DISEASES	Hernias, Diaphragmatic, Congenital	3	27.2727272727273	0.0507089139436357	56-55-3, 53-70-3, 218-01-9	10	353	8530	7.24929178470255	1	1	0.0507089139436357
CTD_CHEMICALS_DISEASES	Polycystic Ovary Syndrome	4	36.3636363636364	0.0590179253583112	56-55-3, 120-12-7, 191-24-2, 218-01-9	10	891	8530	3.8294051627385	1	1	0.0590179253583112
CTD_CHEMICALS_DISEASES	Intellectual Disability	3	27.2727272727273	0.0748408646402691	56-55-3, 50-32-8, 218-01-9	10	439	8530	5.82915717539863	1	1	0.0748408646402691
HTS_ACTIVE	agonism_AhR	4	36.3636363636364	0.0910445529556652	56-55-3, 53-70-3, 50-32-8, 218-01-9	9	590	4173	3.14350282485876	1	1	0.0910445529556652
CTD_CHEMICALS_DISEASES	Barrett Esophagus	3	27.2727272727273	0.166823403160389	56-55-3, 85-01-8, 218-01-9	10	705	8530	3.62978723404255	1	1	0.166823403160389
CTD_CHEMICALS_DISEASES	Respiratory Hypersensitivity	3	27.2727272727273	0.192014313684733	56-55-3, 206-44-0, 218-01-9	10	770	8530	3.32337662337662	1	1	0.192014313684733
CTD_CHEMICALS_DISEASES	Lupus Erythematosus, Systemic	3	27.2727272727273	0.199906507181389	56-55-3, 85-01-8, 218-01-9	10	790	8530	3.23924050632911	1	1	0.199906507181389
CTD_CHEMICALS_DISEASES	Liver Neoplasms	4	36.3636363636364	0.223786456970162	56-55-3, 83-32-9, 206-44-0, 218-01-9	10	1581	8530	2.15812776723593	1	1	0.223786456970162
MULTICASE_TOX_PREDICTION	Tox21 ARE activation assay, only strong actives by NIEHS calls, research only	5	45.4545454545455	0.235252813850228	56-55-3, 53-70-3, 50-32-8, 191-24-2, 218-01-9	10	1961	8032	2.04793472718001	1	1	0.235252813850228
CTD_CHEMICALS_DISEASES	Mesothelioma	3	27.2727272727273	0.262239529814586	56-55-3, 53-70-3, 218-01-9	10	944	8530	2.71080508474576	1	1	0.262239529814586
CTD_CHEMICALS_DISEASES	Primary Ovarian Insufficiency	2	18.1818181818182	0.26761561898875	56-55-3, 218-01-9	10	290	8530	5.88275862068966	1	1	0.26761561898875
CTD_CHEMICALS_DISEASES	Cachexia	2	18.1818181818182	0.342416060975202	56-55-3, 218-01-9	10	388	8530	4.39690721649485	1	1	0.342416060975202
CTD_CHEMICALS_DISEASES	Chondrosarcoma, Mesenchymal	2	18.1818181818182	0.354676290941554	56-55-3, 218-01-9	10	405	8530	4.21234567901235	1	1	0.354676290941554
CTD_CHEMICALS_DISEASES	Dermatitis, Contact	3	27.2727272727273	0.371765050144617	83-32-9, 191-24-2, 218-01-9	10	1209	8530	2.1166253101737	1	1	0.371765050144617
CTD_CHEMICALS_DISEASES	Urinary Bladder Neoplasms	4	36.3636363636364	0.401659256023774	56-55-3, 83-32-9, 191-24-2, 218-01-9	10	1748	8530	1.95194508009153	1	1	0.401659256023774
CTD_CHEMICALS_DISEASES	Prostate cancer, familial	2	18.1818181818182	0.4043798661607	56-55-3, 218-01-9	10	477	8530	3.57651991614256	1	1	0.4043798661607
CTD_CHEMICALS_DISEASES	Cholangiocarcinoma	2	18.1818181818182	0.441912627136784	191-24-2, 218-01-9	10	535	8530	3.18878504672897	1	1	0.441912627136784
CTD_CHEMICALS_DISEASES	Substance-Related Disorders	2	18.1818181818182	0.448788789059661	56-55-3, 218-01-9	10	546	8530	3.12454212454212	1	1	0.448788789059661
HTS_ACTIVE	activation_Nrf2	4	36.3636363636364	0.457975100052759	56-55-3, 53-70-3, 191-24-2, 218-01-9	9	1141	4173	1.62547472976921	1	1	0.457975100052759
CTD_CHEMICALS_DISEASES	Osteoporosis, Postmenopausal	2	18.1818181818182	0.474951477910247	56-55-3, 218-01-9	10	589	8530	2.89643463497453	1	1	0.474951477910247
MULTICASE_TOX_PREDICTION	Tox21 ARE activation assay, strong and weak actives by NIEHS calls, research only	5	45.4545454545455	0.478018371225875	56-55-3, 53-70-3, 50-32-8, 191-24-2, 218-01-9	10	2553	8032	1.57305131218175	1	1	0.478018371225875
CTD_CHEMICALS_DISEASES	Liver Neoplasms, Experimental	3	27.2727272727273	0.656360013201798	56-55-3, 83-32-9, 218-01-9	10	1457	8530	1.75634866163349	1	1	0.656360013201798
CTD_CHEMICALS_DISEASES	Liver Cirrhosis, Experimental	4	36.3636363636364	0.719828606893784	56-55-3, 120-12-7, 206-44-0, 218-01-9	10	2423	8530	1.40817168799009	1	1	0.719828606893784
CTD_CHEMICALS_DISEASES	Squamous Cell Carcinoma of Head and Neck	2	18.1818181818182	1	56-55-3, 218-01-9	10	1031	8530	1.65470417070805	1	1	1
CTD_PATHWAY	KEGG:04380|Osteoclast differentiation	3	27.2727272727273	1	56-55-3, 50-32-8, 218-01-9	8	1221	3849	1.18212530712531	1	1	1

Annotation Cluster 24	Enrichment Score: 1.2488603854266
Category	Term	Count	%	PValue	CASRNs	List Total	Pop Hits	Pop Total	Fold Enrichment	Bonferroni	Benjamini	FDR
CTD_CHEMICALS_DISEASES	Acid Phosphatase Deficiency	3	27.2727272727273	1.48124094549888e-05	85-01-8, 129-00-0, 120-12-7	10	6	8530	426.5	1	0.00639896088455515	1.48124094549888e-05
CTD_CHEMICALS_DISEASES	Salmonella Infections, Animal	4	36.3636363636364	0.0030024684201317	83-32-9, 129-00-0, 120-12-7, 206-44-0	10	297	8530	11.4882154882155	1	1	0.0030024684201317
CTD_CHEMICALS_DISEASES	Common Variable Immunodeficiency	3	27.2727272727273	0.00446284445366068	129-00-0, 120-12-7, 218-01-9	10	98	8530	26.1122448979592	1	1	0.00446284445366068
CTD_CHEMICALS_DISEASES	Leishmaniasis, Visceral	4	36.3636363636364	0.0303604658364313	83-32-9, 129-00-0, 120-12-7, 206-44-0	10	688	8530	4.9593023255814	1	1	0.0303604658364313
CTD_CHEMICALS_DISEASES	Inflammatory Bowel Diseases	4	36.3636363636364	0.0365965470545591	56-55-3, 129-00-0, 120-12-7, 218-01-9	10	739	8530	4.617050067659	1	1	0.0365965470545591
CTD_CHEMICALS_DISEASES	Bone Resorption	3	27.2727272727273	0.0501903430802688	83-32-9, 129-00-0, 120-12-7	10	351	8530	7.29059829059829	1	1	0.0501903430802688
CTD_CHEMICALS_DISEASES	Hypersensitivity	4	36.3636363636364	0.0560654991308512	56-55-3, 129-00-0, 53-70-3, 120-12-7	10	873	8530	3.90836197021764	1	1	0.0560654991308512
CTD_CHEMICALS_DISEASES	Diabetes Mellitus	4	36.3636363636364	0.062904930898229	85-01-8, 83-32-9, 129-00-0, 120-12-7	10	914	8530	3.73304157549234	1	1	0.062904930898229
CTD_CHEMICALS_DISEASES	Subarachnoid Hemorrhage	4	36.3636363636364	0.0742009573531017	85-01-8, 129-00-0, 120-12-7, 218-01-9	10	977	8530	3.49232343909928	1	1	0.0742009573531017
CTD_CHEMICALS_DISEASES	Hypopituitarism	2	18.1818181818182	0.17116073502318	129-00-0, 120-12-7	10	176	8530	9.69318181818182	1	1	0.17116073502318
CTD_CHEMICALS_DISEASES	Heart Failure	4	36.3636363636364	0.188817685894531	83-32-9, 129-00-0, 120-12-7, 218-01-9	10	1460	8530	2.33698630136986	1	1	0.188817685894531
TOXCAST_ACTIVE	APR_HepG2_OxidativeStress_72h_up	3	27.2727272727273	0.189166768409049	129-00-0, 120-12-7, 206-44-0	7	233	1723	3.16922133660331	1	1	0.189166768409049
CTD_CHEMICALS_DISEASES	Pneumonia	3	27.2727272727273	0.256898860845331	83-32-9, 129-00-0, 120-12-7	10	931	8530	2.74865735767991	1	1	0.256898860845331
CTD_CHEMICALS_DISEASES	Brain Injuries	3	27.2727272727273	0.261006183998182	56-55-3, 129-00-0, 120-12-7	10	941	8530	2.71944739638682	1	1	0.261006183998182
CTD_CHEMICALS_DISEASES	Sepsis	3	27.2727272727273	0.313507567321241	129-00-0, 120-12-7, 206-44-0	10	1068	8530	2.39606741573034	1	1	0.313507567321241
CTD_CHEMICALS_DISEASES	Cholestasis	3	27.2727272727273	0.342086056329732	129-00-0, 53-70-3, 120-12-7	10	1137	8530	2.25065963060686	1	1	0.342086056329732
CTD_PATHWAY	KEGG:05144|Malaria	4	36.3636363636364	0.387133481369952	129-00-0, 120-12-7, 50-32-8, 206-44-0	8	1006	3849	1.91302186878728	1	1	0.387133481369952
CTD_CHEMICALS_DISEASES	Cell Transformation, Neoplastic	3	27.2727272727273	0.67249613139473	83-32-9, 129-00-0, 120-12-7	10	1558	8530	1.64249037227214	1	1	0.67249613139473

Annotation Cluster 25	Enrichment Score: 1.24107158914146
Category	Term	Count	%	PValue	CASRNs	List Total	Pop Hits	Pop Total	Fold Enrichment	Bonferroni	Benjamini	FDR
LEADSCOPE_TOXICITY	Genetic Toxicity -UDS rat hepatocytes	5	45.4545454545455	0.000224560809570683	56-55-3, 83-32-9, 53-70-3, 120-12-7, 50-32-8	10	284	7444	13.1056338028169	1	0.0940909792101163	0.000224560809570683
CTD_CHEMICALS_DISEASES	Glaucoma 3, primary infantile, B	3	27.2727272727273	0.0111321969088127	83-32-9, 53-70-3, 120-12-7	10	157	8530	16.2993630573248	1	1	0.0111321969088127
HTS_ACTIVE	agonism_RSP	5	45.4545454545455	0.0136585978987229	56-55-3, 53-70-3, 120-12-7, 50-32-8, 218-01-9	9	552	4173	4.19987922705314	1	1	0.0136585978987229
CTD_CHEMICALS_DISEASES	Precancerous Conditions	5	45.4545454545455	0.0336313442300668	83-32-9, 53-70-3, 120-12-7, 50-32-8, 218-01-9	10	1277	8530	3.33985904463587	1	1	0.0336313442300668
CTD_CHEM2DISEASE	Lung Neoplasms	3	27.2727272727273	0.0348636919615052	53-70-3, 50-32-8, 218-01-9	8	239	5441	8.53713389121339	1	1	0.0348636919615052
CTD_CHEMICALS_DISEASES	Liver Cirrhosis	5	45.4545454545455	0.041749838497056	83-32-9, 120-12-7, 50-32-8, 191-24-2, 218-01-9	10	1363	8530	3.12912692589875	1	1	0.041749838497056
CTD_CHEMICALS_DISEASES	Atrophy	3	27.2727272727273	0.0612216929665671	83-32-9, 120-12-7, 50-32-8	10	392	8530	6.52806122448979	1	1	0.0612216929665671
CTD_CHEMICALS_DISEASES	Seizures	5	45.4545454545455	0.0808093523513679	56-55-3, 83-32-9, 53-70-3, 50-32-8, 218-01-9	10	1675	8530	2.54626865671642	1	1	0.0808093523513679
CTD_CHEMICALS_DISEASES	Growth Disorders	3	27.2727272727273	0.180294747163775	83-32-9, 53-70-3, 120-12-7	10	740	8530	3.45810810810811	1	1	0.180294747163775
CTD_CHEMICALS_DISEASES	Weight Gain	3	27.2727272727273	0.313507567321241	83-32-9, 53-70-3, 120-12-7	10	1068	8530	2.39606741573034	1	1	0.313507567321241
CTD_CHEMICALS_DISEASES	Pulmonary Fibrosis	3	27.2727272727273	0.370943760703869	83-32-9, 53-70-3, 120-12-7	10	1207	8530	2.12013256006628	1	1	0.370943760703869
CTD_CHEMICALS_DISEASES	Pulmonary Disease, Chronic Obstructive	3	27.2727272727273	0.634859175577902	83-32-9, 53-70-3, 50-32-8	10	1303	8530	1.96392939370683	1	1	0.634859175577902
CTD_CHEMICALS_DISEASES	Neoplasms	3	27.2727272727273	0.667409585981077	83-32-9, 120-12-7, 50-32-8	10	1527	8530	1.67583497053045	1	1	0.667409585981077

Annotation Cluster 26	Enrichment Score: 1.23960388618423
Category	Term	Count	%	PValue	CASRNs	List Total	Pop Hits	Pop Total	Fold Enrichment	Bonferroni	Benjamini	FDR
CTD_CHEMICALS_DISEASES	Cecal Neoplasms	5	45.4545454545455	3.30427679482527e-05	85-01-8, 129-00-0, 120-12-7, 206-44-0, 218-01-9	10	199	8530	21.4321608040201	1	0.0141423046818521	3.30427679482527e-05
CTD_CHEMICALS_DISEASES	Hepatolenticular Degeneration	5	45.4545454545455	0.00313940745083899	129-00-0, 53-70-3, 120-12-7, 206-44-0, 218-01-9	10	653	8530	6.53139356814701	1	1	0.00313940745083899
CTD_CHEMICALS_DISEASES	Prostatic Intraepithelial Neoplasia	5	45.4545454545455	0.00394778910211831	56-55-3, 129-00-0, 53-70-3, 206-44-0, 218-01-9	10	695	8530	6.13669064748201	1	1	0.00394778910211831
CTD_CHEMICALS_DISEASES	Common Variable Immunodeficiency	3	27.2727272727273	0.00446284445366068	129-00-0, 120-12-7, 218-01-9	10	98	8530	26.1122448979592	1	1	0.00446284445366068
CTD_CHEMICALS_DISEASES	Myocardial Reperfusion Injury	5	45.4545454545455	0.0324133082386259	85-01-8, 129-00-0, 120-12-7, 206-44-0, 218-01-9	10	1263	8530	3.37688044338876	1	1	0.0324133082386259
CTD_CHEMICALS_DISEASES	Asbestosis	3	27.2727272727273	0.0677625988799753	129-00-0, 53-70-3, 206-44-0	10	415	8530	6.16626506024096	1	1	0.0677625988799753
CTD_CHEMICALS_DISEASES	Shock, Hemorrhagic	3	27.2727272727273	0.166441966912268	129-00-0, 206-44-0, 218-01-9	10	704	8530	3.63494318181818	1	1	0.166441966912268
TOXCAST_ACTIVE	APR_HepG2_OxidativeStress_72h_up	3	27.2727272727273	0.189166768409049	129-00-0, 120-12-7, 206-44-0	7	233	1723	3.16922133660331	1	1	0.189166768409049
CTD_CHEMICALS_DISEASES	Multiple Myeloma	3	27.2727272727273	0.242984082478121	129-00-0, 53-70-3, 206-44-0	10	897	8530	2.85284280936455	1	1	0.242984082478121
CTD_CHEMICALS_DISEASES	Esophageal Neoplasms	3	27.2727272727273	0.299001685160361	53-70-3, 206-44-0, 218-01-9	10	1033	8530	2.47725072604066	1	1	0.299001685160361
CTD_CHEMICALS_DISEASES	Sepsis	3	27.2727272727273	0.313507567321241	129-00-0, 120-12-7, 206-44-0	10	1068	8530	2.39606741573034	1	1	0.313507567321241
CTD_CHEMICALS_DISEASES	Cholestasis	3	27.2727272727273	0.342086056329732	129-00-0, 53-70-3, 120-12-7	10	1137	8530	2.25065963060686	1	1	0.342086056329732
CTD_CHEMICALS_DISEASES	Parkinson Disease	4	36.3636363636364	0.382515735612742	129-00-0, 53-70-3, 206-44-0, 218-01-9	10	1590	8530	2.14591194968554	1	1	0.382515735612742
CTD_CHEMICALS_DISEASES	Acute Kidney Injury	3	27.2727272727273	0.675999919190567	129-00-0, 53-70-3, 206-44-0	10	1579	8530	1.62064597846738	1	1	0.675999919190567
PHARMACTIONLIST	Chemical Actions and Uses	3	27.2727272727273	1	129-00-0, 53-70-3, 206-44-0	3	2720	2720	1	1	1	1

Annotation Cluster 27	Enrichment Score: 1.21744640111199
Category	Term	Count	%	PValue	CASRNs	List Total	Pop Hits	Pop Total	Fold Enrichment	Bonferroni	Benjamini	FDR
TOXPRINT_STRUCTURE	ring:fused_PAH_pyrene	3	27.2727272727273	3.71505131915305e-05	129-00-0, 50-32-8, 191-24-2	10	9	8337	277.9	1	0.015826118619592	3.71505131915305e-05
CTD_CHEMICALS_DISEASES	Esophageal Squamous Cell Carcinoma	5	45.4545454545455	0.0145592296527602	83-32-9, 129-00-0, 120-12-7, 50-32-8, 191-24-2	10	1000	8530	4.265	1	1	0.0145592296527602
CTD_CHEMICALS_DISEASES	Precancerous Conditions	5	45.4545454545455	0.0336313442300668	83-32-9, 53-70-3, 120-12-7, 50-32-8, 218-01-9	10	1277	8530	3.33985904463587	1	1	0.0336313442300668
CTD_CHEMICALS_DISEASES	Liver Cirrhosis	5	45.4545454545455	0.041749838497056	83-32-9, 120-12-7, 50-32-8, 191-24-2, 218-01-9	10	1363	8530	3.12912692589875	1	1	0.041749838497056
CTD_CHEMICALS_DISEASES	Bone Resorption	3	27.2727272727273	0.0501903430802688	83-32-9, 129-00-0, 120-12-7	10	351	8530	7.29059829059829	1	1	0.0501903430802688
CTD_CHEMICALS_DISEASES	Atrophy	3	27.2727272727273	0.0612216929665671	83-32-9, 120-12-7, 50-32-8	10	392	8530	6.52806122448979	1	1	0.0612216929665671
CTD_CHEMICALS_DISEASES	Birth Weight	3	27.2727272727273	0.0643195376919312	83-32-9, 120-12-7, 191-24-2	10	403	8530	6.34987593052109	1	1	0.0643195376919312
CTD_CHEMICALS_DISEASES	Melanoma	4	36.3636363636364	0.135405138270814	83-32-9, 50-32-8, 191-24-2, 218-01-9	10	1258	8530	2.71224165341812	1	1	0.135405138270814
CTD_CHEMICALS_DISEASES	Adenocarcinoma of Lung	3	27.2727272727273	0.171032253904042	83-32-9, 50-32-8, 191-24-2	10	716	8530	3.57402234636872	1	1	0.171032253904042
CTD_CHEMICALS_DISEASES	Pneumonia	3	27.2727272727273	0.256898860845331	83-32-9, 129-00-0, 120-12-7	10	931	8530	2.74865735767991	1	1	0.256898860845331
CTD_CHEMICALS_DISEASES	Dermatitis, Contact	3	27.2727272727273	0.371765050144617	83-32-9, 191-24-2, 218-01-9	10	1209	8530	2.1166253101737	1	1	0.371765050144617
CTD_CHEMICALS_DISEASES	Neoplasms	3	27.2727272727273	0.667409585981077	83-32-9, 120-12-7, 50-32-8	10	1527	8530	1.67583497053045	1	1	0.667409585981077
CTD_CHEMICALS_DISEASES	Cell Transformation, Neoplastic	3	27.2727272727273	0.67249613139473	83-32-9, 129-00-0, 120-12-7	10	1558	8530	1.64249037227214	1	1	0.67249613139473

Annotation Cluster 28	Enrichment Score: 1.17738616648361
Category	Term	Count	%	PValue	CASRNs	List Total	Pop Hits	Pop Total	Fold Enrichment	Bonferroni	Benjamini	FDR
CTD_CHEMICALS_DISEASES	Acid Phosphatase Deficiency	3	27.2727272727273	1.48124094549888e-05	85-01-8, 129-00-0, 120-12-7	10	6	8530	426.5	1	0.00639896088455515	1.48124094549888e-05
CTD_CHEM2DISEASE	Kidney Diseases	4	36.3636363636364	0.0236141489826933	85-01-8, 120-12-7, 50-32-8, 218-01-9	8	528	5441	5.15246212121212	1	1	0.0236141489826933
CTD_CHEMICALS_DISEASES	Gastroesophageal Reflux	3	27.2727272727273	0.0473753861758162	85-01-8, 83-32-9, 120-12-7	10	340	8530	7.52647058823529	1	1	0.0473753861758162
CTD_CHEMICALS_DISEASES	Lung Diseases	4	36.3636363636364	0.0528778761421798	85-01-8, 53-70-3, 120-12-7, 206-44-0	10	853	8530	4	1	1	0.0528778761421798
CTD_CHEMICALS_DISEASES	Diabetes Mellitus	4	36.3636363636364	0.062904930898229	85-01-8, 83-32-9, 129-00-0, 120-12-7	10	914	8530	3.73304157549234	1	1	0.062904930898229
CTD_CHEMICALS_DISEASES	Dermatitis, Allergic Contact	4	36.3636363636364	0.0728994138136532	85-01-8, 53-70-3, 120-12-7, 206-44-0	10	970	8530	3.51752577319588	1	1	0.0728994138136532
CTD_CHEMICALS_DISEASES	Subarachnoid Hemorrhage	4	36.3636363636364	0.0742009573531017	85-01-8, 129-00-0, 120-12-7, 218-01-9	10	977	8530	3.49232343909928	1	1	0.0742009573531017
CTD_CHEMICALS_DISEASES	Vascular Diseases	3	27.2727272727273	0.119534503557826	85-01-8, 83-32-9, 120-12-7	10	576	8530	4.44270833333333	1	1	0.119534503557826
CTD_CHEMICALS_DISEASES	Lymphoma, T-Cell, Cutaneous	3	27.2727272727273	0.121636788051319	85-01-8, 53-70-3, 120-12-7	10	582	8530	4.39690721649485	1	1	0.121636788051319
TOXCAST_ACTIVE	BSK_3C_TissueFactor_down	3	27.2727272727273	0.154424933343467	85-01-8, 120-12-7, 206-44-0	7	206	1723	3.58460471567268	1	1	0.154424933343467
CTD_CHEMICALS_DISEASES	Schizophrenia	4	36.3636363636364	0.182956008427525	85-01-8, 53-70-3, 120-12-7, 218-01-9	10	1439	8530	2.37109103544128	1	1	0.182956008427525
CTD_CHEMICALS_DISEASES	Fever	3	27.2727272727273	0.216660816884384	85-01-8, 83-32-9, 120-12-7	10	832	8530	3.07572115384615	1	1	0.216660816884384
CTD_CHEMICALS_DISEASES	Tobacco Use Disorder	3	27.2727272727273	0.228353107168394	85-01-8, 120-12-7, 206-44-0	10	861	8530	2.97212543554007	1	1	0.228353107168394
CTD_CHEMICALS_DISEASES	Splenic Diseases	2	18.1818181818182	0.360375176281143	85-01-8, 120-12-7	10	413	8530	4.13075060532688	1	1	0.360375176281143
LEADSCOPE_TOXICITY	Genetic Toxicity -SCE in vitro	3	27.2727272727273	1	85-01-8, 83-32-9, 120-12-7	10	1780	7444	1.25460674157303	1	1	1

Annotation Cluster 29	Enrichment Score: 1.12712193585386
Category	Term	Count	%	PValue	CASRNs	List Total	Pop Hits	Pop Total	Fold Enrichment	Bonferroni	Benjamini	FDR
CTD_CHEM2DISEASE	Poisoning	5	45.4545454545455	0.000156737874869242	56-55-3, 85-01-8, 129-00-0, 53-70-3, 206-44-0	8	259	5441	13.1298262548263	1	0.0659866453199507	0.000156737874869242
CTD_CHEMICALS_DISEASES	Prostatic Intraepithelial Neoplasia	5	45.4545454545455	0.00394778910211831	56-55-3, 129-00-0, 53-70-3, 206-44-0, 218-01-9	10	695	8530	6.13669064748201	1	1	0.00394778910211831
CTD_CHEMICALS_DISEASES	Pulmonary Emphysema	5	45.4545454545455	0.00919421506065424	56-55-3, 85-01-8, 83-32-9, 129-00-0, 206-44-0	10	878	8530	4.85763097949886	1	1	0.00919421506065424
CTD_CHEMICALS_DISEASES	MELAS Syndrome	4	36.3636363636364	0.0124726155525753	56-55-3, 85-01-8, 129-00-0, 206-44-0	10	494	8530	6.90688259109312	1	1	0.0124726155525753
CTD_CHEMICALS_DISEASES	Hepatitis, Alcoholic	4	36.3636363636364	0.0242576204028539	56-55-3, 85-01-8, 83-32-9, 129-00-0	10	632	8530	5.39873417721519	1	1	0.0242576204028539
CTD_CHEMICALS_DISEASES	Lung Injury	5	45.4545454545455	0.0327584036148547	56-55-3, 83-32-9, 129-00-0, 206-44-0, 218-01-9	10	1267	8530	3.36621941594317	1	1	0.0327584036148547
CTD_CHEMICALS_DISEASES	Carcinoma, Ductal, Breast	3	27.2727272727273	0.0329682879109437	56-55-3, 85-01-8, 206-44-0	10	279	8530	9.17204301075269	1	1	0.0329682879109437
CTD_CHEMICALS_DISEASES	Nasopharyngeal Carcinoma	3	27.2727272727273	0.0565471056732694	56-55-3, 85-01-8, 53-70-3	10	375	8530	6.824	1	1	0.0565471056732694
CTD_CHEMICALS_DISEASES	Keratosis	4	36.3636363636364	0.0570408678767359	85-01-8, 83-32-9, 129-00-0, 206-44-0	10	879	8530	3.88168373151308	1	1	0.0570408678767359
CTD_CHEMICALS_DISEASES	Osteoarthritis	4	36.3636363636364	0.0670967823321621	56-55-3, 85-01-8, 129-00-0, 53-70-3	10	938	8530	3.63752665245203	1	1	0.0670967823321621
CTD_CHEMICALS_DISEASES	Asbestosis	3	27.2727272727273	0.0677625988799753	129-00-0, 53-70-3, 206-44-0	10	415	8530	6.16626506024096	1	1	0.0677625988799753
CTD_CHEMICALS_DISEASES	Craniofacial Abnormalities	3	27.2727272727273	0.0706812626860664	85-01-8, 129-00-0, 53-70-3	10	425	8530	6.02117647058824	1	1	0.0706812626860664
TOXCAST_ACTIVE	ATG_RXRb_TRANS_up	4	36.3636363636364	0.0798472184314157	85-01-8, 83-32-9, 129-00-0, 206-44-0	7	317	1723	3.10590356016224	1	1	0.0798472184314157
TOXCAST_ACTIVE	OT_ER_ERbERb_1440	3	27.2727272727273	0.129974102328696	56-55-3, 129-00-0, 206-44-0	7	186	1723	3.97004608294931	1	1	0.129974102328696
TOXCAST_ACTIVE	BSK_3C_Proliferation_down	4	36.3636363636364	0.144440962418179	56-55-3, 85-01-8, 129-00-0, 206-44-0	7	403	1723	2.44310528181496	1	1	0.144440962418179
TOXCAST_ACTIVE	OT_ER_ERaERb_0480	3	27.2727272727273	0.177390641717901	85-01-8, 129-00-0, 206-44-0	7	224	1723	3.29655612244898	1	1	0.177390641717901
CTD_CHEMICALS_DISEASES	Multiple Myeloma	3	27.2727272727273	0.242984082478121	129-00-0, 53-70-3, 206-44-0	10	897	8530	2.85284280936455	1	1	0.242984082478121
CTD_CHEMICALS_DISEASES	Thyroid Neoplasms	3	27.2727272727273	0.335880289441011	56-55-3, 83-32-9, 129-00-0	10	1122	8530	2.2807486631016	1	1	0.335880289441011
TOXCAST_ACTIVE	Tox21_MitochondrialToxicity_ratio	3	27.2727272727273	0.613276243968899	56-55-3, 129-00-0, 206-44-0	7	366	1723	2.0175644028103	1	1	0.613276243968899
CTD_CHEMICALS_DISEASES	Acute Kidney Injury	3	27.2727272727273	0.675999919190567	129-00-0, 53-70-3, 206-44-0	10	1579	8530	1.62064597846738	1	1	0.675999919190567
TOXCAST_ACTIVE	ATG_PXRE_CIS_up	5	45.4545454545455	0.687436654504306	56-55-3, 85-01-8, 83-32-9, 129-00-0, 206-44-0	7	881	1723	1.39695151613426	1	1	0.687436654504306
PHARMACTIONLIST	Chemical Actions and Uses	3	27.2727272727273	1	129-00-0, 53-70-3, 206-44-0	3	2720	2720	1	1	1	1
CTD_CHEMICALS_DISEASES	Prostatic Neoplasms	4	36.3636363636364	1	56-55-3, 85-01-8, 53-70-3, 206-44-0	10	2979	8530	1.14535078885532	1	1	1

Annotation Cluster 30	Enrichment Score: 1.10081847333141
Category	Term	Count	%	PValue	CASRNs	List Total	Pop Hits	Pop Total	Fold Enrichment	Bonferroni	Benjamini	FDR
CTD_CHEMICALS_DISEASES	Acid Phosphatase Deficiency	3	27.2727272727273	1.48124094549888e-05	85-01-8, 129-00-0, 120-12-7	10	6	8530	426.5	1	0.00639896088455515	1.48124094549888e-05
CTD_CHEMICALS_DISEASES	Cecal Neoplasms	5	45.4545454545455	3.30427679482527e-05	85-01-8, 129-00-0, 120-12-7, 206-44-0, 218-01-9	10	199	8530	21.4321608040201	1	0.0141423046818521	3.30427679482527e-05
CTD_CHEM2DISEASE	Immune System Diseases	3	27.2727272727273	0.00097573533203122	129-00-0, 50-32-8, 218-01-9	8	38	5441	53.6940789473684	1	0.401027221464831	0.00097573533203122
CTD_CHEM2DISEASE	Congenital Abnormalities	3	27.2727272727273	0.00196673204493313	85-01-8, 129-00-0, 50-32-8	8	54	5441	37.7847222222222	1	0.792593014108051	0.00196673204493313
CTD_CHEMICALS_DISEASES	Common Variable Immunodeficiency	3	27.2727272727273	0.00446284445366068	129-00-0, 120-12-7, 218-01-9	10	98	8530	26.1122448979592	1	1	0.00446284445366068
CTD_CHEMICALS_DISEASES	MELAS Syndrome	4	36.3636363636364	0.0124726155525753	56-55-3, 85-01-8, 129-00-0, 206-44-0	10	494	8530	6.90688259109312	1	1	0.0124726155525753
CTD_CHEMICALS_DISEASES	Bronchiectasis	3	27.2727272727273	0.0155509940314743	85-01-8, 129-00-0, 218-01-9	10	187	8530	13.6844919786096	1	1	0.0155509940314743
CTD_CHEMICALS_DISEASES	Hepatitis, Alcoholic	4	36.3636363636364	0.0242576204028539	56-55-3, 85-01-8, 83-32-9, 129-00-0	10	632	8530	5.39873417721519	1	1	0.0242576204028539
TOXINS_TARGETS	BE0001111	2	18.1818181818182	0.0278072087512771	85-01-8, 129-00-0	10	11	3520	64	1	1	0.0278072087512771
CTD_CHEMICALS_DISEASES	Myocardial Reperfusion Injury	5	45.4545454545455	0.0324133082386259	85-01-8, 129-00-0, 120-12-7, 206-44-0, 218-01-9	10	1263	8530	3.37688044338876	1	1	0.0324133082386259
MESH	Phenanthrenes	2	18.1818181818182	0.042155871082203	85-01-8, 218-01-9	10	26	5450	41.9230769230769	1	1	0.042155871082203
CTD_CHEMICALS_DISEASES	Musculoskeletal Pain	3	27.2727272727273	0.0476286689937421	56-55-3, 129-00-0, 218-01-9	10	341	8530	7.50439882697947	1	1	0.0476286689937421
CTD_CHEMICALS_DISEASES	Neoplasm Recurrence, Local	4	36.3636363636364	0.0520963047169056	85-01-8, 129-00-0, 53-70-3, 218-01-9	10	848	8530	4.02358490566038	1	1	0.0520963047169056
CTD_CHEM2DISEASE	Abnormalities, Multiple	2	18.1818181818182	0.0540553678994355	85-01-8, 129-00-0	8	43	5441	31.6337209302326	1	1	0.0540553678994355
CTD_CHEMICALS_DISEASES	Keratosis	4	36.3636363636364	0.0570408678767359	85-01-8, 83-32-9, 129-00-0, 206-44-0	10	879	8530	3.88168373151308	1	1	0.0570408678767359
CTD_PATHWAY	KEGG:00053|Ascorbate and aldarate metabolism	3	27.2727272727273	0.0573854457206732	85-01-8, 129-00-0, 50-32-8	8	222	3849	6.50168918918919	1	1	0.0573854457206732
CTD_CHEMICALS_DISEASES	Diabetes Mellitus	4	36.3636363636364	0.062904930898229	85-01-8, 83-32-9, 129-00-0, 120-12-7	10	914	8530	3.73304157549234	1	1	0.062904930898229
CTD_CHEMICALS_DISEASES	Osteoarthritis	4	36.3636363636364	0.0670967823321621	56-55-3, 85-01-8, 129-00-0, 53-70-3	10	938	8530	3.63752665245203	1	1	0.0670967823321621
CTD_CHEM2DISEASE	Craniofacial Abnormalities	2	18.1818181818182	0.0698961824046082	85-01-8, 129-00-0	8	56	5441	24.2901785714286	1	1	0.0698961824046082
CTD_CHEMICALS_DISEASES	Craniofacial Abnormalities	3	27.2727272727273	0.0706812626860664	85-01-8, 129-00-0, 53-70-3	10	425	8530	6.02117647058824	1	1	0.0706812626860664
CTD_PATHWAY	KEGG:00040|Pentose and glucuronate interconversions	3	27.2727272727273	0.0710320732305736	85-01-8, 129-00-0, 50-32-8	8	250	3849	5.7735	1	1	0.0710320732305736
CTD_CHEMICALS_DISEASES	Subarachnoid Hemorrhage	4	36.3636363636364	0.0742009573531017	85-01-8, 129-00-0, 120-12-7, 218-01-9	10	977	8530	3.49232343909928	1	1	0.0742009573531017
CTD_PATHWAY	KEGG:00860|Porphyrin and chlorophyll metabolism	3	27.2727272727273	0.0798317590780795	85-01-8, 129-00-0, 50-32-8	8	267	3849	5.40589887640449	1	1	0.0798317590780795
TOXCAST_ACTIVE	ATG_RXRb_TRANS_up	4	36.3636363636364	0.0798472184314157	85-01-8, 83-32-9, 129-00-0, 206-44-0	7	317	1723	3.10590356016224	1	1	0.0798472184314157
CTD_CHEMICALS_DISEASES	Psoriasis	4	36.3636363636364	0.0991187969560934	85-01-8, 129-00-0, 206-44-0, 218-01-9	10	1101	8530	3.09900090826521	1	1	0.0991187969560934
CTD_CHEMICALS_DISEASES	Pleural Diseases	3	27.2727272727273	0.12233991496354	85-01-8, 129-00-0, 218-01-9	10	584	8530	4.38184931506849	1	1	0.12233991496354
TOXCAST_ACTIVE	BSK_3C_Proliferation_down	4	36.3636363636364	0.144440962418179	56-55-3, 85-01-8, 129-00-0, 206-44-0	7	403	1723	2.44310528181496	1	1	0.144440962418179
CTD_PATHWAY	KEGG:00983|Drug metabolism - other enzymes	3	27.2727272727273	0.146415299751299	85-01-8, 129-00-0, 50-32-8	8	380	3849	3.79835526315789	1	1	0.146415299751299
CTD_CHEMICALS_DISEASES	Shock, Hemorrhagic	3	27.2727272727273	0.166441966912268	129-00-0, 206-44-0, 218-01-9	10	704	8530	3.63494318181818	1	1	0.166441966912268
CTD_CHEMICALS_DISEASES	Barrett Esophagus	3	27.2727272727273	0.166823403160389	56-55-3, 85-01-8, 218-01-9	10	705	8530	3.62978723404255	1	1	0.166823403160389
CTD_CHEMICALS_DISEASES	Leukemia	3	27.2727272727273	0.176808931941653	85-01-8, 53-70-3, 218-01-9	10	731	8530	3.50068399452804	1	1	0.176808931941653
TOXCAST_ACTIVE	OT_ER_ERaERb_0480	3	27.2727272727273	0.177390641717901	85-01-8, 129-00-0, 206-44-0	7	224	1723	3.29655612244898	1	1	0.177390641717901
CTD_CHEMICALS_DISEASES	Lupus Erythematosus, Systemic	3	27.2727272727273	0.199906507181389	56-55-3, 85-01-8, 218-01-9	10	790	8530	3.23924050632911	1	1	0.199906507181389
CTD_CHEMICALS_DISEASES	Lichenoid Eruptions	2	18.1818181818182	0.277163712558962	85-01-8, 218-01-9	10	302	8530	5.64900662251656	1	1	0.277163712558962
CTD_CHEMICALS_DISEASES	Amphetamine-Related Disorders	3	27.2727272727273	0.293203180204688	85-01-8, 129-00-0, 218-01-9	10	1019	8530	2.51128557409225	1	1	0.293203180204688
CTD_CHEMICALS_DISEASES	HIV Wasting Syndrome	2	18.1818181818182	0.32027445616685	85-01-8, 218-01-9	10	358	8530	4.76536312849162	1	1	0.32027445616685
CTD_CHEMICALS_DISEASES	Malaria	2	18.1818181818182	0.447544208191865	85-01-8, 129-00-0	10	544	8530	3.13602941176471	1	1	0.447544208191865
CTD_CHEMICALS_DISEASES	Crohn Disease	2	18.1818181818182	0.505676160696766	85-01-8, 129-00-0	10	642	8530	2.65732087227414	1	1	0.505676160696766
CTD_CHEMICALS_DISEASES	Hemolytic-Uremic Syndrome	2	18.1818181818182	0.543277031954032	85-01-8, 129-00-0	10	711	8530	2.39943741209564	1	1	0.543277031954032
CTD_CHEMICALS_DISEASES	Osteoporosis	2	18.1818181818182	0.564395020626945	85-01-8, 129-00-0	10	752	8530	2.2686170212766	1	1	0.564395020626945
CTD_CHEMICALS_DISEASES	Neuroblastoma	2	18.1818181818182	0.589927938479228	85-01-8, 218-01-9	10	804	8530	2.12189054726368	1	1	0.589927938479228
CTD_CHEMICALS_DISEASES	Diabetic Neuropathies	2	18.1818181818182	0.594682651038969	85-01-8, 129-00-0	10	814	8530	2.0958230958231	1	1	0.594682651038969
CTD_CHEMICALS_DISEASES	Infarction, Middle Cerebral Artery	2	18.1818181818182	0.610940639299149	85-01-8, 218-01-9	10	849	8530	2.00942285041225	1	1	0.610940639299149
CTD_CHEMICALS_DISEASES	Cardiomegaly	3	27.2727272727273	0.630082022029842	83-32-9, 129-00-0, 218-01-9	10	1263	8530	2.02612826603325	1	1	0.630082022029842
CTD_CHEMICALS_DISEASES	Fatty Liver	3	27.2727272727273	0.654837368186469	83-32-9, 129-00-0, 218-01-9	10	1447	8530	1.76848652384243	1	1	0.654837368186469
HTS_ACTIVE	cytotoxicity_RXR/agonism	4	36.3636363636364	0.698422986144893	85-01-8, 129-00-0, 50-32-8, 206-44-0	9	1213	4173	1.52899148117615	1	1	0.698422986144893
CTD_CHEMICALS_DISEASES	Hepatomegaly	2	18.1818181818182	1	85-01-8, 129-00-0	10	1278	8530	1.33489827856025	1	1	1
CTD_CHEMICALS_DISEASES	Neoplasms, Experimental	2	18.1818181818182	1	85-01-8, 129-00-0	10	916	8530	1.86244541484716	1	1	1
CTD_CHEMICALS_DISEASES	Drug-Related Side Effects and Adverse Reactions	2	18.1818181818182	1	85-01-8, 129-00-0	10	1632	8530	1.0453431372549	1	1	1

Annotation Cluster 31	Enrichment Score: 1.08299146205884
Category	Term	Count	%	PValue	CASRNs	List Total	Pop Hits	Pop Total	Fold Enrichment	Bonferroni	Benjamini	FDR
CTD_CHEMICALS_DISEASES	Sleep Disorders, Circadian Rhythm	3	27.2727272727273	0.00108856578631984	56-55-3, 53-70-3, 218-01-9	10	48	8530	53.3125	1	0.445223406604813	0.00108856578631984
CTD_CHEMICALS_DISEASES	Prostatic Intraepithelial Neoplasia	5	45.4545454545455	0.00394778910211831	56-55-3, 129-00-0, 53-70-3, 206-44-0, 218-01-9	10	695	8530	6.13669064748201	1	1	0.00394778910211831
CTD_CHEMICALS_DISEASES	Carcinoma, Pancreatic Ductal	4	36.3636363636364	0.00625214424581279	56-55-3, 129-00-0, 53-70-3, 218-01-9	10	385	8530	8.86233766233766	1	1	0.00625214424581279
CTD_CHEMICALS_DISEASES	Pulmonary Emphysema	5	45.4545454545455	0.00919421506065424	56-55-3, 85-01-8, 83-32-9, 129-00-0, 206-44-0	10	878	8530	4.85763097949886	1	1	0.00919421506065424
CTD_CHEMICALS_DISEASES	Infertility, Male	5	45.4545454545455	0.028531244554579	56-55-3, 83-32-9, 129-00-0, 53-70-3, 218-01-9	10	1216	8530	3.50740131578947	1	1	0.028531244554579
CTD_CHEMICALS_DISEASES	Lung Injury	5	45.4545454545455	0.0327584036148547	56-55-3, 83-32-9, 129-00-0, 206-44-0, 218-01-9	10	1267	8530	3.36621941594317	1	1	0.0327584036148547
CTD_CHEMICALS_DISEASES	MIGRAINE WITH OR WITHOUT AURA, SUSCEPTIBILITY TO, 1	4	36.3636363636364	0.0429178509269492	56-55-3, 129-00-0, 206-44-0, 218-01-9	10	786	8530	4.34096692111959	1	1	0.0429178509269492
CTD_CHEMICALS_DISEASES	Musculoskeletal Pain	3	27.2727272727273	0.0476286689937421	56-55-3, 129-00-0, 218-01-9	10	341	8530	7.50439882697947	1	1	0.0476286689937421
CTD_CHEMICALS_DISEASES	Hernias, Diaphragmatic, Congenital	3	27.2727272727273	0.0507089139436357	56-55-3, 53-70-3, 218-01-9	10	353	8530	7.24929178470255	1	1	0.0507089139436357
CTD_CHEMICALS_DISEASES	Seizures	5	45.4545454545455	0.0808093523513679	56-55-3, 83-32-9, 53-70-3, 50-32-8, 218-01-9	10	1675	8530	2.54626865671642	1	1	0.0808093523513679
TOXCAST_ACTIVE	OT_ER_ERbERb_1440	3	27.2727272727273	0.129974102328696	56-55-3, 129-00-0, 206-44-0	7	186	1723	3.97004608294931	1	1	0.129974102328696
CTD_CHEMICALS_DISEASES	Shock, Hemorrhagic	3	27.2727272727273	0.166441966912268	129-00-0, 206-44-0, 218-01-9	10	704	8530	3.63494318181818	1	1	0.166441966912268
CTD_CHEMICALS_DISEASES	Respiratory Hypersensitivity	3	27.2727272727273	0.192014313684733	56-55-3, 206-44-0, 218-01-9	10	770	8530	3.32337662337662	1	1	0.192014313684733
CTD_CHEMICALS_DISEASES	Liver Neoplasms	4	36.3636363636364	0.223786456970162	56-55-3, 83-32-9, 206-44-0, 218-01-9	10	1581	8530	2.15812776723593	1	1	0.223786456970162
CTD_CHEMICALS_DISEASES	Mesothelioma	3	27.2727272727273	0.262239529814586	56-55-3, 53-70-3, 218-01-9	10	944	8530	2.71080508474576	1	1	0.262239529814586
CTD_CHEMICALS_DISEASES	Thyroid Neoplasms	3	27.2727272727273	0.335880289441011	56-55-3, 83-32-9, 129-00-0	10	1122	8530	2.2807486631016	1	1	0.335880289441011
TOXCAST_ACTIVE	Tox21_MitochondrialToxicity_ratio	3	27.2727272727273	0.613276243968899	56-55-3, 129-00-0, 206-44-0	7	366	1723	2.0175644028103	1	1	0.613276243968899
CTD_CHEMICALS_DISEASES	Cardiomegaly	3	27.2727272727273	0.630082022029842	83-32-9, 129-00-0, 218-01-9	10	1263	8530	2.02612826603325	1	1	0.630082022029842
CTD_CHEMICALS_DISEASES	Fatty Liver	3	27.2727272727273	0.654837368186469	83-32-9, 129-00-0, 218-01-9	10	1447	8530	1.76848652384243	1	1	0.654837368186469
CTD_CHEMICALS_DISEASES	Liver Neoplasms, Experimental	3	27.2727272727273	0.656360013201798	56-55-3, 83-32-9, 218-01-9	10	1457	8530	1.75634866163349	1	1	0.656360013201798
TOXCAST_ACTIVE	ATG_PXRE_CIS_up	5	45.4545454545455	0.687436654504306	56-55-3, 85-01-8, 83-32-9, 129-00-0, 206-44-0	7	881	1723	1.39695151613426	1	1	0.687436654504306

Annotation Cluster 32	Enrichment Score: 1.07209746389928
Category	Term	Count	%	PValue	CASRNs	List Total	Pop Hits	Pop Total	Fold Enrichment	Bonferroni	Benjamini	FDR
CTD_CHEM2DISEASE	Liver Neoplasms, Experimental	4	36.3636363636364	0.00213090951793363	56-55-3, 129-00-0, 50-32-8, 218-01-9	8	224	5441	12.1450892857143	1	0.856625626209318	0.00213090951793363
CTD_CHEMICALS_DISEASES	Carcinoma, Pancreatic Ductal	4	36.3636363636364	0.00625214424581279	56-55-3, 129-00-0, 53-70-3, 218-01-9	10	385	8530	8.86233766233766	1	1	0.00625214424581279
CTD_CHEMICALS_DISEASES	MELAS Syndrome	4	36.3636363636364	0.0124726155525753	56-55-3, 85-01-8, 129-00-0, 206-44-0	10	494	8530	6.90688259109312	1	1	0.0124726155525753
CTD_CHEMICALS_DISEASES	Hepatitis, Alcoholic	4	36.3636363636364	0.0242576204028539	56-55-3, 85-01-8, 83-32-9, 129-00-0	10	632	8530	5.39873417721519	1	1	0.0242576204028539
CTD_CHEMICALS_DISEASES	Inflammatory Bowel Diseases	4	36.3636363636364	0.0365965470545591	56-55-3, 129-00-0, 120-12-7, 218-01-9	10	739	8530	4.617050067659	1	1	0.0365965470545591
CTD_CHEMICALS_DISEASES	HIV Infections	4	36.3636363636364	0.0411143263159188	56-55-3, 129-00-0, 53-70-3, 191-24-2	10	773	8530	4.41397153945666	1	1	0.0411143263159188
CTD_CHEMICALS_DISEASES	MIGRAINE WITH OR WITHOUT AURA, SUSCEPTIBILITY TO, 1	4	36.3636363636364	0.0429178509269492	56-55-3, 129-00-0, 206-44-0, 218-01-9	10	786	8530	4.34096692111959	1	1	0.0429178509269492
CTD_CHEMICALS_DISEASES	Musculoskeletal Pain	3	27.2727272727273	0.0476286689937421	56-55-3, 129-00-0, 218-01-9	10	341	8530	7.50439882697947	1	1	0.0476286689937421
CTD_CHEMICALS_DISEASES	Hypersensitivity	4	36.3636363636364	0.0560654991308512	56-55-3, 129-00-0, 53-70-3, 120-12-7	10	873	8530	3.90836197021764	1	1	0.0560654991308512
CTD_CHEMICALS_DISEASES	Osteoarthritis	4	36.3636363636364	0.0670967823321621	56-55-3, 85-01-8, 129-00-0, 53-70-3	10	938	8530	3.63752665245203	1	1	0.0670967823321621
CTD_CHEM2DISEASE	Edema	3	27.2727272727273	0.0850043809378351	56-55-3, 129-00-0, 50-32-8	8	391	5441	5.21835038363171	1	1	0.0850043809378351
CTD_CHEM2DISEASE	Prenatal Injuries	2	18.1818181818182	0.12872238909214	56-55-3, 129-00-0	8	106	5441	12.8325471698113	1	1	0.12872238909214
TOXCAST_ACTIVE	OT_ER_ERbERb_1440	3	27.2727272727273	0.129974102328696	56-55-3, 129-00-0, 206-44-0	7	186	1723	3.97004608294931	1	1	0.129974102328696
TOXCAST_ACTIVE	BSK_3C_Proliferation_down	4	36.3636363636364	0.144440962418179	56-55-3, 85-01-8, 129-00-0, 206-44-0	7	403	1723	2.44310528181496	1	1	0.144440962418179
HTS_ACTIVE	cytotoxicity_MMP/inhibition	4	36.3636363636364	0.162512486661459	56-55-3, 129-00-0, 50-32-8, 206-44-0	9	755	4173	2.45651214128035	1	1	0.162512486661459
CTD_CHEM2DISEASE	Abnormalities, Drug-Induced	2	18.1818181818182	0.198279564250426	56-55-3, 129-00-0	8	169	5441	8.04881656804734	1	1	0.198279564250426
CTD_CHEMICALS_DISEASES	Brain Injuries	3	27.2727272727273	0.261006183998182	56-55-3, 129-00-0, 120-12-7	10	941	8530	2.71944739638682	1	1	0.261006183998182
CTD_CHEMICALS_DISEASES	Chloracne	2	18.1818181818182	0.321023052580763	56-55-3, 129-00-0	10	359	8530	4.75208913649025	1	1	0.321023052580763
CTD_CHEMICALS_DISEASES	Thyroid Neoplasms	3	27.2727272727273	0.335880289441011	56-55-3, 83-32-9, 129-00-0	10	1122	8530	2.2807486631016	1	1	0.335880289441011
TOXCAST_ACTIVE	APR_HepG2_MitoMembPot_24h_dn	2	18.1818181818182	0.48672539424856	56-55-3, 129-00-0	7	181	1723	2.71981057616417	1	1	0.48672539424856
TOXCAST_ACTIVE	Tox21_MitochondrialToxicity_ratio	3	27.2727272727273	0.613276243968899	56-55-3, 129-00-0, 206-44-0	7	366	1723	2.0175644028103	1	1	0.613276243968899
CTD_CHEMICALS_DISEASES	Osteosarcoma	2	18.1818181818182	1	56-55-3, 129-00-0	10	1150	8530	1.48347826086957	1	1	1

Annotation Cluster 33	Enrichment Score: 1.04444291698934
Category	Term	Count	%	PValue	CASRNs	List Total	Pop Hits	Pop Total	Fold Enrichment	Bonferroni	Benjamini	FDR
CTD_CHEMICALS_DISEASES	Cecal Neoplasms	5	45.4545454545455	3.30427679482527e-05	85-01-8, 129-00-0, 120-12-7, 206-44-0, 218-01-9	10	199	8530	21.4321608040201	1	0.0141423046818521	3.30427679482527e-05
CTD_CHEMICALS_DISEASES	Uterine Cervical Neoplasms	4	36.3636363636364	0.0176261147308594	56-55-3, 85-01-8, 206-44-0, 218-01-9	10	561	8530	6.08199643493761	1	1	0.0176261147308594
CTD_CHEMICALS_DISEASES	Status Epilepticus	5	45.4545454545455	0.0315607300258116	56-55-3, 85-01-8, 120-12-7, 206-44-0, 218-01-9	10	1253	8530	3.40383080606544	1	1	0.0315607300258116
CTD_CHEMICALS_DISEASES	Myocardial Reperfusion Injury	5	45.4545454545455	0.0324133082386259	85-01-8, 129-00-0, 120-12-7, 206-44-0, 218-01-9	10	1263	8530	3.37688044338876	1	1	0.0324133082386259
CTD_CHEMICALS_DISEASES	Carcinoma, Ductal, Breast	3	27.2727272727273	0.0329682879109437	56-55-3, 85-01-8, 206-44-0	10	279	8530	9.17204301075269	1	1	0.0329682879109437
TOXCAST_ACTIVE	BSK_3C_TissueFactor_down	3	27.2727272727273	0.154424933343467	85-01-8, 120-12-7, 206-44-0	7	206	1723	3.58460471567268	1	1	0.154424933343467
CTD_CHEMICALS_DISEASES	Papilloma	3	27.2727272727273	0.15697318292029	56-55-3, 120-12-7, 206-44-0	10	679	8530	3.76877761413844	1	1	0.15697318292029
CTD_CHEMICALS_DISEASES	Barrett Esophagus	3	27.2727272727273	0.166823403160389	56-55-3, 85-01-8, 218-01-9	10	705	8530	3.62978723404255	1	1	0.166823403160389
MULTICASE_TOX_PREDICTION	ARE activation in keratinocytes at 100uM	7	63.6363636363636	0.174729825180559	56-55-3, 85-01-8, 53-70-3, 120-12-7, 50-32-8, 206-44-0, 218-01-9	10	3313	8032	1.69707214005433	1	1	0.174729825180559
CTD_CHEMICALS_DISEASES	Respiratory Hypersensitivity	3	27.2727272727273	0.192014313684733	56-55-3, 206-44-0, 218-01-9	10	770	8530	3.32337662337662	1	1	0.192014313684733
TOXCAST_ACTIVE	APR_HepG2_CellCycleArrest_72h_dn	3	27.2727272727273	0.194456910104031	56-55-3, 120-12-7, 206-44-0	7	237	1723	3.11573236889693	1	1	0.194456910104031
CTD_CHEMICALS_DISEASES	Lupus Erythematosus, Systemic	3	27.2727272727273	0.199906507181389	56-55-3, 85-01-8, 218-01-9	10	790	8530	3.23924050632911	1	1	0.199906507181389
CTD_CHEMICALS_DISEASES	Hypertension, Pulmonary	3	27.2727272727273	0.216259316457712	56-55-3, 120-12-7, 206-44-0	10	831	8530	3.07942238267148	1	1	0.216259316457712
CTD_CHEMICALS_DISEASES	Tobacco Use Disorder	3	27.2727272727273	0.228353107168394	85-01-8, 120-12-7, 206-44-0	10	861	8530	2.97212543554007	1	1	0.228353107168394
TOXCAST_ACTIVE	Tox21_ERa_LUC_BG1_Agonist	3	27.2727272727273	0.25588015414235	56-55-3, 120-12-7, 206-44-0	7	282	1723	2.61854103343465	1	1	0.25588015414235
TOXCAST_ACTIVE	APR_HepG2_CellLoss_24h_dn	3	27.2727272727273	0.261472967484519	56-55-3, 120-12-7, 206-44-0	7	286	1723	2.58191808191808	1	1	0.261472967484519
TOXCAST_ACTIVE	APR_HepG2_CellLoss_72h_dn	3	27.2727272727273	0.643283797131192	56-55-3, 120-12-7, 206-44-0	7	430	1723	1.71727574750831	1	1	0.643283797131192
CTD_CHEMICALS_DISEASES	Liver Cirrhosis, Experimental	4	36.3636363636364	0.719828606893784	56-55-3, 120-12-7, 206-44-0, 218-01-9	10	2423	8530	1.40817168799009	1	1	0.719828606893784

Annotation Cluster 34	Enrichment Score: 1.02978153747149
Category	Term	Count	%	PValue	CASRNs	List Total	Pop Hits	Pop Total	Fold Enrichment	Bonferroni	Benjamini	FDR
CTD_CHEMICALS_DISEASES	Acid Phosphatase Deficiency	3	27.2727272727273	1.48124094549888e-05	85-01-8, 129-00-0, 120-12-7	10	6	8530	426.5	1	0.00639896088455515	1.48124094549888e-05
CTD_CHEMICALS_DISEASES	Glaucoma 3, primary infantile, B	3	27.2727272727273	0.0111321969088127	83-32-9, 53-70-3, 120-12-7	10	157	8530	16.2993630573248	1	1	0.0111321969088127
CTD_CHEMICALS_DISEASES	Liver Diseases	5	45.4545454545455	0.0427660072190052	85-01-8, 83-32-9, 129-00-0, 53-70-3, 120-12-7	10	1373	8530	3.10633648943918	1	1	0.0427660072190052
CTD_CHEMICALS_DISEASES	Gastroesophageal Reflux	3	27.2727272727273	0.0473753861758162	85-01-8, 83-32-9, 120-12-7	10	340	8530	7.52647058823529	1	1	0.0473753861758162
CTD_CHEMICALS_DISEASES	Bone Resorption	3	27.2727272727273	0.0501903430802688	83-32-9, 129-00-0, 120-12-7	10	351	8530	7.29059829059829	1	1	0.0501903430802688
CTD_CHEMICALS_DISEASES	Diabetes Mellitus	4	36.3636363636364	0.062904930898229	85-01-8, 83-32-9, 129-00-0, 120-12-7	10	914	8530	3.73304157549234	1	1	0.062904930898229
CTD_CHEMICALS_DISEASES	Craniofacial Abnormalities	3	27.2727272727273	0.0706812626860664	85-01-8, 129-00-0, 53-70-3	10	425	8530	6.02117647058824	1	1	0.0706812626860664
CTD_CHEMICALS_DISEASES	Vascular Diseases	3	27.2727272727273	0.119534503557826	85-01-8, 83-32-9, 120-12-7	10	576	8530	4.44270833333333	1	1	0.119534503557826
CTD_CHEMICALS_DISEASES	Lymphoma, T-Cell, Cutaneous	3	27.2727272727273	0.121636788051319	85-01-8, 53-70-3, 120-12-7	10	582	8530	4.39690721649485	1	1	0.121636788051319
CTD_CHEMICALS_DISEASES	Growth Disorders	3	27.2727272727273	0.180294747163775	83-32-9, 53-70-3, 120-12-7	10	740	8530	3.45810810810811	1	1	0.180294747163775
CTD_CHEMICALS_DISEASES	Fever	3	27.2727272727273	0.216660816884384	85-01-8, 83-32-9, 120-12-7	10	832	8530	3.07572115384615	1	1	0.216660816884384
CTD_CHEMICALS_DISEASES	Pneumonia	3	27.2727272727273	0.256898860845331	83-32-9, 129-00-0, 120-12-7	10	931	8530	2.74865735767991	1	1	0.256898860845331
CTD_CHEMICALS_DISEASES	Weight Gain	3	27.2727272727273	0.313507567321241	83-32-9, 53-70-3, 120-12-7	10	1068	8530	2.39606741573034	1	1	0.313507567321241
CTD_CHEMICALS_DISEASES	Cholestasis	3	27.2727272727273	0.342086056329732	129-00-0, 53-70-3, 120-12-7	10	1137	8530	2.25065963060686	1	1	0.342086056329732
CTD_CHEMICALS_DISEASES	Pulmonary Fibrosis	3	27.2727272727273	0.370943760703869	83-32-9, 53-70-3, 120-12-7	10	1207	8530	2.12013256006628	1	1	0.370943760703869
CTD_CHEMICALS_DISEASES	Cell Transformation, Neoplastic	3	27.2727272727273	0.67249613139473	83-32-9, 129-00-0, 120-12-7	10	1558	8530	1.64249037227214	1	1	0.67249613139473
LEADSCOPE_TOXICITY	Genetic Toxicity -SCE in vitro	3	27.2727272727273	1	85-01-8, 83-32-9, 120-12-7	10	1780	7444	1.25460674157303	1	1	1
CTD_CHEMICALS_DISEASES	Breast Neoplasms	3	27.2727272727273	1	85-01-8, 83-32-9, 53-70-3	10	2515	8530	1.01749502982107	1	1	1

Annotation Cluster 35	Enrichment Score: 0.967928026132215
Category	Term	Count	%	PValue	CASRNs	List Total	Pop Hits	Pop Total	Fold Enrichment	Bonferroni	Benjamini	FDR
CTD_CHEMICALS_DISEASES	Common Variable Immunodeficiency	3	27.2727272727273	0.00446284445366068	129-00-0, 120-12-7, 218-01-9	10	98	8530	26.1122448979592	1	1	0.00446284445366068
CTD_CHEM2DISEASE	Kidney Diseases	4	36.3636363636364	0.0236141489826933	85-01-8, 120-12-7, 50-32-8, 218-01-9	8	528	5441	5.15246212121212	1	1	0.0236141489826933
CTD_CHEMICALS_DISEASES	Inflammatory Bowel Diseases	4	36.3636363636364	0.0365965470545591	56-55-3, 129-00-0, 120-12-7, 218-01-9	10	739	8530	4.617050067659	1	1	0.0365965470545591
CTD_CHEMICALS_DISEASES	Polycystic Ovary Syndrome	4	36.3636363636364	0.0590179253583112	56-55-3, 120-12-7, 191-24-2, 218-01-9	10	891	8530	3.8294051627385	1	1	0.0590179253583112
CTD_CHEMICALS_DISEASES	Subarachnoid Hemorrhage	4	36.3636363636364	0.0742009573531017	85-01-8, 129-00-0, 120-12-7, 218-01-9	10	977	8530	3.49232343909928	1	1	0.0742009573531017
CTD_CHEMICALS_DISEASES	Schizophrenia	4	36.3636363636364	0.182956008427525	85-01-8, 53-70-3, 120-12-7, 218-01-9	10	1439	8530	2.37109103544128	1	1	0.182956008427525
CTD_CHEMICALS_DISEASES	Heart Failure	4	36.3636363636364	0.188817685894531	83-32-9, 129-00-0, 120-12-7, 218-01-9	10	1460	8530	2.33698630136986	1	1	0.188817685894531
CTD_CHEMICALS_DISEASES	Astrocytoma	2	18.1818181818182	0.498291732576832	120-12-7, 218-01-9	10	629	8530	2.71224165341812	1	1	0.498291732576832
CTD_CHEMICALS_DISEASES	Liver Cirrhosis, Experimental	4	36.3636363636364	0.719828606893784	56-55-3, 120-12-7, 206-44-0, 218-01-9	10	2423	8530	1.40817168799009	1	1	0.719828606893784
CTD_CHEMICALS_DISEASES	Disease Models, Animal	2	18.1818181818182	1	120-12-7, 218-01-9	10	1416	8530	1.20480225988701	1	1	1

Annotation Cluster 36	Enrichment Score: 0.93464880499206
Category	Term	Count	%	PValue	CASRNs	List Total	Pop Hits	Pop Total	Fold Enrichment	Bonferroni	Benjamini	FDR
CTD_CHEMICALS_DISEASES	Salmonella Infections, Animal	4	36.3636363636364	0.0030024684201317	83-32-9, 129-00-0, 120-12-7, 206-44-0	10	297	8530	11.4882154882155	1	1	0.0030024684201317
CTD_CHEMICALS_DISEASES	Hepatitis, Alcoholic	4	36.3636363636364	0.0242576204028539	56-55-3, 85-01-8, 83-32-9, 129-00-0	10	632	8530	5.39873417721519	1	1	0.0242576204028539
CTD_CHEMICALS_DISEASES	Leishmaniasis, Visceral	4	36.3636363636364	0.0303604658364313	83-32-9, 129-00-0, 120-12-7, 206-44-0	10	688	8530	4.9593023255814	1	1	0.0303604658364313
CTD_CHEMICALS_DISEASES	Bone Resorption	3	27.2727272727273	0.0501903430802688	83-32-9, 129-00-0, 120-12-7	10	351	8530	7.29059829059829	1	1	0.0501903430802688
CTD_CHEMICALS_DISEASES	Keratosis	4	36.3636363636364	0.0570408678767359	85-01-8, 83-32-9, 129-00-0, 206-44-0	10	879	8530	3.88168373151308	1	1	0.0570408678767359
CTD_CHEMICALS_DISEASES	Diabetes Mellitus	4	36.3636363636364	0.062904930898229	85-01-8, 83-32-9, 129-00-0, 120-12-7	10	914	8530	3.73304157549234	1	1	0.062904930898229
TOXCAST_ACTIVE	ATG_RXRb_TRANS_up	4	36.3636363636364	0.0798472184314157	85-01-8, 83-32-9, 129-00-0, 206-44-0	7	317	1723	3.10590356016224	1	1	0.0798472184314157
CTD_CHEMICALS_DISEASES	Heart Failure	4	36.3636363636364	0.188817685894531	83-32-9, 129-00-0, 120-12-7, 218-01-9	10	1460	8530	2.33698630136986	1	1	0.188817685894531
CTD_CHEMICALS_DISEASES	Pneumonia	3	27.2727272727273	0.256898860845331	83-32-9, 129-00-0, 120-12-7	10	931	8530	2.74865735767991	1	1	0.256898860845331
CTD_CHEMICALS_DISEASES	Thyroid Neoplasms	3	27.2727272727273	0.335880289441011	56-55-3, 83-32-9, 129-00-0	10	1122	8530	2.2807486631016	1	1	0.335880289441011
CTD_CHEMICALS_DISEASES	Glioblastoma	2	18.1818181818182	0.571901432281054	83-32-9, 129-00-0	10	767	8530	2.22425032594524	1	1	0.571901432281054
CTD_CHEMICALS_DISEASES	Cardiomegaly	3	27.2727272727273	0.630082022029842	83-32-9, 129-00-0, 218-01-9	10	1263	8530	2.02612826603325	1	1	0.630082022029842
CTD_CHEMICALS_DISEASES	Fatty Liver	3	27.2727272727273	0.654837368186469	83-32-9, 129-00-0, 218-01-9	10	1447	8530	1.76848652384243	1	1	0.654837368186469
CTD_CHEMICALS_DISEASES	Cell Transformation, Neoplastic	3	27.2727272727273	0.67249613139473	83-32-9, 129-00-0, 120-12-7	10	1558	8530	1.64249037227214	1	1	0.67249613139473

Annotation Cluster 37	Enrichment Score: 0.907328615722254
Category	Term	Count	%	PValue	CASRNs	List Total	Pop Hits	Pop Total	Fold Enrichment	Bonferroni	Benjamini	FDR
CTD_CHEMICALS_DISEASES	Acid Phosphatase Deficiency	3	27.2727272727273	1.48124094549888e-05	85-01-8, 129-00-0, 120-12-7	10	6	8530	426.5	1	0.00639896088455515	1.48124094549888e-05
TOXPRINT_STRUCTURE	ring:fused_PAH_pyrene	3	27.2727272727273	3.71505131915305e-05	129-00-0, 50-32-8, 191-24-2	10	9	8337	277.9	1	0.015826118619592	3.71505131915305e-05
CTD_CHEM2DISEASE	Immune System Diseases	3	27.2727272727273	0.00097573533203122	129-00-0, 50-32-8, 218-01-9	8	38	5441	53.6940789473684	1	0.401027221464831	0.00097573533203122
CTD_CHEMICALS_DISEASES	Spherocytosis, Hereditary	3	27.2727272727273	0.00104378054269197	53-70-3, 50-32-8, 191-24-2	10	47	8530	54.4468085106383	1	0.427950022503709	0.00104378054269197
CTD_CHEM2DISEASE	Congenital Abnormalities	3	27.2727272727273	0.00196673204493313	85-01-8, 129-00-0, 50-32-8	8	54	5441	37.7847222222222	1	0.792593014108051	0.00196673204493313
CTD_CHEM2DISEASE	Liver Neoplasms, Experimental	4	36.3636363636364	0.00213090951793363	56-55-3, 129-00-0, 50-32-8, 218-01-9	8	224	5441	12.1450892857143	1	0.856625626209318	0.00213090951793363
CTD_PATHWAY	KEGG:00190|Oxidative phosphorylation	3	27.2727272727273	0.0126424328215557	129-00-0, 50-32-8, 206-44-0	8	99	3849	14.5795454545455	1	1	0.0126424328215557
MESH	Pyrenes	2	18.1818181818182	0.0131432978524386	129-00-0, 50-32-8	10	8	5450	136.25	1	1	0.0131432978524386
CTD_CHEMICALS_DISEASES	Esophageal Squamous Cell Carcinoma	5	45.4545454545455	0.0145592296527602	83-32-9, 129-00-0, 120-12-7, 50-32-8, 191-24-2	10	1000	8530	4.265	1	1	0.0145592296527602
CTD_CHEMICALS_DISEASES	Bronchiectasis	3	27.2727272727273	0.0155509940314743	85-01-8, 129-00-0, 218-01-9	10	187	8530	13.6844919786096	1	1	0.0155509940314743
TOXINS_TARGETS	BE0001111	2	18.1818181818182	0.0278072087512771	85-01-8, 129-00-0	10	11	3520	64	1	1	0.0278072087512771
CTD_CHEM2DISEASE	Necrosis	4	36.3636363636364	0.0313619372463322	129-00-0, 53-70-3, 50-32-8, 218-01-9	8	587	5441	4.63458262350937	1	1	0.0313619372463322
CTD_CHEM2DISEASE	Nervous System Malformations	2	18.1818181818182	0.0429536812591613	129-00-0, 50-32-8	8	34	5441	40.0073529411765	1	1	0.0429536812591613
CTD_CHEM2DISEASE	Abnormalities, Multiple	2	18.1818181818182	0.0540553678994355	85-01-8, 129-00-0	8	43	5441	31.6337209302326	1	1	0.0540553678994355
CTD_PATHWAY	KEGG:00053|Ascorbate and aldarate metabolism	3	27.2727272727273	0.0573854457206732	85-01-8, 129-00-0, 50-32-8	8	222	3849	6.50168918918919	1	1	0.0573854457206732
CTD_PATHWAY	KEGG:05012|Parkinson's disease	3	27.2727272727273	0.0675187204673791	129-00-0, 50-32-8, 206-44-0	8	243	3849	5.93981481481481	1	1	0.0675187204673791
CTD_CHEM2DISEASE	Craniofacial Abnormalities	2	18.1818181818182	0.0698961824046082	85-01-8, 129-00-0	8	56	5441	24.2901785714286	1	1	0.0698961824046082
CTD_CHEMICALS_DISEASES	Craniofacial Abnormalities	3	27.2727272727273	0.0706812626860664	85-01-8, 129-00-0, 53-70-3	10	425	8530	6.02117647058824	1	1	0.0706812626860664
CTD_PATHWAY	KEGG:00040|Pentose and glucuronate interconversions	3	27.2727272727273	0.0710320732305736	85-01-8, 129-00-0, 50-32-8	8	250	3849	5.7735	1	1	0.0710320732305736
CTD_PATHWAY	KEGG:00860|Porphyrin and chlorophyll metabolism	3	27.2727272727273	0.0798317590780795	85-01-8, 129-00-0, 50-32-8	8	267	3849	5.40589887640449	1	1	0.0798317590780795
CTD_CHEM2DISEASE	Heart Defects, Congenital	2	18.1818181818182	0.0831218173460642	129-00-0, 50-32-8	8	67	5441	20.3022388059701	1	1	0.0831218173460642
CTD_CHEM2DISEASE	Edema	3	27.2727272727273	0.0850043809378351	56-55-3, 129-00-0, 50-32-8	8	391	5441	5.21835038363171	1	1	0.0850043809378351
CTD_CHEMICALS_DISEASES	Loeys-Dietz Syndrome	2	18.1818181818182	0.0901192365103538	50-32-8, 191-24-2	10	89	8530	19.1685393258427	1	1	0.0901192365103538
CTD_CHEMICALS_DISEASES	Pleural Diseases	3	27.2727272727273	0.12233991496354	85-01-8, 129-00-0, 218-01-9	10	584	8530	4.38184931506849	1	1	0.12233991496354
CTD_PATHWAY	KEGG:00983|Drug metabolism - other enzymes	3	27.2727272727273	0.146415299751299	85-01-8, 129-00-0, 50-32-8	8	380	3849	3.79835526315789	1	1	0.146415299751299
HTS_ACTIVE	cytotoxicity_MMP/inhibition	4	36.3636363636364	0.162512486661459	56-55-3, 129-00-0, 50-32-8, 206-44-0	9	755	4173	2.45651214128035	1	1	0.162512486661459
CTD_CHEMICALS_DISEASES	Respiratory Distress Syndrome, Adult	3	27.2727272727273	0.164918237164603	85-01-8, 50-32-8, 206-44-0	10	700	8530	3.65571428571429	1	1	0.164918237164603
CTD_CHEMICALS_DISEASES	Adenocarcinoma of Lung	3	27.2727272727273	0.171032253904042	83-32-9, 50-32-8, 191-24-2	10	716	8530	3.57402234636872	1	1	0.171032253904042
TOXCAST_ACTIVE	OT_ER_ERaERb_0480	3	27.2727272727273	0.177390641717901	85-01-8, 129-00-0, 206-44-0	7	224	1723	3.29655612244898	1	1	0.177390641717901
CTD_PATHWAY	KEGG:03010|Ribosome	2	18.1818181818182	0.179226600532983	85-01-8, 50-32-8	8	107	3849	8.99299065420561	1	1	0.179226600532983
CTD_CHEMICALS_DISEASES	Aortic Valve Insufficiency	2	18.1818181818182	0.248182450112441	129-00-0, 191-24-2	10	266	8530	6.41353383458647	1	1	0.248182450112441
TOXINS_TARGETS	BE0003543	2	18.1818181818182	0.268407472839142	129-00-0, 50-32-8	10	120	3520	5.86666666666667	1	1	0.268407472839142
CTD_PATHWAY	KEGG:05145|Toxoplasmosis	2	18.1818181818182	0.268679271701465	129-00-0, 50-32-8	8	1436	3849	0.670090529247911	1	1	0.268679271701465
CTD_PATHWAY	KEGG:00514|Other types of O-glycan biosynthesis	2	18.1818181818182	0.278185350328085	85-01-8, 50-32-8	8	175	3849	5.49857142857143	1	1	0.278185350328085
CTD_CHEMICALS_DISEASES	Amphetamine-Related Disorders	3	27.2727272727273	0.293203180204688	85-01-8, 129-00-0, 218-01-9	10	1019	8530	2.51128557409225	1	1	0.293203180204688
CTD_CHEM2DISEASE	Neoplasms	2	18.1818181818182	0.304590802965827	129-00-0, 50-32-8	8	275	5441	4.94636363636364	1	1	0.304590802965827
CTD_PATHWAY	KEGG:00500|Starch and sucrose metabolism	2	18.1818181818182	0.318478210425066	85-01-8, 50-32-8	8	205	3849	4.69390243902439	1	1	0.318478210425066
CTD_PATHWAY	KEGG:05144|Malaria	4	36.3636363636364	0.387133481369952	129-00-0, 120-12-7, 50-32-8, 206-44-0	8	1006	3849	1.91302186878728	1	1	0.387133481369952
CTD_PATHWAY	KEGG:04612|Antigen processing and presentation	2	18.1818181818182	0.389745507387723	129-00-0, 50-32-8	8	262	3849	3.67270992366412	1	1	0.389745507387723
HTS_ACTIVE	agonism_AR/partial	2	18.1818181818182	0.398877605240494	50-32-8, 191-24-2	9	257	4173	3.6083009079118	1	1	0.398877605240494
CTD_PATHWAY	KEGG:00591|Linoleic acid metabolism	2	18.1818181818182	0.446903664496002	129-00-0, 50-32-8	8	312	3849	3.08413461538462	1	1	0.446903664496002
CTD_CHEMICALS_DISEASES	Malaria	2	18.1818181818182	0.447544208191865	85-01-8, 129-00-0	10	544	8530	3.13602941176471	1	1	0.447544208191865
CTD_CHEMICALS_DISEASES	Radiation Injuries, Experimental	2	18.1818181818182	0.497719659295848	129-00-0, 50-32-8	10	628	8530	2.71656050955414	1	1	0.497719659295848
CTD_CHEMICALS_DISEASES	Crohn Disease	2	18.1818181818182	0.505676160696766	85-01-8, 129-00-0	10	642	8530	2.65732087227414	1	1	0.505676160696766
TOXINS_TARGETS	BE0000956	2	18.1818181818182	0.543014151288898	129-00-0, 50-32-8	10	293	3520	2.40273037542662	1	1	0.543014151288898
CTD_CHEMICALS_DISEASES	Hemolytic-Uremic Syndrome	2	18.1818181818182	0.543277031954032	85-01-8, 129-00-0	10	711	8530	2.39943741209564	1	1	0.543277031954032
CTD_PATHWAY	KEGG:04141|Protein processing in endoplasmic reticulum	2	18.1818181818182	0.558536330428943	129-00-0, 50-32-8	8	424	3849	2.26945754716981	1	1	0.558536330428943
CTD_CHEMICALS_DISEASES	Osteoporosis	2	18.1818181818182	0.564395020626945	85-01-8, 129-00-0	10	752	8530	2.2686170212766	1	1	0.564395020626945
CTD_CHEMICALS_DISEASES	Abortion, Spontaneous	2	18.1818181818182	0.577332830179072	129-00-0, 191-24-2	10	778	8530	2.19280205655527	1	1	0.577332830179072
CTD_CHEMICALS_DISEASES	Diabetic Neuropathies	2	18.1818181818182	0.594682651038969	85-01-8, 129-00-0	10	814	8530	2.0958230958231	1	1	0.594682651038969
CTD_CHEMICALS_DISEASES	Occupational Diseases	2	18.1818181818182	0.605433006902818	129-00-0, 191-24-2	10	837	8530	2.03823178016726	1	1	0.605433006902818
CTD_PATHWAY	KEGG:05143|African trypanosomiasis	3	27.2727272727273	0.665735416775702	129-00-0, 50-32-8, 206-44-0	8	890	3849	1.62176966292135	1	1	0.665735416775702
CTD_PATHWAY	KEGG:05010|Alzheimer's disease	2	18.1818181818182	0.685225914501366	129-00-0, 50-32-8	8	994	3849	0.968058350100604	1	1	0.685225914501366
HTS_ACTIVE	cytotoxicity_RXR/agonism	4	36.3636363636364	0.698422986144893	85-01-8, 129-00-0, 50-32-8, 206-44-0	9	1213	4173	1.52899148117615	1	1	0.698422986144893
CTD_PATHWAY	KEGG:05330|Allograft rejection	2	18.1818181818182	1	129-00-0, 50-32-8	8	505	3849	1.90544554455446	1	1	1
CTD_CHEMICALS_DISEASES	Drug-Related Side Effects and Adverse Reactions	2	18.1818181818182	1	85-01-8, 129-00-0	10	1632	8530	1.0453431372549	1	1	1
CTD_CHEMICALS_DISEASES	Neoplasms, Experimental	2	18.1818181818182	1	85-01-8, 129-00-0	10	916	8530	1.86244541484716	1	1	1
CTD_PATHWAY	KEGG:04650|Natural killer cell mediated cytotoxicity	2	18.1818181818182	1	129-00-0, 50-32-8	8	788	3849	1.22112944162437	1	1	1
CTD_PATHWAY	KEGG:05016|Huntington's disease	2	18.1818181818182	1	129-00-0, 50-32-8	8	654	3849	1.47133027522936	1	1	1
CTD_CHEMICALS_DISEASES	Hyperalgesia	2	18.1818181818182	1	85-01-8, 50-32-8	10	1311	8530	1.30129672006102	1	1	1
CTD_CHEM2DISEASE	Drug-Induced Liver Injury	2	18.1818181818182	1	85-01-8, 50-32-8	8	836	5441	1.62709330143541	1	1	1
CTD_CHEMICALS_DISEASES	Hepatomegaly	2	18.1818181818182	1	85-01-8, 129-00-0	10	1278	8530	1.33489827856025	1	1	1
CTD_PATHWAY	KEGG:05416|Viral myocarditis	2	18.1818181818182	1	129-00-0, 50-32-8	8	522	3849	1.8433908045977	1	1	1
CTD_CHEMICALS_DISEASES	Necrosis	2	18.1818181818182	1	85-01-8, 50-32-8	10	1533	8530	1.11285061969993	1	1	1

Annotation Cluster 38	Enrichment Score: 0.890580709278992
Category	Term	Count	%	PValue	CASRNs	List Total	Pop Hits	Pop Total	Fold Enrichment	Bonferroni	Benjamini	FDR
CTD_CHEMICALS_DISEASES	Bronchiectasis	3	27.2727272727273	0.0155509940314743	85-01-8, 129-00-0, 218-01-9	10	187	8530	13.6844919786096	1	1	0.0155509940314743
CTD_CHEMICALS_DISEASES	Uterine Cervical Neoplasms	4	36.3636363636364	0.0176261147308594	56-55-3, 85-01-8, 206-44-0, 218-01-9	10	561	8530	6.08199643493761	1	1	0.0176261147308594
CTD_CHEM2DISEASE	Kidney Diseases	4	36.3636363636364	0.0236141489826933	85-01-8, 120-12-7, 50-32-8, 218-01-9	8	528	5441	5.15246212121212	1	1	0.0236141489826933
MESH	Phenanthrenes	2	18.1818181818182	0.042155871082203	85-01-8, 218-01-9	10	26	5450	41.9230769230769	1	1	0.042155871082203
CTD_CHEMICALS_DISEASES	Neoplasm Recurrence, Local	4	36.3636363636364	0.0520963047169056	85-01-8, 129-00-0, 53-70-3, 218-01-9	10	848	8530	4.02358490566038	1	1	0.0520963047169056
CTD_CHEMICALS_DISEASES	Subarachnoid Hemorrhage	4	36.3636363636364	0.0742009573531017	85-01-8, 129-00-0, 120-12-7, 218-01-9	10	977	8530	3.49232343909928	1	1	0.0742009573531017
CTD_CHEMICALS_DISEASES	Psoriasis	4	36.3636363636364	0.0991187969560934	85-01-8, 129-00-0, 206-44-0, 218-01-9	10	1101	8530	3.09900090826521	1	1	0.0991187969560934
CTD_CHEMICALS_DISEASES	Pleural Diseases	3	27.2727272727273	0.12233991496354	85-01-8, 129-00-0, 218-01-9	10	584	8530	4.38184931506849	1	1	0.12233991496354
CTD_CHEMICALS_DISEASES	Barrett Esophagus	3	27.2727272727273	0.166823403160389	56-55-3, 85-01-8, 218-01-9	10	705	8530	3.62978723404255	1	1	0.166823403160389
CTD_CHEMICALS_DISEASES	Leukemia	3	27.2727272727273	0.176808931941653	85-01-8, 53-70-3, 218-01-9	10	731	8530	3.50068399452804	1	1	0.176808931941653
CTD_CHEMICALS_DISEASES	Schizophrenia	4	36.3636363636364	0.182956008427525	85-01-8, 53-70-3, 120-12-7, 218-01-9	10	1439	8530	2.37109103544128	1	1	0.182956008427525
CTD_CHEMICALS_DISEASES	Lupus Erythematosus, Systemic	3	27.2727272727273	0.199906507181389	56-55-3, 85-01-8, 218-01-9	10	790	8530	3.23924050632911	1	1	0.199906507181389
CTD_CHEMICALS_DISEASES	Lichenoid Eruptions	2	18.1818181818182	0.277163712558962	85-01-8, 218-01-9	10	302	8530	5.64900662251656	1	1	0.277163712558962
CTD_CHEMICALS_DISEASES	Amphetamine-Related Disorders	3	27.2727272727273	0.293203180204688	85-01-8, 129-00-0, 218-01-9	10	1019	8530	2.51128557409225	1	1	0.293203180204688
CTD_CHEMICALS_DISEASES	HIV Wasting Syndrome	2	18.1818181818182	0.32027445616685	85-01-8, 218-01-9	10	358	8530	4.76536312849162	1	1	0.32027445616685
CTD_CHEMICALS_DISEASES	Neuroblastoma	2	18.1818181818182	0.589927938479228	85-01-8, 218-01-9	10	804	8530	2.12189054726368	1	1	0.589927938479228
CTD_CHEMICALS_DISEASES	Infarction, Middle Cerebral Artery	2	18.1818181818182	0.610940639299149	85-01-8, 218-01-9	10	849	8530	2.00942285041225	1	1	0.610940639299149
CTD_CHEMICALS_DISEASES	Carcinoma, Hepatocellular	4	36.3636363636364	0.720280042241255	85-01-8, 83-32-9, 206-44-0, 218-01-9	10	2428	8530	1.40527182866557	1	1	0.720280042241255

Annotation Cluster 39	Enrichment Score: 0.876394243354993
Category	Term	Count	%	PValue	CASRNs	List Total	Pop Hits	Pop Total	Fold Enrichment	Bonferroni	Benjamini	FDR
CTD_CHEMICALS_DISEASES	Carcinoma, Pancreatic Ductal	4	36.3636363636364	0.00625214424581279	56-55-3, 129-00-0, 53-70-3, 218-01-9	10	385	8530	8.86233766233766	1	1	0.00625214424581279
CTD_CHEM2DISEASE	Necrosis	4	36.3636363636364	0.0313619372463322	129-00-0, 53-70-3, 50-32-8, 218-01-9	8	587	5441	4.63458262350937	1	1	0.0313619372463322
CTD_CHEMICALS_DISEASES	HIV Infections	4	36.3636363636364	0.0411143263159188	56-55-3, 129-00-0, 53-70-3, 191-24-2	10	773	8530	4.41397153945666	1	1	0.0411143263159188
CTD_CHEMICALS_DISEASES	Neoplasm Recurrence, Local	4	36.3636363636364	0.0520963047169056	85-01-8, 129-00-0, 53-70-3, 218-01-9	10	848	8530	4.02358490566038	1	1	0.0520963047169056
CTD_CHEMICALS_DISEASES	Hypersensitivity	4	36.3636363636364	0.0560654991308512	56-55-3, 129-00-0, 53-70-3, 120-12-7	10	873	8530	3.90836197021764	1	1	0.0560654991308512
CTD_CHEMICALS_DISEASES	Osteoarthritis	4	36.3636363636364	0.0670967823321621	56-55-3, 85-01-8, 129-00-0, 53-70-3	10	938	8530	3.63752665245203	1	1	0.0670967823321621
CTD_CHEMICALS_DISEASES	Asbestosis	3	27.2727272727273	0.0677625988799753	129-00-0, 53-70-3, 206-44-0	10	415	8530	6.16626506024096	1	1	0.0677625988799753
CTD_CHEMICALS_DISEASES	Craniofacial Abnormalities	3	27.2727272727273	0.0706812626860664	85-01-8, 129-00-0, 53-70-3	10	425	8530	6.02117647058824	1	1	0.0706812626860664
CTD_CHEMICALS_DISEASES	Multiple Myeloma	3	27.2727272727273	0.242984082478121	129-00-0, 53-70-3, 206-44-0	10	897	8530	2.85284280936455	1	1	0.242984082478121
CTD_CHEMICALS_DISEASES	Cholestasis	3	27.2727272727273	0.342086056329732	129-00-0, 53-70-3, 120-12-7	10	1137	8530	2.25065963060686	1	1	0.342086056329732
CTD_CHEMICALS_DISEASES	Parkinson Disease	4	36.3636363636364	0.382515735612742	129-00-0, 53-70-3, 206-44-0, 218-01-9	10	1590	8530	2.14591194968554	1	1	0.382515735612742
CTD_CHEMICALS_DISEASES	Recurrence	2	18.1818181818182	0.439393365205156	129-00-0, 53-70-3	10	531	8530	3.21280602636535	1	1	0.439393365205156
CTD_CHEMICALS_DISEASES	Acute Kidney Injury	3	27.2727272727273	0.675999919190567	129-00-0, 53-70-3, 206-44-0	10	1579	8530	1.62064597846738	1	1	0.675999919190567
CTD_CHEMICALS_DISEASES	Kidney Neoplasms	2	18.1818181818182	1	129-00-0, 53-70-3	10	1060	8530	1.60943396226415	1	1	1
PHARMACTIONLIST	Chemical Actions and Uses	3	27.2727272727273	1	129-00-0, 53-70-3, 206-44-0	3	2720	2720	1	1	1	1

Annotation Cluster 40	Enrichment Score: 0.867606976599151
Category	Term	Count	%	PValue	CASRNs	List Total	Pop Hits	Pop Total	Fold Enrichment	Bonferroni	Benjamini	FDR
CTD_CHEMICALS_DISEASES	MELAS Syndrome	4	36.3636363636364	0.0124726155525753	56-55-3, 85-01-8, 129-00-0, 206-44-0	10	494	8530	6.90688259109312	1	1	0.0124726155525753
CTD_CHEMICALS_DISEASES	Uterine Cervical Neoplasms	4	36.3636363636364	0.0176261147308594	56-55-3, 85-01-8, 206-44-0, 218-01-9	10	561	8530	6.08199643493761	1	1	0.0176261147308594
CTD_CHEMICALS_DISEASES	Carcinoma, Ductal, Breast	3	27.2727272727273	0.0329682879109437	56-55-3, 85-01-8, 206-44-0	10	279	8530	9.17204301075269	1	1	0.0329682879109437
CTD_CHEMICALS_DISEASES	Lung Diseases	4	36.3636363636364	0.0528778761421798	85-01-8, 53-70-3, 120-12-7, 206-44-0	10	853	8530	4	1	1	0.0528778761421798
CTD_CHEMICALS_DISEASES	Keratosis	4	36.3636363636364	0.0570408678767359	85-01-8, 83-32-9, 129-00-0, 206-44-0	10	879	8530	3.88168373151308	1	1	0.0570408678767359
CTD_CHEMICALS_DISEASES	Dermatitis, Allergic Contact	4	36.3636363636364	0.0728994138136532	85-01-8, 53-70-3, 120-12-7, 206-44-0	10	970	8530	3.51752577319588	1	1	0.0728994138136532
TOXCAST_ACTIVE	ATG_RXRb_TRANS_up	4	36.3636363636364	0.0798472184314157	85-01-8, 83-32-9, 129-00-0, 206-44-0	7	317	1723	3.10590356016224	1	1	0.0798472184314157
CTD_CHEMICALS_DISEASES	Psoriasis	4	36.3636363636364	0.0991187969560934	85-01-8, 129-00-0, 206-44-0, 218-01-9	10	1101	8530	3.09900090826521	1	1	0.0991187969560934
TOXCAST_ACTIVE	BSK_3C_Proliferation_down	4	36.3636363636364	0.144440962418179	56-55-3, 85-01-8, 129-00-0, 206-44-0	7	403	1723	2.44310528181496	1	1	0.144440962418179
TOXCAST_ACTIVE	BSK_3C_TissueFactor_down	3	27.2727272727273	0.154424933343467	85-01-8, 120-12-7, 206-44-0	7	206	1723	3.58460471567268	1	1	0.154424933343467
CTD_CHEMICALS_DISEASES	Respiratory Distress Syndrome, Adult	3	27.2727272727273	0.164918237164603	85-01-8, 50-32-8, 206-44-0	10	700	8530	3.65571428571429	1	1	0.164918237164603
TOXCAST_ACTIVE	OT_ER_ERaERb_0480	3	27.2727272727273	0.177390641717901	85-01-8, 129-00-0, 206-44-0	7	224	1723	3.29655612244898	1	1	0.177390641717901
CTD_CHEMICALS_DISEASES	Tobacco Use Disorder	3	27.2727272727273	0.228353107168394	85-01-8, 120-12-7, 206-44-0	10	861	8530	2.97212543554007	1	1	0.228353107168394
CTD_CHEMICALS_DISEASES	Adrenal Gland Neoplasms	2	18.1818181818182	0.255522945208953	85-01-8, 206-44-0	10	275	8530	6.20363636363636	1	1	0.255522945208953
HTS_ACTIVE	cytotoxicity_RXR/agonism	4	36.3636363636364	0.698422986144893	85-01-8, 129-00-0, 50-32-8, 206-44-0	9	1213	4173	1.52899148117615	1	1	0.698422986144893
CTD_CHEMICALS_DISEASES	Carcinoma, Hepatocellular	4	36.3636363636364	0.720280042241255	85-01-8, 83-32-9, 206-44-0, 218-01-9	10	2428	8530	1.40527182866557	1	1	0.720280042241255
CTD_CHEMICALS_DISEASES	Skin Neoplasms	2	18.1818181818182	1	85-01-8, 206-44-0	10	1169	8530	1.45936698032506	1	1	1
CTD_CHEMICALS_DISEASES	Prostatic Neoplasms	4	36.3636363636364	1	56-55-3, 85-01-8, 53-70-3, 206-44-0	10	2979	8530	1.14535078885532	1	1	1

Annotation Cluster 41	Enrichment Score: 0.859015212714438
Category	Term	Count	%	PValue	CASRNs	List Total	Pop Hits	Pop Total	Fold Enrichment	Bonferroni	Benjamini	FDR
CTD_CHEMICALS_DISEASES	MELAS Syndrome	4	36.3636363636364	0.0124726155525753	56-55-3, 85-01-8, 129-00-0, 206-44-0	10	494	8530	6.90688259109312	1	1	0.0124726155525753
CTD_CHEMICALS_DISEASES	Uterine Cervical Neoplasms	4	36.3636363636364	0.0176261147308594	56-55-3, 85-01-8, 206-44-0, 218-01-9	10	561	8530	6.08199643493761	1	1	0.0176261147308594
CTD_CHEMICALS_DISEASES	Hepatitis, Alcoholic	4	36.3636363636364	0.0242576204028539	56-55-3, 85-01-8, 83-32-9, 129-00-0	10	632	8530	5.39873417721519	1	1	0.0242576204028539
CTD_CHEMICALS_DISEASES	Carcinoma, Ductal, Breast	3	27.2727272727273	0.0329682879109437	56-55-3, 85-01-8, 206-44-0	10	279	8530	9.17204301075269	1	1	0.0329682879109437
CTD_CHEM2DISEASE	Cardiovascular Abnormalities	2	18.1818181818182	0.039228389203514	56-55-3, 85-01-8	8	31	5441	43.8790322580645	1	1	0.039228389203514
CTD_CHEMICALS_DISEASES	Nasopharyngeal Carcinoma	3	27.2727272727273	0.0565471056732694	56-55-3, 85-01-8, 53-70-3	10	375	8530	6.824	1	1	0.0565471056732694
CTD_CHEMICALS_DISEASES	Osteoarthritis	4	36.3636363636364	0.0670967823321621	56-55-3, 85-01-8, 129-00-0, 53-70-3	10	938	8530	3.63752665245203	1	1	0.0670967823321621
TOXCAST_ACTIVE	BSK_3C_Proliferation_down	4	36.3636363636364	0.144440962418179	56-55-3, 85-01-8, 129-00-0, 206-44-0	7	403	1723	2.44310528181496	1	1	0.144440962418179
CTD_CHEMICALS_DISEASES	Barrett Esophagus	3	27.2727272727273	0.166823403160389	56-55-3, 85-01-8, 218-01-9	10	705	8530	3.62978723404255	1	1	0.166823403160389
CTD_CHEMICALS_DISEASES	Lupus Erythematosus, Systemic	3	27.2727272727273	0.199906507181389	56-55-3, 85-01-8, 218-01-9	10	790	8530	3.23924050632911	1	1	0.199906507181389
CTD_CHEMICALS_DISEASES	Mitochondrial Myopathies	2	18.1818181818182	0.321023052580763	56-55-3, 85-01-8	10	359	8530	4.75208913649025	1	1	0.321023052580763
CTD_CHEMICALS_DISEASES	Leukemia-Lymphoma, Adult T-Cell	2	18.1818181818182	0.352527601086329	56-55-3, 85-01-8	10	402	8530	4.24378109452736	1	1	0.352527601086329
CTD_CHEMICALS_DISEASES	Hepatitis, Autoimmune	2	18.1818181818182	0.400371969452248	56-55-3, 85-01-8	10	471	8530	3.62208067940552	1	1	0.400371969452248
TOXINS_TARGETS	BE0000123	4	36.3636363636364	0.436518670567954	56-55-3, 85-01-8, 53-70-3, 50-32-8	10	806	3520	1.7468982630273	1	1	0.436518670567954
CTD_CHEMICALS_DISEASES	Prostatic Neoplasms	4	36.3636363636364	1	56-55-3, 85-01-8, 53-70-3, 206-44-0	10	2979	8530	1.14535078885532	1	1	1
CTD_CHEMICALS_DISEASES	Wounds and Injuries	2	18.1818181818182	1	56-55-3, 85-01-8	10	893	8530	1.91041433370661	1	1	1
CTD_CHEMICALS_DISEASES	Genetic Predisposition to Disease	2	18.1818181818182	1	56-55-3, 85-01-8	10	859	8530	1.9860302677532	1	1	1

Annotation Cluster 42	Enrichment Score: 0.835767523938347
Category	Term	Count	%	PValue	CASRNs	List Total	Pop Hits	Pop Total	Fold Enrichment	Bonferroni	Benjamini	FDR
CTD_CHEMICALS_DISEASES	Salmonella Infections, Animal	4	36.3636363636364	0.0030024684201317	83-32-9, 129-00-0, 120-12-7, 206-44-0	10	297	8530	11.4882154882155	1	1	0.0030024684201317
TOXPRINT_STRUCTURE	ring:fused_PAH_acenaphthylene	2	18.1818181818182	0.0107487338058778	83-32-9, 206-44-0	10	10	8337	166.74	1	1	0.0107487338058778
CTD_CHEMICALS_DISEASES	COVID-19	4	36.3636363636364	0.0228528205999287	56-55-3, 83-32-9, 120-12-7, 206-44-0	10	618	8530	5.5210355987055	1	1	0.0228528205999287
CTD_CHEMICALS_DISEASES	Leishmaniasis, Visceral	4	36.3636363636364	0.0303604658364313	83-32-9, 129-00-0, 120-12-7, 206-44-0	10	688	8530	4.9593023255814	1	1	0.0303604658364313
CTD_CHEMICALS_DISEASES	Keratosis	4	36.3636363636364	0.0570408678767359	85-01-8, 83-32-9, 129-00-0, 206-44-0	10	879	8530	3.88168373151308	1	1	0.0570408678767359
TOXCAST_ACTIVE	ATG_RXRb_TRANS_up	4	36.3636363636364	0.0798472184314157	85-01-8, 83-32-9, 129-00-0, 206-44-0	7	317	1723	3.10590356016224	1	1	0.0798472184314157
MULTICASE_TOX_PREDICTION	Human volume of distribution (L/kg)	2	18.1818181818182	0.0899835202104833	83-32-9, 206-44-0	10	3340	8032	0.480958083832335	1	1	0.0899835202104833
CTD_CHEMICALS_DISEASES	Arthritis, Psoriatic	3	27.2727272727273	0.136276999402798	83-32-9, 120-12-7, 206-44-0	10	623	8530	4.10754414125201	1	1	0.136276999402798
CTD_CHEMICALS_DISEASES	Insulin Resistance	4	36.3636363636364	0.140878430714406	83-32-9, 53-70-3, 120-12-7, 206-44-0	10	1280	8530	2.665625	1	1	0.140878430714406
CTD_CHEMICALS_DISEASES	Cardiotoxicity	3	27.2727272727273	0.148753429443634	83-32-9, 120-12-7, 206-44-0	10	657	8530	3.89497716894977	1	1	0.148753429443634
CTD_CHEMICALS_DISEASES	Liver Neoplasms	4	36.3636363636364	0.223786456970162	56-55-3, 83-32-9, 206-44-0, 218-01-9	10	1581	8530	2.15812776723593	1	1	0.223786456970162
MULTICASE_TOX_PREDICTION	RCA survival pre-implantation, mouse	2	18.1818181818182	0.250386685897428	83-32-9, 206-44-0	10	253	8032	6.34940711462451	1	1	0.250386685897428
CTD_CHEMICALS_DISEASES	Inflammation	4	36.3636363636364	0.388050053679453	83-32-9, 120-12-7, 50-32-8, 206-44-0	10	1643	8530	2.07668898356665	1	1	0.388050053679453
CTD_CHEMICALS_DISEASES	Heart Defects, Congenital	2	18.1818181818182	0.392284187411397	83-32-9, 206-44-0	10	459	8530	3.71677559912854	1	1	0.392284187411397
CTD_CHEMICALS_DISEASES	Pneumonia, Pneumococcal	2	18.1818181818182	0.467160789434157	83-32-9, 206-44-0	10	576	8530	2.96180555555556	1	1	0.467160789434157
MULTICASE_TOX_PREDICTION	RCA fetal weight decrease, mouse	2	18.1818181818182	0.478986404467199	83-32-9, 206-44-0	10	561	8032	2.86345811051693	1	1	0.478986404467199
MULTICASE_TOX_PREDICTION	RCA survival post-implantation, mouse	2	18.1818181818182	0.534561946509471	83-32-9, 206-44-0	10	654	8032	2.45626911314985	1	1	0.534561946509471
CTD_CHEMICALS_DISEASES	Carcinoma, Hepatocellular	4	36.3636363636364	0.720280042241255	85-01-8, 83-32-9, 206-44-0, 218-01-9	10	2428	8530	1.40527182866557	1	1	0.720280042241255
MULTICASE_TOX_PREDICTION	BSEP inhibition at 10uM	2	18.1818181818182	1	83-32-9, 206-44-0	10	1427	8032	1.12571829011913	1	1	1
CTD_CHEMICALS_DISEASES	Metabolic Syndrome	2	18.1818181818182	1	83-32-9, 206-44-0	10	867	8530	1.9677047289504	1	1	1

Annotation Cluster 43	Enrichment Score: 0.807211839730706
Category	Term	Count	%	PValue	CASRNs	List Total	Pop Hits	Pop Total	Fold Enrichment	Bonferroni	Benjamini	FDR
HTS_ACTIVE	activation_EndoRS	4	36.3636363636364	0.000328932112757107	53-70-3, 120-12-7, 206-44-0, 191-24-2	9	78	4173	23.7777777777778	1	0.136835758906957	0.000328932112757107
CTD_CHEMICALS_DISEASES	Salmonella Infections, Animal	4	36.3636363636364	0.0030024684201317	83-32-9, 129-00-0, 120-12-7, 206-44-0	10	297	8530	11.4882154882155	1	1	0.0030024684201317
CTD_CHEMICALS_DISEASES	COVID-19	4	36.3636363636364	0.0228528205999287	56-55-3, 83-32-9, 120-12-7, 206-44-0	10	618	8530	5.5210355987055	1	1	0.0228528205999287
CTD_CHEMICALS_DISEASES	Leishmaniasis, Visceral	4	36.3636363636364	0.0303604658364313	83-32-9, 129-00-0, 120-12-7, 206-44-0	10	688	8530	4.9593023255814	1	1	0.0303604658364313
CTD_CHEMICALS_DISEASES	Lung Diseases	4	36.3636363636364	0.0528778761421798	85-01-8, 53-70-3, 120-12-7, 206-44-0	10	853	8530	4	1	1	0.0528778761421798
CTD_CHEMICALS_DISEASES	Dermatitis, Allergic Contact	4	36.3636363636364	0.0728994138136532	85-01-8, 53-70-3, 120-12-7, 206-44-0	10	970	8530	3.51752577319588	1	1	0.0728994138136532
CTD_CHEMICALS_DISEASES	Arthritis, Psoriatic	3	27.2727272727273	0.136276999402798	83-32-9, 120-12-7, 206-44-0	10	623	8530	4.10754414125201	1	1	0.136276999402798
CTD_CHEMICALS_DISEASES	Insulin Resistance	4	36.3636363636364	0.140878430714406	83-32-9, 53-70-3, 120-12-7, 206-44-0	10	1280	8530	2.665625	1	1	0.140878430714406
CTD_CHEMICALS_DISEASES	Cardiotoxicity	3	27.2727272727273	0.148753429443634	83-32-9, 120-12-7, 206-44-0	10	657	8530	3.89497716894977	1	1	0.148753429443634
TOXCAST_ACTIVE	BSK_3C_TissueFactor_down	3	27.2727272727273	0.154424933343467	85-01-8, 120-12-7, 206-44-0	7	206	1723	3.58460471567268	1	1	0.154424933343467
CTD_CHEMICALS_DISEASES	Papilloma	3	27.2727272727273	0.15697318292029	56-55-3, 120-12-7, 206-44-0	10	679	8530	3.76877761413844	1	1	0.15697318292029
TOXCAST_ACTIVE	APR_HepG2_OxidativeStress_72h_up	3	27.2727272727273	0.189166768409049	129-00-0, 120-12-7, 206-44-0	7	233	1723	3.16922133660331	1	1	0.189166768409049
TOXCAST_ACTIVE	APR_HepG2_CellCycleArrest_72h_dn	3	27.2727272727273	0.194456910104031	56-55-3, 120-12-7, 206-44-0	7	237	1723	3.11573236889693	1	1	0.194456910104031
CTD_CHEMICALS_DISEASES	Hypertension, Pulmonary	3	27.2727272727273	0.216259316457712	56-55-3, 120-12-7, 206-44-0	10	831	8530	3.07942238267148	1	1	0.216259316457712
CTD_CHEMICALS_DISEASES	Tobacco Use Disorder	3	27.2727272727273	0.228353107168394	85-01-8, 120-12-7, 206-44-0	10	861	8530	2.97212543554007	1	1	0.228353107168394
CTD_CHEMICALS_DISEASES	Breast Neoplasms, Male	2	18.1818181818182	0.242428771439614	120-12-7, 206-44-0	10	259	8530	6.58687258687259	1	1	0.242428771439614
TOXCAST_ACTIVE	Tox21_ERa_LUC_BG1_Agonist	3	27.2727272727273	0.25588015414235	56-55-3, 120-12-7, 206-44-0	7	282	1723	2.61854103343465	1	1	0.25588015414235
TOXCAST_ACTIVE	APR_HepG2_CellLoss_24h_dn	3	27.2727272727273	0.261472967484519	56-55-3, 120-12-7, 206-44-0	7	286	1723	2.58191808191808	1	1	0.261472967484519
TOXCAST_ACTIVE	Tox21_ESRE_BLA_ratio	2	18.1818181818182	0.304403341271129	120-12-7, 206-44-0	7	101	1723	4.87411598302687	1	1	0.304403341271129
CTD_CHEMICALS_DISEASES	Sepsis	3	27.2727272727273	0.313507567321241	129-00-0, 120-12-7, 206-44-0	10	1068	8530	2.39606741573034	1	1	0.313507567321241
CTD_PATHWAY	KEGG:05144|Malaria	4	36.3636363636364	0.387133481369952	129-00-0, 120-12-7, 50-32-8, 206-44-0	8	1006	3849	1.91302186878728	1	1	0.387133481369952
CTD_CHEMICALS_DISEASES	Inflammation	4	36.3636363636364	0.388050053679453	83-32-9, 120-12-7, 50-32-8, 206-44-0	10	1643	8530	2.07668898356665	1	1	0.388050053679453
TOXCAST_ACTIVE	APR_HepG2_CellLoss_72h_dn	3	27.2727272727273	0.643283797131192	56-55-3, 120-12-7, 206-44-0	7	430	1723	1.71727574750831	1	1	0.643283797131192
CTD_PATHWAY	KEGG:04620|Toll-like receptor signaling pathway	4	36.3636363636364	0.699174155964701	56-55-3, 120-12-7, 50-32-8, 206-44-0	8	1333	3849	1.4437359339835	1	1	0.699174155964701
CTD_CHEMICALS_DISEASES	Liver Cirrhosis, Experimental	4	36.3636363636364	0.719828606893784	56-55-3, 120-12-7, 206-44-0, 218-01-9	10	2423	8530	1.40817168799009	1	1	0.719828606893784
CTD_PATHWAY	KEGG:05142|Chagas disease (American trypanosomiasis)	4	36.3636363636364	1	56-55-3, 120-12-7, 50-32-8, 206-44-0	8	1545	3849	1.24563106796117	1	1	1
CTD_CHEMICALS_DISEASES	Skin Diseases	2	18.1818181818182	1	120-12-7, 206-44-0	10	934	8530	1.82655246252677	1	1	1
CTD_CHEMICALS_DISEASES	Stroke	2	18.1818181818182	1	120-12-7, 206-44-0	10	1044	8530	1.63409961685824	1	1	1

Annotation Cluster 44	Enrichment Score: 0.802894176880108
Category	Term	Count	%	PValue	CASRNs	List Total	Pop Hits	Pop Total	Fold Enrichment	Bonferroni	Benjamini	FDR
CTD_CHEMICALS_DISEASES	Acid Phosphatase Deficiency	3	27.2727272727273	1.48124094549888e-05	85-01-8, 129-00-0, 120-12-7	10	6	8530	426.5	1	0.00639896088455515	1.48124094549888e-05
LEADSCOPE_TOXICITY	Genetic Toxicity -UDS rat hepatocytes	5	45.4545454545455	0.000224560809570683	56-55-3, 83-32-9, 53-70-3, 120-12-7, 50-32-8	10	284	7444	13.1056338028169	1	0.0940909792101163	0.000224560809570683
CTD_CHEMICALS_DISEASES	Salmonella Infections, Animal	4	36.3636363636364	0.0030024684201317	83-32-9, 129-00-0, 120-12-7, 206-44-0	10	297	8530	11.4882154882155	1	1	0.0030024684201317
CTD_CHEMICALS_DISEASES	Common Variable Immunodeficiency	3	27.2727272727273	0.00446284445366068	129-00-0, 120-12-7, 218-01-9	10	98	8530	26.1122448979592	1	1	0.00446284445366068
CTD_CHEMICALS_DISEASES	Glaucoma 3, primary infantile, B	3	27.2727272727273	0.0111321969088127	83-32-9, 53-70-3, 120-12-7	10	157	8530	16.2993630573248	1	1	0.0111321969088127
CTD_CHEMICALS_DISEASES	Esophageal Squamous Cell Carcinoma	5	45.4545454545455	0.0145592296527602	83-32-9, 129-00-0, 120-12-7, 50-32-8, 191-24-2	10	1000	8530	4.265	1	1	0.0145592296527602
CTD_CHEMICALS_DISEASES	COVID-19	4	36.3636363636364	0.0228528205999287	56-55-3, 83-32-9, 120-12-7, 206-44-0	10	618	8530	5.5210355987055	1	1	0.0228528205999287
CTD_CHEMICALS_DISEASES	Leishmaniasis, Visceral	4	36.3636363636364	0.0303604658364313	83-32-9, 129-00-0, 120-12-7, 206-44-0	10	688	8530	4.9593023255814	1	1	0.0303604658364313
CTD_CHEMICALS_DISEASES	Precancerous Conditions	5	45.4545454545455	0.0336313442300668	83-32-9, 53-70-3, 120-12-7, 50-32-8, 218-01-9	10	1277	8530	3.33985904463587	1	1	0.0336313442300668
CTD_CHEMICALS_DISEASES	Liver Cirrhosis	5	45.4545454545455	0.041749838497056	83-32-9, 120-12-7, 50-32-8, 191-24-2, 218-01-9	10	1363	8530	3.12912692589875	1	1	0.041749838497056
CTD_CHEMICALS_DISEASES	Liver Diseases	5	45.4545454545455	0.0427660072190052	85-01-8, 83-32-9, 129-00-0, 53-70-3, 120-12-7	10	1373	8530	3.10633648943918	1	1	0.0427660072190052
CTD_CHEMICALS_DISEASES	Gastroesophageal Reflux	3	27.2727272727273	0.0473753861758162	85-01-8, 83-32-9, 120-12-7	10	340	8530	7.52647058823529	1	1	0.0473753861758162
CTD_CHEMICALS_DISEASES	Bone Resorption	3	27.2727272727273	0.0501903430802688	83-32-9, 129-00-0, 120-12-7	10	351	8530	7.29059829059829	1	1	0.0501903430802688
CTD_CHEMICALS_DISEASES	Mouth Neoplasms	4	36.3636363636364	0.0608609592342952	83-32-9, 53-70-3, 120-12-7, 191-24-2	10	902	8530	3.78270509977827	1	1	0.0608609592342952
CTD_CHEMICALS_DISEASES	Atrophy	3	27.2727272727273	0.0612216929665671	83-32-9, 120-12-7, 50-32-8	10	392	8530	6.52806122448979	1	1	0.0612216929665671
CTD_CHEMICALS_DISEASES	Diabetes Mellitus	4	36.3636363636364	0.062904930898229	85-01-8, 83-32-9, 129-00-0, 120-12-7	10	914	8530	3.73304157549234	1	1	0.062904930898229
CTD_CHEMICALS_DISEASES	Birth Weight	3	27.2727272727273	0.0643195376919312	83-32-9, 120-12-7, 191-24-2	10	403	8530	6.34987593052109	1	1	0.0643195376919312
CTD_CHEMICALS_DISEASES	Vascular Diseases	3	27.2727272727273	0.119534503557826	85-01-8, 83-32-9, 120-12-7	10	576	8530	4.44270833333333	1	1	0.119534503557826
CTD_CHEMICALS_DISEASES	Lymphoma, T-Cell, Cutaneous	3	27.2727272727273	0.121636788051319	85-01-8, 53-70-3, 120-12-7	10	582	8530	4.39690721649485	1	1	0.121636788051319
CTD_CHEMICALS_DISEASES	Arthritis, Psoriatic	3	27.2727272727273	0.136276999402798	83-32-9, 120-12-7, 206-44-0	10	623	8530	4.10754414125201	1	1	0.136276999402798
CTD_CHEMICALS_DISEASES	Glaucoma 3, Primary Congenital, A	2	18.1818181818182	0.13751445260415	83-32-9, 120-12-7	10	139	8530	12.273381294964	1	1	0.13751445260415
CTD_CHEMICALS_DISEASES	Insulin Resistance	4	36.3636363636364	0.140878430714406	83-32-9, 53-70-3, 120-12-7, 206-44-0	10	1280	8530	2.665625	1	1	0.140878430714406
CTD_CHEMICALS_DISEASES	Cardiotoxicity	3	27.2727272727273	0.148753429443634	83-32-9, 120-12-7, 206-44-0	10	657	8530	3.89497716894977	1	1	0.148753429443634
CTD_CHEMICALS_DISEASES	Leishmaniasis, Cutaneous	3	27.2727272727273	0.150984227321103	56-55-3, 83-32-9, 120-12-7	10	663	8530	3.85972850678733	1	1	0.150984227321103
TOXCAST_ACTIVE	BSK_3C_TissueFactor_down	3	27.2727272727273	0.154424933343467	85-01-8, 120-12-7, 206-44-0	7	206	1723	3.58460471567268	1	1	0.154424933343467
CTD_CHEMICALS_DISEASES	Staphylococcal Infections	2	18.1818181818182	0.161281835266818	83-32-9, 50-32-8	10	165	8530	10.3393939393939	1	1	0.161281835266818
CTD_CHEMICALS_DISEASES	Adenocarcinoma of Lung	3	27.2727272727273	0.171032253904042	83-32-9, 50-32-8, 191-24-2	10	716	8530	3.57402234636872	1	1	0.171032253904042
CTD_CHEMICALS_DISEASES	Hypopituitarism	2	18.1818181818182	0.17116073502318	129-00-0, 120-12-7	10	176	8530	9.69318181818182	1	1	0.17116073502318
CTD_CHEMICALS_DISEASES	Growth Disorders	3	27.2727272727273	0.180294747163775	83-32-9, 53-70-3, 120-12-7	10	740	8530	3.45810810810811	1	1	0.180294747163775
CTD_CHEMICALS_DISEASES	Heart Failure	4	36.3636363636364	0.188817685894531	83-32-9, 129-00-0, 120-12-7, 218-01-9	10	1460	8530	2.33698630136986	1	1	0.188817685894531
TOXCAST_ACTIVE	APR_HepG2_OxidativeStress_72h_up	3	27.2727272727273	0.189166768409049	129-00-0, 120-12-7, 206-44-0	7	233	1723	3.16922133660331	1	1	0.189166768409049
CTD_CHEMICALS_DISEASES	Hyperventilation	2	18.1818181818182	0.201044920926842	83-32-9, 120-12-7	10	210	8530	8.12380952380953	1	1	0.201044920926842
CTD_CHEMICALS_DISEASES	Ureteral Neoplasms	2	18.1818181818182	0.212215599537122	83-32-9, 120-12-7	10	223	8530	7.65022421524664	1	1	0.212215599537122
CTD_CHEMICALS_DISEASES	Fever	3	27.2727272727273	0.216660816884384	85-01-8, 83-32-9, 120-12-7	10	832	8530	3.07572115384615	1	1	0.216660816884384
CTD_CHEMICALS_DISEASES	Peanut Hypersensitivity	2	18.1818181818182	0.22493216116227	83-32-9, 120-12-7	10	238	8530	7.16806722689076	1	1	0.22493216116227
CTD_CHEMICALS_DISEASES	Tobacco Use Disorder	3	27.2727272727273	0.228353107168394	85-01-8, 120-12-7, 206-44-0	10	861	8530	2.97212543554007	1	1	0.228353107168394
CTD_CHEMICALS_DISEASES	Pancreatic cancer, adult	2	18.1818181818182	0.230803859941091	83-32-9, 120-12-7	10	245	8530	6.96326530612245	1	1	0.230803859941091
CTD_CHEMICALS_DISEASES	Nystagmus, Congenital	2	18.1818181818182	0.249819207724245	83-32-9, 120-12-7	10	268	8530	6.36567164179104	1	1	0.249819207724245
CTD_CHEMICALS_DISEASES	Pneumonia	3	27.2727272727273	0.256898860845331	83-32-9, 129-00-0, 120-12-7	10	931	8530	2.74865735767991	1	1	0.256898860845331
CTD_CHEMICALS_DISEASES	Brain Injuries	3	27.2727272727273	0.261006183998182	56-55-3, 129-00-0, 120-12-7	10	941	8530	2.71944739638682	1	1	0.261006183998182
CTD_CHEM2DISEASE	Breast Neoplasms	2	18.1818181818182	0.301757357955877	120-12-7, 50-32-8	8	272	5441	5.00091911764706	1	1	0.301757357955877
CTD_CHEMICALS_DISEASES	Weight Gain	3	27.2727272727273	0.313507567321241	83-32-9, 53-70-3, 120-12-7	10	1068	8530	2.39606741573034	1	1	0.313507567321241
CTD_CHEMICALS_DISEASES	Sepsis	3	27.2727272727273	0.313507567321241	129-00-0, 120-12-7, 206-44-0	10	1068	8530	2.39606741573034	1	1	0.313507567321241
CTD_CHEMICALS_DISEASES	Thyroid Neoplasms	3	27.2727272727273	0.335880289441011	56-55-3, 83-32-9, 129-00-0	10	1122	8530	2.2807486631016	1	1	0.335880289441011
CTD_CHEMICALS_DISEASES	Cholestasis	3	27.2727272727273	0.342086056329732	129-00-0, 53-70-3, 120-12-7	10	1137	8530	2.25065963060686	1	1	0.342086056329732
CTD_CHEMICALS_DISEASES	Down Syndrome	2	18.1818181818182	0.34604332328449	85-01-8, 83-32-9	10	393	8530	4.34096692111959	1	1	0.34604332328449
CTD_CHEMICALS_DISEASES	Glucose Intolerance	2	18.1818181818182	0.356105227249033	83-32-9, 120-12-7	10	407	8530	4.19164619164619	1	1	0.356105227249033
CTD_CHEMICALS_DISEASES	Splenic Diseases	2	18.1818181818182	0.360375176281143	85-01-8, 120-12-7	10	413	8530	4.13075060532688	1	1	0.360375176281143
CTD_CHEMICALS_DISEASES	Pulmonary Fibrosis	3	27.2727272727273	0.370943760703869	83-32-9, 53-70-3, 120-12-7	10	1207	8530	2.12013256006628	1	1	0.370943760703869
CTD_CHEMICALS_DISEASES	Dermatitis, Contact	3	27.2727272727273	0.371765050144617	83-32-9, 191-24-2, 218-01-9	10	1209	8530	2.1166253101737	1	1	0.371765050144617
CTD_CHEMICALS_DISEASES	Inflammation	4	36.3636363636364	0.388050053679453	83-32-9, 120-12-7, 50-32-8, 206-44-0	10	1643	8530	2.07668898356665	1	1	0.388050053679453
CTD_CHEMICALS_DISEASES	Tachycardia	2	18.1818181818182	0.481464339303244	83-32-9, 120-12-7	10	600	8530	2.84333333333333	1	1	0.481464339303244
CTD_CHEMICALS_DISEASES	Behcet Syndrome	2	18.1818181818182	0.532112052535401	120-12-7, 50-32-8	10	690	8530	2.47246376811594	1	1	0.532112052535401
CTD_CHEMICALS_DISEASES	Splenomegaly	2	18.1818181818182	0.560852163935467	83-32-9, 120-12-7	10	745	8530	2.28993288590604	1	1	0.560852163935467
CTD_CHEMICALS_DISEASES	Glioblastoma	2	18.1818181818182	0.571901432281054	83-32-9, 129-00-0	10	767	8530	2.22425032594524	1	1	0.571901432281054
CTD_CHEMICALS_DISEASES	Cardiomegaly	3	27.2727272727273	0.630082022029842	83-32-9, 129-00-0, 218-01-9	10	1263	8530	2.02612826603325	1	1	0.630082022029842
CTD_CHEMICALS_DISEASES	Pulmonary Disease, Chronic Obstructive	3	27.2727272727273	0.634859175577902	83-32-9, 53-70-3, 50-32-8	10	1303	8530	1.96392939370683	1	1	0.634859175577902
CTD_CHEMICALS_DISEASES	Fatty Liver	3	27.2727272727273	0.654837368186469	83-32-9, 129-00-0, 218-01-9	10	1447	8530	1.76848652384243	1	1	0.654837368186469
CTD_CHEMICALS_DISEASES	Neoplasms	3	27.2727272727273	0.667409585981077	83-32-9, 120-12-7, 50-32-8	10	1527	8530	1.67583497053045	1	1	0.667409585981077
CTD_CHEMICALS_DISEASES	Cell Transformation, Neoplastic	3	27.2727272727273	0.67249613139473	83-32-9, 129-00-0, 120-12-7	10	1558	8530	1.64249037227214	1	1	0.67249613139473
CTD_CHEMICALS_DISEASES	Breast Neoplasms	3	27.2727272727273	1	85-01-8, 83-32-9, 53-70-3	10	2515	8530	1.01749502982107	1	1	1
CTD_CHEMICALS_DISEASES	Adenocarcinoma	2	18.1818181818182	1	83-32-9, 53-70-3	10	1419	8530	1.20225510923185	1	1	1
CTD_PATHWAY	KEGG:04622|RIG-I-like receptor signaling pathway	2	18.1818181818182	1	120-12-7, 50-32-8	8	658	3849	1.46238601823708	1	1	1
LEADSCOPE_TOXICITY	Genetic Toxicity -SCE in vitro	3	27.2727272727273	1	85-01-8, 83-32-9, 120-12-7	10	1780	7444	1.25460674157303	1	1	1
CTD_PATHWAY	KEGG:04621|NOD-like receptor signaling pathway	3	27.2727272727273	1	56-55-3, 120-12-7, 50-32-8	8	1293	3849	1.11629930394432	1	1	1
CTD_CHEMICALS_DISEASES	Reperfusion Injury	3	27.2727272727273	1	83-32-9, 53-70-3, 191-24-2	10	1799	8530	1.4224569205114	1	1	1
CTD_PATHWAY	KEGG:05140|Leishmaniasis	3	27.2727272727273	1	56-55-3, 120-12-7, 50-32-8	8	1374	3849	1.05049126637555	1	1	1
TOXCAST_ACTIVE	Tox21_Aromatase_Inhibition	2	18.1818181818182	1	83-32-9, 53-70-3	7	382	1723	1.28870605833957	1	1	1
CTD_CHEMICALS_DISEASES	Nervous System Diseases	2	18.1818181818182	1	120-12-7, 50-32-8	10	1505	8530	1.13355481727575	1	1	1
CTD_CHEMICALS_DISEASES	Ovarian Neoplasms	2	18.1818181818182	1	83-32-9, 191-24-2	10	1135	8530	1.50308370044053	1	1	1

Annotation Cluster 45	Enrichment Score: 0.800981756908998
Category	Term	Count	%	PValue	CASRNs	List Total	Pop Hits	Pop Total	Fold Enrichment	Bonferroni	Benjamini	FDR
MESH	Benz(a)Anthracenes	3	27.2727272727273	3.62427966031961e-05	56-55-3, 53-70-3, 191-24-2	10	6	5450	272.5	1	0.0154756741495647	3.62427966031961e-05
HTS_ACTIVE	activation_EndoRS	4	36.3636363636364	0.000328932112757107	53-70-3, 120-12-7, 206-44-0, 191-24-2	9	78	4173	23.7777777777778	1	0.136835758906957	0.000328932112757107
CTD_CHEMICALS_DISEASES	Spherocytosis, Hereditary	3	27.2727272727273	0.00104378054269197	53-70-3, 50-32-8, 191-24-2	10	47	8530	54.4468085106383	1	0.427950022503709	0.00104378054269197
CTD_CHEMICALS_DISEASES	Spinal Cord Injuries	4	36.3636363636364	0.0460657166304461	53-70-3, 206-44-0, 191-24-2, 218-01-9	10	808	8530	4.22277227722772	1	1	0.0460657166304461
CTD_CHEMICALS_DISEASES	Lung Diseases	4	36.3636363636364	0.0528778761421798	85-01-8, 53-70-3, 120-12-7, 206-44-0	10	853	8530	4	1	1	0.0528778761421798
CTD_CHEMICALS_DISEASES	Mouth Neoplasms	4	36.3636363636364	0.0608609592342952	83-32-9, 53-70-3, 120-12-7, 191-24-2	10	902	8530	3.78270509977827	1	1	0.0608609592342952
CTD_CHEMICALS_DISEASES	Asbestosis	3	27.2727272727273	0.0677625988799753	129-00-0, 53-70-3, 206-44-0	10	415	8530	6.16626506024096	1	1	0.0677625988799753
CTD_CHEMICALS_DISEASES	Dermatitis, Allergic Contact	4	36.3636363636364	0.0728994138136532	85-01-8, 53-70-3, 120-12-7, 206-44-0	10	970	8530	3.51752577319588	1	1	0.0728994138136532
CTD_CHEMICALS_DISEASES	Hemangioblastoma	2	18.1818181818182	0.084279060619438	53-70-3, 206-44-0	10	83	8530	20.5542168674699	1	1	0.084279060619438
CTD_PATHWAY	KEGG:03320|PPAR signaling pathway	3	27.2727272727273	0.125702003437735	53-70-3, 50-32-8, 206-44-0	8	347	3849	4.15958213256484	1	1	0.125702003437735
CTD_CHEMICALS_DISEASES	Insulin Resistance	4	36.3636363636364	0.140878430714406	83-32-9, 53-70-3, 120-12-7, 206-44-0	10	1280	8530	2.665625	1	1	0.140878430714406
CTD_CHEMICALS_DISEASES	Heart Valve Diseases	3	27.2727272727273	0.15697318292029	85-01-8, 53-70-3, 191-24-2	10	679	8530	3.76877761413844	1	1	0.15697318292029
CTD_CHEMICALS_DISEASES	Calcinosis	3	27.2727272727273	0.214654502836388	53-70-3, 206-44-0, 191-24-2	10	827	8530	3.09431680773882	1	1	0.214654502836388
CTD_CHEMICALS_DISEASES	Cleft Lip	2	18.1818181818182	0.224090102911481	53-70-3, 206-44-0	10	237	8530	7.19831223628692	1	1	0.224090102911481
CTD_CHEMICALS_DISEASES	Vitamin A Deficiency	2	18.1818181818182	0.2358052386995	53-70-3, 206-44-0	10	251	8530	6.79681274900398	1	1	0.2358052386995
CTD_CHEMICALS_DISEASES	Mouth Diseases	2	18.1818181818182	0.237465929474481	53-70-3, 191-24-2	10	253	8530	6.74308300395257	1	1	0.237465929474481
CTD_CHEMICALS_DISEASES	Breast Neoplasms, Male	2	18.1818181818182	0.242428771439614	120-12-7, 206-44-0	10	259	8530	6.58687258687259	1	1	0.242428771439614
CTD_CHEMICALS_DISEASES	Multiple Myeloma	3	27.2727272727273	0.242984082478121	129-00-0, 53-70-3, 206-44-0	10	897	8530	2.85284280936455	1	1	0.242984082478121
CTD_CHEMICALS_DISEASES	Esophageal Neoplasms	3	27.2727272727273	0.299001685160361	53-70-3, 206-44-0, 218-01-9	10	1033	8530	2.47725072604066	1	1	0.299001685160361
TOXCAST_ACTIVE	Tox21_ESRE_BLA_ratio	2	18.1818181818182	0.304403341271129	120-12-7, 206-44-0	7	101	1723	4.87411598302687	1	1	0.304403341271129
CTD_CHEMICALS_DISEASES	Small Cell Lung Carcinoma	2	18.1818181818182	0.363914220576094	53-70-3, 206-44-0	10	418	8530	4.08133971291866	1	1	0.363914220576094
CTD_CHEMICALS_DISEASES	Parkinson Disease	4	36.3636363636364	0.382515735612742	129-00-0, 53-70-3, 206-44-0, 218-01-9	10	1590	8530	2.14591194968554	1	1	0.382515735612742
CTD_CHEMICALS_DISEASES	Pre-Eclampsia	2	18.1818181818182	0.408363933011906	53-70-3, 206-44-0	10	483	8530	3.53209109730849	1	1	0.408363933011906
CTD_CHEMICALS_DISEASES	Carotid Artery Diseases	2	18.1818181818182	0.479695265391553	53-70-3, 206-44-0	10	597	8530	2.85762144053601	1	1	0.479695265391553
HTS_ACTIVE	activation_p53	2	18.1818181818182	0.543204307132219	53-70-3, 191-24-2	9	389	4173	2.38389031705227	1	1	0.543204307132219
CTD_PATHWAY	KEGG:04350|TGF-beta signaling pathway	3	27.2727272727273	0.62140532293499	53-70-3, 50-32-8, 206-44-0	8	718	3849	2.01027158774373	1	1	0.62140532293499
CTD_CHEMICALS_DISEASES	Acute Kidney Injury	3	27.2727272727273	0.675999919190567	129-00-0, 53-70-3, 206-44-0	10	1579	8530	1.62064597846738	1	1	0.675999919190567
CTD_PATHWAY	KEGG:05215|Prostate cancer	4	36.3636363636364	0.69359369890391	56-55-3, 53-70-3, 50-32-8, 206-44-0	8	1292	3849	1.48955108359133	1	1	0.69359369890391
CTD_CHEMICALS_DISEASES	Stomach Neoplasms	2	18.1818181818182	0.69440236222211	206-44-0, 191-24-2	10	1974	8530	0.864235055724418	1	1	0.69440236222211
CTD_CHEMICALS_DISEASES	Reperfusion Injury	3	27.2727272727273	1	83-32-9, 53-70-3, 191-24-2	10	1799	8530	1.4224569205114	1	1	1
PHARMACTIONLIST	Chemical Actions and Uses	3	27.2727272727273	1	129-00-0, 53-70-3, 206-44-0	3	2720	2720	1	1	1	1
CTD_CHEMICALS_DISEASES	Prostatic Neoplasms	4	36.3636363636364	1	56-55-3, 85-01-8, 53-70-3, 206-44-0	10	2979	8530	1.14535078885532	1	1	1
CTD_CHEMICALS_DISEASES	Stroke	2	18.1818181818182	1	120-12-7, 206-44-0	10	1044	8530	1.63409961685824	1	1	1
CTD_CHEMICALS_DISEASES	Skin Diseases	2	18.1818181818182	1	120-12-7, 206-44-0	10	934	8530	1.82655246252677	1	1	1
CTD_CHEMICALS_DISEASES	Ischemia	2	18.1818181818182	1	53-70-3, 206-44-0	10	882	8530	1.93424036281179	1	1	1

Annotation Cluster 46	Enrichment Score: 0.788414811029314
Category	Term	Count	%	PValue	CASRNs	List Total	Pop Hits	Pop Total	Fold Enrichment	Bonferroni	Benjamini	FDR
CTD_CHEMICALS_DISEASES	Hepatitis, Alcoholic	4	36.3636363636364	0.0242576204028539	56-55-3, 85-01-8, 83-32-9, 129-00-0	10	632	8530	5.39873417721519	1	1	0.0242576204028539
CTD_CHEMICALS_DISEASES	Gastroesophageal Reflux	3	27.2727272727273	0.0473753861758162	85-01-8, 83-32-9, 120-12-7	10	340	8530	7.52647058823529	1	1	0.0473753861758162
CTD_CHEMICALS_DISEASES	Keratosis	4	36.3636363636364	0.0570408678767359	85-01-8, 83-32-9, 129-00-0, 206-44-0	10	879	8530	3.88168373151308	1	1	0.0570408678767359
CTD_CHEMICALS_DISEASES	Diabetes Mellitus	4	36.3636363636364	0.062904930898229	85-01-8, 83-32-9, 129-00-0, 120-12-7	10	914	8530	3.73304157549234	1	1	0.062904930898229
TOXCAST_ACTIVE	ATG_RXRb_TRANS_up	4	36.3636363636364	0.0798472184314157	85-01-8, 83-32-9, 129-00-0, 206-44-0	7	317	1723	3.10590356016224	1	1	0.0798472184314157
CTD_CHEMICALS_DISEASES	Vascular Diseases	3	27.2727272727273	0.119534503557826	85-01-8, 83-32-9, 120-12-7	10	576	8530	4.44270833333333	1	1	0.119534503557826
CTD_CHEMICALS_DISEASES	Fever	3	27.2727272727273	0.216660816884384	85-01-8, 83-32-9, 120-12-7	10	832	8530	3.07572115384615	1	1	0.216660816884384
CTD_CHEMICALS_DISEASES	Down Syndrome	2	18.1818181818182	0.34604332328449	85-01-8, 83-32-9	10	393	8530	4.34096692111959	1	1	0.34604332328449
CTD_CHEMICALS_DISEASES	Carcinoma, Hepatocellular	4	36.3636363636364	0.720280042241255	85-01-8, 83-32-9, 206-44-0, 218-01-9	10	2428	8530	1.40527182866557	1	1	0.720280042241255
CTD_CHEMICALS_DISEASES	Breast Neoplasms	3	27.2727272727273	1	85-01-8, 83-32-9, 53-70-3	10	2515	8530	1.01749502982107	1	1	1
LEADSCOPE_TOXICITY	Genetic Toxicity -SCE in vitro	3	27.2727272727273	1	85-01-8, 83-32-9, 120-12-7	10	1780	7444	1.25460674157303	1	1	1

Annotation Cluster 47	Enrichment Score: 0.783523841196929
Category	Term	Count	%	PValue	CASRNs	List Total	Pop Hits	Pop Total	Fold Enrichment	Bonferroni	Benjamini	FDR
CTD_CHEM2DISEASE	Congenital Abnormalities	3	27.2727272727273	0.00196673204493313	85-01-8, 129-00-0, 50-32-8	8	54	5441	37.7847222222222	1	0.792593014108051	0.00196673204493313
CTD_CHEM2DISEASE	Kidney Diseases	4	36.3636363636364	0.0236141489826933	85-01-8, 120-12-7, 50-32-8, 218-01-9	8	528	5441	5.15246212121212	1	1	0.0236141489826933
CTD_PATHWAY	KEGG:00053|Ascorbate and aldarate metabolism	3	27.2727272727273	0.0573854457206732	85-01-8, 129-00-0, 50-32-8	8	222	3849	6.50168918918919	1	1	0.0573854457206732
CTD_PATHWAY	KEGG:00040|Pentose and glucuronate interconversions	3	27.2727272727273	0.0710320732305736	85-01-8, 129-00-0, 50-32-8	8	250	3849	5.7735	1	1	0.0710320732305736
CTD_PATHWAY	KEGG:00860|Porphyrin and chlorophyll metabolism	3	27.2727272727273	0.0798317590780795	85-01-8, 129-00-0, 50-32-8	8	267	3849	5.40589887640449	1	1	0.0798317590780795
CTD_PATHWAY	KEGG:00983|Drug metabolism - other enzymes	3	27.2727272727273	0.146415299751299	85-01-8, 129-00-0, 50-32-8	8	380	3849	3.79835526315789	1	1	0.146415299751299
CTD_CHEMICALS_DISEASES	Respiratory Distress Syndrome, Adult	3	27.2727272727273	0.164918237164603	85-01-8, 50-32-8, 206-44-0	10	700	8530	3.65571428571429	1	1	0.164918237164603
CTD_PATHWAY	KEGG:03010|Ribosome	2	18.1818181818182	0.179226600532983	85-01-8, 50-32-8	8	107	3849	8.99299065420561	1	1	0.179226600532983
CTD_PATHWAY	KEGG:00514|Other types of O-glycan biosynthesis	2	18.1818181818182	0.278185350328085	85-01-8, 50-32-8	8	175	3849	5.49857142857143	1	1	0.278185350328085
CTD_PATHWAY	KEGG:00500|Starch and sucrose metabolism	2	18.1818181818182	0.318478210425066	85-01-8, 50-32-8	8	205	3849	4.69390243902439	1	1	0.318478210425066
TOXINS_TARGETS	BE0000123	4	36.3636363636364	0.436518670567954	56-55-3, 85-01-8, 53-70-3, 50-32-8	10	806	3520	1.7468982630273	1	1	0.436518670567954
HTS_ACTIVE	cytotoxicity_RXR/agonism	4	36.3636363636364	0.698422986144893	85-01-8, 129-00-0, 50-32-8, 206-44-0	9	1213	4173	1.52899148117615	1	1	0.698422986144893
CTD_CHEMICALS_DISEASES	Necrosis	2	18.1818181818182	1	85-01-8, 50-32-8	10	1533	8530	1.11285061969993	1	1	1
CTD_CHEM2DISEASE	Drug-Induced Liver Injury	2	18.1818181818182	1	85-01-8, 50-32-8	8	836	5441	1.62709330143541	1	1	1
CTD_CHEMICALS_DISEASES	Hyperalgesia	2	18.1818181818182	1	85-01-8, 50-32-8	10	1311	8530	1.30129672006102	1	1	1

Annotation Cluster 48	Enrichment Score: 0.766940345457499
Category	Term	Count	%	PValue	CASRNs	List Total	Pop Hits	Pop Total	Fold Enrichment	Bonferroni	Benjamini	FDR
CTD_CHEM2DISEASE	Immunologic Deficiency Syndromes	4	36.3636363636364	5.89598544801171e-07	56-55-3, 53-70-3, 50-32-8, 218-01-9	8	15	5441	181.366666666667	1	0.000258833761167714	5.89598544801171e-07
TOXPRINT_STRUCTURE	ring:fused_PAH_benz(a)anthracene	3	27.2727272727273	2.16954225653909e-05	56-55-3, 53-70-3, 50-32-8	10	7	8337	357.3	1	0.00935072712568346	2.16954225653909e-05
CTD_CHEM2DISEASE	Sarcoma	3	27.2727272727273	0.00119209936666582	56-55-3, 53-70-3, 50-32-8	8	42	5441	48.5803571428571	1	0.486376541599653	0.00119209936666582
CTD_CHEM2DISEASE	Liver Neoplasms, Experimental	4	36.3636363636364	0.00213090951793363	56-55-3, 129-00-0, 50-32-8, 218-01-9	8	224	5441	12.1450892857143	1	0.856625626209318	0.00213090951793363
CTD_CHEM2DISEASE	Hypertrophy	3	27.2727272727273	0.00470341717948041	56-55-3, 50-32-8, 206-44-0	8	84	5441	24.2901785714286	1	1	0.00470341717948041
CTD_CHEM2DISEASE	Adenoma	3	27.2727272727273	0.00754375979623929	56-55-3, 53-70-3, 50-32-8	8	107	5441	19.0689252336449	1	1	0.00754375979623929
CTD_CHEM2DISEASE	Skin Neoplasms	3	27.2727272727273	0.011160363438817	56-55-3, 53-70-3, 50-32-8	8	131	5441	15.5753816793893	1	1	0.011160363438817
CTD_CHEM2DISEASE	Liver Neoplasms	3	27.2727272727273	0.0378937552950221	56-55-3, 53-70-3, 50-32-8	8	250	5441	8.1615	1	1	0.0378937552950221
CTD_CHEMICALS_DISEASES	Intellectual Disability	3	27.2727272727273	0.0748408646402691	56-55-3, 50-32-8, 218-01-9	10	439	8530	5.82915717539863	1	1	0.0748408646402691
CTD_CHEM2DISEASE	Edema	3	27.2727272727273	0.0850043809378351	56-55-3, 129-00-0, 50-32-8	8	391	5441	5.21835038363171	1	1	0.0850043809378351
HTS_ACTIVE	agonism_AhR	4	36.3636363636364	0.0910445529556652	56-55-3, 53-70-3, 50-32-8, 218-01-9	9	590	4173	3.14350282485876	1	1	0.0910445529556652
CTD_CHEM2DISEASE	Micronuclei, Chromosome-Defective	2	18.1818181818182	0.109090160184938	56-55-3, 50-32-8	8	89	5441	15.2837078651685	1	1	0.109090160184938
CTD_CHEMICALS_DISEASES	Arthritis, Rheumatoid	4	36.3636363636364	0.134912068564149	56-55-3, 83-32-9, 53-70-3, 50-32-8	10	1256	8530	2.71656050955414	1	1	0.134912068564149
HTS_ACTIVE	cytotoxicity_MMP/inhibition	4	36.3636363636364	0.162512486661459	56-55-3, 129-00-0, 50-32-8, 206-44-0	9	755	4173	2.45651214128035	1	1	0.162512486661459
CTD_CHEM2DISEASE	Urinary Bladder Neoplasms	2	18.1818181818182	0.169075812519261	56-55-3, 50-32-8	8	142	5441	9.57922535211268	1	1	0.169075812519261
CTD_CHEMICALS_DISEASES	Vitiligo	3	27.2727272727273	0.185354843152422	56-55-3, 53-70-3, 50-32-8	10	753	8530	3.39840637450199	1	1	0.185354843152422
CTD_CHEM2DISEASE	Carcinoma, Hepatocellular	2	18.1818181818182	0.224531175615222	56-55-3, 50-32-8	8	194	5441	7.01159793814433	1	1	0.224531175615222
CTD_CHEMICALS_DISEASES	Osteochondrodysplasias	2	18.1818181818182	0.381349690969447	56-55-3, 50-32-8	10	443	8530	3.8510158013544	1	1	0.381349690969447
TOXINS_TARGETS	BE0000123	4	36.3636363636364	0.436518670567954	56-55-3, 85-01-8, 53-70-3, 50-32-8	10	806	3520	1.7468982630273	1	1	0.436518670567954
CTD_PATHWAY	KEGG:04010|MAPK signaling pathway	2	18.1818181818182	0.437172334982122	56-55-3, 50-32-8	8	1272	3849	0.756485849056604	1	1	0.437172334982122
CTD_PATHWAY	KEGG:04670|Leukocyte transendothelial migration	2	18.1818181818182	0.522089976649053	56-55-3, 50-32-8	8	385	3849	2.49935064935065	1	1	0.522089976649053
CTD_PATHWAY	KEGG:04520|Adherens junction	2	18.1818181818182	0.578892401882583	56-55-3, 50-32-8	8	447	3849	2.15268456375839	1	1	0.578892401882583
CTD_PATHWAY	KEGG:05214|Glioma	3	27.2727272727273	0.674665603494797	56-55-3, 50-32-8, 206-44-0	8	919	3849	1.5705930359086	1	1	0.674665603494797
CTD_PATHWAY	KEGG:04060|Cytokine-cytokine receptor interaction	2	18.1818181818182	0.680976260888029	56-55-3, 50-32-8	8	1094	3849	0.879570383912249	1	1	0.680976260888029
CTD_PATHWAY	KEGG:05160|Hepatitis C	2	18.1818181818182	0.680985796826041	56-55-3, 50-32-8	8	1107	3849	0.869241192411924	1	1	0.680985796826041
CTD_PATHWAY	KEGG:04722|Neurotrophin signaling pathway	2	18.1818181818182	0.681384996707683	56-55-3, 50-32-8	8	1066	3849	0.902673545966229	1	1	0.681384996707683
CTD_PATHWAY	KEGG:05162|Measles	2	18.1818181818182	0.685732583858352	56-55-3, 50-32-8	8	988	3849	0.973937246963563	1	1	0.685732583858352
CTD_PATHWAY	KEGG:05215|Prostate cancer	4	36.3636363636364	0.69359369890391	56-55-3, 53-70-3, 50-32-8, 206-44-0	8	1292	3849	1.48955108359133	1	1	0.69359369890391
CTD_PATHWAY	KEGG:04620|Toll-like receptor signaling pathway	4	36.3636363636364	0.699174155964701	56-55-3, 120-12-7, 50-32-8, 206-44-0	8	1333	3849	1.4437359339835	1	1	0.699174155964701
CTD_PATHWAY	KEGG:05152|Tuberculosis	3	27.2727272727273	0.709344124047658	56-55-3, 50-32-8, 206-44-0	8	1541	3849	0.936648280337443	1	1	0.709344124047658
CTD_CHEMICALS_DISEASES	Kidney Failure, Chronic	2	18.1818181818182	1	56-55-3, 50-32-8	10	1232	8530	1.38474025974026	1	1	1
CTD_PATHWAY	KEGG:05332|Graft-versus-host disease	2	18.1818181818182	1	56-55-3, 50-32-8	8	673	3849	1.42979197622585	1	1	1
CTD_PATHWAY	KEGG:04914|Progesterone-mediated oocyte maturation	2	18.1818181818182	1	56-55-3, 50-32-8	8	660	3849	1.45795454545455	1	1	1
CTD_PATHWAY	KEGG:05223|Non-small cell lung cancer	2	18.1818181818182	1	56-55-3, 50-32-8	8	917	3849	1.04934569247546	1	1	1
CTD_PATHWAY	KEGG:04012|ErbB signaling pathway	2	18.1818181818182	1	56-55-3, 50-32-8	8	817	3849	1.17778457772338	1	1	1
CTD_PATHWAY	KEGG:04621|NOD-like receptor signaling pathway	3	27.2727272727273	1	56-55-3, 120-12-7, 50-32-8	8	1293	3849	1.11629930394432	1	1	1
CTD_PATHWAY	KEGG:04912|GnRH signaling pathway	2	18.1818181818182	1	56-55-3, 50-32-8	8	671	3849	1.43405365126677	1	1	1
CTD_PATHWAY	KEGG:05142|Chagas disease (American trypanosomiasis)	4	36.3636363636364	1	56-55-3, 120-12-7, 50-32-8, 206-44-0	8	1545	3849	1.24563106796117	1	1	1
CTD_PATHWAY	KEGG:05213|Endometrial cancer	2	18.1818181818182	1	56-55-3, 50-32-8	8	883	3849	1.08975084937712	1	1	1
CTD_PATHWAY	KEGG:04380|Osteoclast differentiation	3	27.2727272727273	1	56-55-3, 50-32-8, 218-01-9	8	1221	3849	1.18212530712531	1	1	1
CTD_PATHWAY	KEGG:05140|Leishmaniasis	3	27.2727272727273	1	56-55-3, 120-12-7, 50-32-8	8	1374	3849	1.05049126637555	1	1	1
CTD_PATHWAY	KEGG:05020|Prion diseases	3	27.2727272727273	1	56-55-3, 50-32-8, 206-44-0	8	994	3849	1.45208752515091	1	1	1
CTD_PATHWAY	KEGG:04810|Regulation of actin cytoskeleton	2	18.1818181818182	1	56-55-3, 50-32-8	8	508	3849	1.89419291338583	1	1	1
CTD_PATHWAY	KEGG:04510|Focal adhesion	2	18.1818181818182	1	56-55-3, 50-32-8	8	913	3849	1.0539430449069	1	1	1
CTD_PATHWAY	KEGG:05219|Bladder cancer	3	27.2727272727273	1	56-55-3, 50-32-8, 206-44-0	8	1098	3849	1.31454918032787	1	1	1
CTD_PATHWAY	KEGG:04640|Hematopoietic cell lineage	2	18.1818181818182	1	56-55-3, 50-32-8	8	605	3849	1.59049586776859	1	1	1

Annotation Cluster 49	Enrichment Score: 0.766940345457499
Category	Term	Count	%	PValue	CASRNs	List Total	Pop Hits	Pop Total	Fold Enrichment	Bonferroni	Benjamini	FDR
CTD_CHEM2DISEASE	Immunologic Deficiency Syndromes	4	36.3636363636364	5.89598544801171e-07	56-55-3, 53-70-3, 50-32-8, 218-01-9	8	15	5441	181.366666666667	1	0.000258833761167714	5.89598544801171e-07
TOXPRINT_STRUCTURE	ring:fused_PAH_benz(a)anthracene	3	27.2727272727273	2.16954225653909e-05	56-55-3, 53-70-3, 50-32-8	10	7	8337	357.3	1	0.00935072712568346	2.16954225653909e-05
CTD_CHEM2DISEASE	Sarcoma	3	27.2727272727273	0.00119209936666582	56-55-3, 53-70-3, 50-32-8	8	42	5441	48.5803571428571	1	0.486376541599653	0.00119209936666582
CTD_CHEM2DISEASE	Liver Neoplasms, Experimental	4	36.3636363636364	0.00213090951793363	56-55-3, 129-00-0, 50-32-8, 218-01-9	8	224	5441	12.1450892857143	1	0.856625626209318	0.00213090951793363
CTD_CHEM2DISEASE	Hypertrophy	3	27.2727272727273	0.00470341717948041	56-55-3, 50-32-8, 206-44-0	8	84	5441	24.2901785714286	1	1	0.00470341717948041
CTD_CHEM2DISEASE	Adenoma	3	27.2727272727273	0.00754375979623929	56-55-3, 53-70-3, 50-32-8	8	107	5441	19.0689252336449	1	1	0.00754375979623929
CTD_CHEM2DISEASE	Skin Neoplasms	3	27.2727272727273	0.011160363438817	56-55-3, 53-70-3, 50-32-8	8	131	5441	15.5753816793893	1	1	0.011160363438817
CTD_CHEM2DISEASE	Liver Neoplasms	3	27.2727272727273	0.0378937552950221	56-55-3, 53-70-3, 50-32-8	8	250	5441	8.1615	1	1	0.0378937552950221
CTD_CHEMICALS_DISEASES	Intellectual Disability	3	27.2727272727273	0.0748408646402691	56-55-3, 50-32-8, 218-01-9	10	439	8530	5.82915717539863	1	1	0.0748408646402691
CTD_CHEM2DISEASE	Edema	3	27.2727272727273	0.0850043809378351	56-55-3, 129-00-0, 50-32-8	8	391	5441	5.21835038363171	1	1	0.0850043809378351
HTS_ACTIVE	agonism_AhR	4	36.3636363636364	0.0910445529556652	56-55-3, 53-70-3, 50-32-8, 218-01-9	9	590	4173	3.14350282485876	1	1	0.0910445529556652
CTD_CHEM2DISEASE	Micronuclei, Chromosome-Defective	2	18.1818181818182	0.109090160184938	56-55-3, 50-32-8	8	89	5441	15.2837078651685	1	1	0.109090160184938
CTD_CHEMICALS_DISEASES	Arthritis, Rheumatoid	4	36.3636363636364	0.134912068564149	56-55-3, 83-32-9, 53-70-3, 50-32-8	10	1256	8530	2.71656050955414	1	1	0.134912068564149
HTS_ACTIVE	cytotoxicity_MMP/inhibition	4	36.3636363636364	0.162512486661459	56-55-3, 129-00-0, 50-32-8, 206-44-0	9	755	4173	2.45651214128035	1	1	0.162512486661459
CTD_CHEM2DISEASE	Urinary Bladder Neoplasms	2	18.1818181818182	0.169075812519261	56-55-3, 50-32-8	8	142	5441	9.57922535211268	1	1	0.169075812519261
CTD_CHEMICALS_DISEASES	Vitiligo	3	27.2727272727273	0.185354843152422	56-55-3, 53-70-3, 50-32-8	10	753	8530	3.39840637450199	1	1	0.185354843152422
CTD_CHEM2DISEASE	Carcinoma, Hepatocellular	2	18.1818181818182	0.224531175615222	56-55-3, 50-32-8	8	194	5441	7.01159793814433	1	1	0.224531175615222
CTD_CHEMICALS_DISEASES	Osteochondrodysplasias	2	18.1818181818182	0.381349690969447	56-55-3, 50-32-8	10	443	8530	3.8510158013544	1	1	0.381349690969447
TOXINS_TARGETS	BE0000123	4	36.3636363636364	0.436518670567954	56-55-3, 85-01-8, 53-70-3, 50-32-8	10	806	3520	1.7468982630273	1	1	0.436518670567954
CTD_PATHWAY	KEGG:04010|MAPK signaling pathway	2	18.1818181818182	0.437172334982122	56-55-3, 50-32-8	8	1272	3849	0.756485849056604	1	1	0.437172334982122
CTD_PATHWAY	KEGG:04670|Leukocyte transendothelial migration	2	18.1818181818182	0.522089976649053	56-55-3, 50-32-8	8	385	3849	2.49935064935065	1	1	0.522089976649053
CTD_PATHWAY	KEGG:04520|Adherens junction	2	18.1818181818182	0.578892401882583	56-55-3, 50-32-8	8	447	3849	2.15268456375839	1	1	0.578892401882583
CTD_PATHWAY	KEGG:05214|Glioma	3	27.2727272727273	0.674665603494797	56-55-3, 50-32-8, 206-44-0	8	919	3849	1.5705930359086	1	1	0.674665603494797
CTD_PATHWAY	KEGG:04060|Cytokine-cytokine receptor interaction	2	18.1818181818182	0.680976260888029	56-55-3, 50-32-8	8	1094	3849	0.879570383912249	1	1	0.680976260888029
CTD_PATHWAY	KEGG:05160|Hepatitis C	2	18.1818181818182	0.680985796826041	56-55-3, 50-32-8	8	1107	3849	0.869241192411924	1	1	0.680985796826041
CTD_PATHWAY	KEGG:04722|Neurotrophin signaling pathway	2	18.1818181818182	0.681384996707683	56-55-3, 50-32-8	8	1066	3849	0.902673545966229	1	1	0.681384996707683
CTD_PATHWAY	KEGG:05162|Measles	2	18.1818181818182	0.685732583858352	56-55-3, 50-32-8	8	988	3849	0.973937246963563	1	1	0.685732583858352
CTD_PATHWAY	KEGG:05215|Prostate cancer	4	36.3636363636364	0.69359369890391	56-55-3, 53-70-3, 50-32-8, 206-44-0	8	1292	3849	1.48955108359133	1	1	0.69359369890391
CTD_PATHWAY	KEGG:04620|Toll-like receptor signaling pathway	4	36.3636363636364	0.699174155964701	56-55-3, 120-12-7, 50-32-8, 206-44-0	8	1333	3849	1.4437359339835	1	1	0.699174155964701
CTD_PATHWAY	KEGG:05152|Tuberculosis	3	27.2727272727273	0.709344124047658	56-55-3, 50-32-8, 206-44-0	8	1541	3849	0.936648280337443	1	1	0.709344124047658
CTD_PATHWAY	KEGG:05213|Endometrial cancer	2	18.1818181818182	1	56-55-3, 50-32-8	8	883	3849	1.08975084937712	1	1	1
CTD_PATHWAY	KEGG:04914|Progesterone-mediated oocyte maturation	2	18.1818181818182	1	56-55-3, 50-32-8	8	660	3849	1.45795454545455	1	1	1
CTD_PATHWAY	KEGG:04012|ErbB signaling pathway	2	18.1818181818182	1	56-55-3, 50-32-8	8	817	3849	1.17778457772338	1	1	1
CTD_PATHWAY	KEGG:05332|Graft-versus-host disease	2	18.1818181818182	1	56-55-3, 50-32-8	8	673	3849	1.42979197622585	1	1	1
CTD_PATHWAY	KEGG:05020|Prion diseases	3	27.2727272727273	1	56-55-3, 50-32-8, 206-44-0	8	994	3849	1.45208752515091	1	1	1
CTD_PATHWAY	KEGG:04510|Focal adhesion	2	18.1818181818182	1	56-55-3, 50-32-8	8	913	3849	1.0539430449069	1	1	1
CTD_CHEMICALS_DISEASES	Kidney Failure, Chronic	2	18.1818181818182	1	56-55-3, 50-32-8	10	1232	8530	1.38474025974026	1	1	1
CTD_PATHWAY	KEGG:05223|Non-small cell lung cancer	2	18.1818181818182	1	56-55-3, 50-32-8	8	917	3849	1.04934569247546	1	1	1
CTD_PATHWAY	KEGG:05140|Leishmaniasis	3	27.2727272727273	1	56-55-3, 120-12-7, 50-32-8	8	1374	3849	1.05049126637555	1	1	1
CTD_PATHWAY	KEGG:04810|Regulation of actin cytoskeleton	2	18.1818181818182	1	56-55-3, 50-32-8	8	508	3849	1.89419291338583	1	1	1
CTD_PATHWAY	KEGG:05142|Chagas disease (American trypanosomiasis)	4	36.3636363636364	1	56-55-3, 120-12-7, 50-32-8, 206-44-0	8	1545	3849	1.24563106796117	1	1	1
CTD_PATHWAY	KEGG:04380|Osteoclast differentiation	3	27.2727272727273	1	56-55-3, 50-32-8, 218-01-9	8	1221	3849	1.18212530712531	1	1	1
CTD_PATHWAY	KEGG:04640|Hematopoietic cell lineage	2	18.1818181818182	1	56-55-3, 50-32-8	8	605	3849	1.59049586776859	1	1	1
CTD_PATHWAY	KEGG:04621|NOD-like receptor signaling pathway	3	27.2727272727273	1	56-55-3, 120-12-7, 50-32-8	8	1293	3849	1.11629930394432	1	1	1
CTD_PATHWAY	KEGG:04912|GnRH signaling pathway	2	18.1818181818182	1	56-55-3, 50-32-8	8	671	3849	1.43405365126677	1	1	1
CTD_PATHWAY	KEGG:05219|Bladder cancer	3	27.2727272727273	1	56-55-3, 50-32-8, 206-44-0	8	1098	3849	1.31454918032787	1	1	1

Annotation Cluster 50	Enrichment Score: 0.755054912004628
Category	Term	Count	%	PValue	CASRNs	List Total	Pop Hits	Pop Total	Fold Enrichment	Bonferroni	Benjamini	FDR
CTD_CHEMICALS_DISEASES	Neoplasm Recurrence, Local	4	36.3636363636364	0.0520963047169056	85-01-8, 129-00-0, 53-70-3, 218-01-9	10	848	8530	4.02358490566038	1	1	0.0520963047169056
CTD_CHEMICALS_DISEASES	Lung Diseases	4	36.3636363636364	0.0528778761421798	85-01-8, 53-70-3, 120-12-7, 206-44-0	10	853	8530	4	1	1	0.0528778761421798
CTD_CHEMICALS_DISEASES	Nasopharyngeal Carcinoma	3	27.2727272727273	0.0565471056732694	56-55-3, 85-01-8, 53-70-3	10	375	8530	6.824	1	1	0.0565471056732694
CTD_CHEMICALS_DISEASES	Osteoarthritis	4	36.3636363636364	0.0670967823321621	56-55-3, 85-01-8, 129-00-0, 53-70-3	10	938	8530	3.63752665245203	1	1	0.0670967823321621
CTD_CHEMICALS_DISEASES	Craniofacial Abnormalities	3	27.2727272727273	0.0706812626860664	85-01-8, 129-00-0, 53-70-3	10	425	8530	6.02117647058824	1	1	0.0706812626860664
CTD_CHEMICALS_DISEASES	Dermatitis, Allergic Contact	4	36.3636363636364	0.0728994138136532	85-01-8, 53-70-3, 120-12-7, 206-44-0	10	970	8530	3.51752577319588	1	1	0.0728994138136532
CTD_CHEMICALS_DISEASES	Lymphoma, T-Cell, Cutaneous	3	27.2727272727273	0.121636788051319	85-01-8, 53-70-3, 120-12-7	10	582	8530	4.39690721649485	1	1	0.121636788051319
CTD_CHEMICALS_DISEASES	Heart Valve Diseases	3	27.2727272727273	0.15697318292029	85-01-8, 53-70-3, 191-24-2	10	679	8530	3.76877761413844	1	1	0.15697318292029
CTD_CHEMICALS_DISEASES	Leukemia	3	27.2727272727273	0.176808931941653	85-01-8, 53-70-3, 218-01-9	10	731	8530	3.50068399452804	1	1	0.176808931941653
CTD_CHEMICALS_DISEASES	Schizophrenia	4	36.3636363636364	0.182956008427525	85-01-8, 53-70-3, 120-12-7, 218-01-9	10	1439	8530	2.37109103544128	1	1	0.182956008427525
TOXINS_TARGETS	BE0000123	4	36.3636363636364	0.436518670567954	56-55-3, 85-01-8, 53-70-3, 50-32-8	10	806	3520	1.7468982630273	1	1	0.436518670567954
CTD_CHEMICALS_DISEASES	Neurodegenerative Diseases	2	18.1818181818182	0.562879776611255	85-01-8, 53-70-3	10	749	8530	2.27770360480641	1	1	0.562879776611255
CTD_CHEMICALS_DISEASES	Manganese Poisoning	2	18.1818181818182	0.577823542837533	85-01-8, 53-70-3	10	779	8530	2.18998716302953	1	1	0.577823542837533
CTD_CHEMICALS_DISEASES	Prostatic Neoplasms	4	36.3636363636364	1	56-55-3, 85-01-8, 53-70-3, 206-44-0	10	2979	8530	1.14535078885532	1	1	1
CTD_CHEMICALS_DISEASES	Breast Neoplasms	3	27.2727272727273	1	85-01-8, 83-32-9, 53-70-3	10	2515	8530	1.01749502982107	1	1	1

Annotation Cluster 51	Enrichment Score: 0.754681114910511
Category	Term	Count	%	PValue	CASRNs	List Total	Pop Hits	Pop Total	Fold Enrichment	Bonferroni	Benjamini	FDR
CTD_CHEMICALS_DISEASES	COVID-19	4	36.3636363636364	0.0228528205999287	56-55-3, 83-32-9, 120-12-7, 206-44-0	10	618	8530	5.5210355987055	1	1	0.0228528205999287
CTD_CHEMICALS_DISEASES	Hepatitis, Alcoholic	4	36.3636363636364	0.0242576204028539	56-55-3, 85-01-8, 83-32-9, 129-00-0	10	632	8530	5.39873417721519	1	1	0.0242576204028539
CTD_CHEMICALS_DISEASES	Arthritis, Rheumatoid	4	36.3636363636364	0.134912068564149	56-55-3, 83-32-9, 53-70-3, 50-32-8	10	1256	8530	2.71656050955414	1	1	0.134912068564149
CTD_CHEMICALS_DISEASES	Leishmaniasis, Cutaneous	3	27.2727272727273	0.150984227321103	56-55-3, 83-32-9, 120-12-7	10	663	8530	3.85972850678733	1	1	0.150984227321103
CTD_CHEMICALS_DISEASES	Nasopharyngeal Neoplasms	2	18.1818181818182	0.220713732118313	56-55-3, 83-32-9	10	233	8530	7.32188841201717	1	1	0.220713732118313
CTD_CHEMICALS_DISEASES	Liver Neoplasms	4	36.3636363636364	0.223786456970162	56-55-3, 83-32-9, 206-44-0, 218-01-9	10	1581	8530	2.15812776723593	1	1	0.223786456970162
CTD_CHEMICALS_DISEASES	Thyroid Neoplasms	3	27.2727272727273	0.335880289441011	56-55-3, 83-32-9, 129-00-0	10	1122	8530	2.2807486631016	1	1	0.335880289441011
CTD_CHEMICALS_DISEASES	Urinary Bladder Neoplasms	4	36.3636363636364	0.401659256023774	56-55-3, 83-32-9, 191-24-2, 218-01-9	10	1748	8530	1.95194508009153	1	1	0.401659256023774
CTD_CHEMICALS_DISEASES	Pain	2	18.1818181818182	0.574871653699535	56-55-3, 83-32-9	10	773	8530	2.20698576972833	1	1	0.574871653699535
CTD_CHEMICALS_DISEASES	Liver Neoplasms, Experimental	3	27.2727272727273	0.656360013201798	56-55-3, 83-32-9, 218-01-9	10	1457	8530	1.75634866163349	1	1	0.656360013201798

Annotation Cluster 52	Enrichment Score: 0.735123820935066
Category	Term	Count	%	PValue	CASRNs	List Total	Pop Hits	Pop Total	Fold Enrichment	Bonferroni	Benjamini	FDR
CTD_CHEM2DISEASE	Poisoning	5	45.4545454545455	0.000156737874869242	56-55-3, 85-01-8, 129-00-0, 53-70-3, 206-44-0	8	259	5441	13.1298262548263	1	0.0659866453199507	0.000156737874869242
CTD_CHEMICALS_DISEASES	Salmonella Infections, Animal	4	36.3636363636364	0.0030024684201317	83-32-9, 129-00-0, 120-12-7, 206-44-0	10	297	8530	11.4882154882155	1	1	0.0030024684201317
CTD_CHEMICALS_DISEASES	Hepatolenticular Degeneration	5	45.4545454545455	0.00313940745083899	129-00-0, 53-70-3, 120-12-7, 206-44-0, 218-01-9	10	653	8530	6.53139356814701	1	1	0.00313940745083899
CTD_CHEMICALS_DISEASES	Prostatic Intraepithelial Neoplasia	5	45.4545454545455	0.00394778910211831	56-55-3, 129-00-0, 53-70-3, 206-44-0, 218-01-9	10	695	8530	6.13669064748201	1	1	0.00394778910211831
CTD_CHEMICALS_DISEASES	MELAS Syndrome	4	36.3636363636364	0.0124726155525753	56-55-3, 85-01-8, 129-00-0, 206-44-0	10	494	8530	6.90688259109312	1	1	0.0124726155525753
CTD_PATHWAY	KEGG:00190|Oxidative phosphorylation	3	27.2727272727273	0.0126424328215557	129-00-0, 50-32-8, 206-44-0	8	99	3849	14.5795454545455	1	1	0.0126424328215557
CTD_CHEMICALS_DISEASES	Leishmaniasis, Visceral	4	36.3636363636364	0.0303604658364313	83-32-9, 129-00-0, 120-12-7, 206-44-0	10	688	8530	4.9593023255814	1	1	0.0303604658364313
CTD_CHEMICALS_DISEASES	MIGRAINE WITH OR WITHOUT AURA, SUSCEPTIBILITY TO, 1	4	36.3636363636364	0.0429178509269492	56-55-3, 129-00-0, 206-44-0, 218-01-9	10	786	8530	4.34096692111959	1	1	0.0429178509269492
CTD_CHEMICALS_DISEASES	Keratosis	4	36.3636363636364	0.0570408678767359	85-01-8, 83-32-9, 129-00-0, 206-44-0	10	879	8530	3.88168373151308	1	1	0.0570408678767359
CTD_PATHWAY	KEGG:05012|Parkinson's disease	3	27.2727272727273	0.0675187204673791	129-00-0, 50-32-8, 206-44-0	8	243	3849	5.93981481481481	1	1	0.0675187204673791
CTD_CHEMICALS_DISEASES	Asbestosis	3	27.2727272727273	0.0677625988799753	129-00-0, 53-70-3, 206-44-0	10	415	8530	6.16626506024096	1	1	0.0677625988799753
CTD_CHEMICALS_DISEASES	Craniofacial Abnormalities	3	27.2727272727273	0.0706812626860664	85-01-8, 129-00-0, 53-70-3	10	425	8530	6.02117647058824	1	1	0.0706812626860664
TOXCAST_ACTIVE	BSK_SAg_IL8_up	2	18.1818181818182	0.0710359236819535	129-00-0, 206-44-0	7	21	1723	23.4421768707483	1	1	0.0710359236819535
TOXCAST_ACTIVE	ATG_RXRb_TRANS_up	4	36.3636363636364	0.0798472184314157	85-01-8, 83-32-9, 129-00-0, 206-44-0	7	317	1723	3.10590356016224	1	1	0.0798472184314157
CTD_CHEMICALS_DISEASES	Hemangioblastoma	2	18.1818181818182	0.084279060619438	53-70-3, 206-44-0	10	83	8530	20.5542168674699	1	1	0.084279060619438
CTD_CHEMICALS_DISEASES	Psoriasis	4	36.3636363636364	0.0991187969560934	85-01-8, 129-00-0, 206-44-0, 218-01-9	10	1101	8530	3.09900090826521	1	1	0.0991187969560934
CTD_PATHWAY	KEGG:03320|PPAR signaling pathway	3	27.2727272727273	0.125702003437735	53-70-3, 50-32-8, 206-44-0	8	347	3849	4.15958213256484	1	1	0.125702003437735
TOXCAST_ACTIVE	OT_ER_ERbERb_1440	3	27.2727272727273	0.129974102328696	56-55-3, 129-00-0, 206-44-0	7	186	1723	3.97004608294931	1	1	0.129974102328696
TOXCAST_ACTIVE	BSK_SAg_Eselectin_up	2	18.1818181818182	0.143961659194792	129-00-0, 206-44-0	7	44	1723	11.1883116883117	1	1	0.143961659194792
TOXCAST_ACTIVE	BSK_3C_Proliferation_down	4	36.3636363636364	0.144440962418179	56-55-3, 85-01-8, 129-00-0, 206-44-0	7	403	1723	2.44310528181496	1	1	0.144440962418179
HTS_ACTIVE	cytotoxicity_MMP/inhibition	4	36.3636363636364	0.162512486661459	56-55-3, 129-00-0, 50-32-8, 206-44-0	9	755	4173	2.45651214128035	1	1	0.162512486661459
CTD_CHEMICALS_DISEASES	Shock, Hemorrhagic	3	27.2727272727273	0.166441966912268	129-00-0, 206-44-0, 218-01-9	10	704	8530	3.63494318181818	1	1	0.166441966912268
TOXCAST_ACTIVE	OT_ER_ERaERb_0480	3	27.2727272727273	0.177390641717901	85-01-8, 129-00-0, 206-44-0	7	224	1723	3.29655612244898	1	1	0.177390641717901
TOXCAST_ACTIVE	APR_HepG2_OxidativeStress_72h_up	3	27.2727272727273	0.189166768409049	129-00-0, 120-12-7, 206-44-0	7	233	1723	3.16922133660331	1	1	0.189166768409049
CTD_CHEMICALS_DISEASES	Calcinosis	3	27.2727272727273	0.214654502836388	53-70-3, 206-44-0, 191-24-2	10	827	8530	3.09431680773882	1	1	0.214654502836388
CTD_CHEMICALS_DISEASES	Cleft Lip	2	18.1818181818182	0.224090102911481	53-70-3, 206-44-0	10	237	8530	7.19831223628692	1	1	0.224090102911481
CTD_CHEMICALS_DISEASES	Vitamin A Deficiency	2	18.1818181818182	0.2358052386995	53-70-3, 206-44-0	10	251	8530	6.79681274900398	1	1	0.2358052386995
CTD_CHEMICALS_DISEASES	Multiple Myeloma	3	27.2727272727273	0.242984082478121	129-00-0, 53-70-3, 206-44-0	10	897	8530	2.85284280936455	1	1	0.242984082478121
TOXCAST_ACTIVE	BSK_CASM3C_LDLR_down	2	18.1818181818182	0.275569692214317	129-00-0, 206-44-0	7	90	1723	5.46984126984127	1	1	0.275569692214317
CTD_CHEMICALS_DISEASES	Esophageal Neoplasms	3	27.2727272727273	0.299001685160361	53-70-3, 206-44-0, 218-01-9	10	1033	8530	2.47725072604066	1	1	0.299001685160361
CTD_CHEMICALS_DISEASES	Sepsis	3	27.2727272727273	0.313507567321241	129-00-0, 120-12-7, 206-44-0	10	1068	8530	2.39606741573034	1	1	0.313507567321241
CTD_CHEMICALS_DISEASES	Cholestasis	3	27.2727272727273	0.342086056329732	129-00-0, 53-70-3, 120-12-7	10	1137	8530	2.25065963060686	1	1	0.342086056329732
CTD_CHEMICALS_DISEASES	Small Cell Lung Carcinoma	2	18.1818181818182	0.363914220576094	53-70-3, 206-44-0	10	418	8530	4.08133971291866	1	1	0.363914220576094
CTD_CHEMICALS_DISEASES	Parkinson Disease	4	36.3636363636364	0.382515735612742	129-00-0, 53-70-3, 206-44-0, 218-01-9	10	1590	8530	2.14591194968554	1	1	0.382515735612742
CTD_PATHWAY	KEGG:05144|Malaria	4	36.3636363636364	0.387133481369952	129-00-0, 120-12-7, 50-32-8, 206-44-0	8	1006	3849	1.91302186878728	1	1	0.387133481369952
CTD_CHEMICALS_DISEASES	Pre-Eclampsia	2	18.1818181818182	0.408363933011906	53-70-3, 206-44-0	10	483	8530	3.53209109730849	1	1	0.408363933011906
CTD_CHEMICALS_DISEASES	Spinocerebellar Ataxia 17	2	18.1818181818182	0.429855858472103	129-00-0, 206-44-0	10	516	8530	3.3062015503876	1	1	0.429855858472103
CTD_CHEMICALS_DISEASES	Recurrence	2	18.1818181818182	0.439393365205156	129-00-0, 53-70-3	10	531	8530	3.21280602636535	1	1	0.439393365205156
TOXCAST_ACTIVE	BSK_CASM3C_HLADR_down	2	18.1818181818182	0.453875394334063	129-00-0, 206-44-0	7	165	1723	2.98354978354978	1	1	0.453875394334063
CTD_CHEMICALS_DISEASES	Carotid Artery Diseases	2	18.1818181818182	0.479695265391553	53-70-3, 206-44-0	10	597	8530	2.85762144053601	1	1	0.479695265391553
CTD_CHEMICALS_DISEASES	Sarcoma	2	18.1818181818182	0.505111577631572	129-00-0, 206-44-0	10	641	8530	2.66146645865835	1	1	0.505111577631572
TOXCAST_ACTIVE	OT_ER_ERaERb_1440	2	18.1818181818182	0.536589238584339	129-00-0, 206-44-0	7	207	1723	2.37819185645273	1	1	0.536589238584339
CTD_CHEMICALS_DISEASES	Colitis	2	18.1818181818182	0.54798907356077	129-00-0, 206-44-0	10	720	8530	2.36944444444444	1	1	0.54798907356077
TOXCAST_ACTIVE	ATG_DR5_CIS_up	2	18.1818181818182	0.570417049153801	129-00-0, 206-44-0	7	226	1723	2.17825537294564	1	1	0.570417049153801
TOXCAST_ACTIVE	BSK_KF3CT_MMP9_down	2	18.1818181818182	0.587377686987493	129-00-0, 206-44-0	7	236	1723	2.08595641646489	1	1	0.587377686987493
TOXCAST_ACTIVE	Tox21_MitochondrialToxicity_ratio	3	27.2727272727273	0.613276243968899	56-55-3, 129-00-0, 206-44-0	7	366	1723	2.0175644028103	1	1	0.613276243968899
CTD_PATHWAY	KEGG:04350|TGF-beta signaling pathway	3	27.2727272727273	0.62140532293499	53-70-3, 50-32-8, 206-44-0	8	718	3849	2.01027158774373	1	1	0.62140532293499
CTD_PATHWAY	KEGG:05143|African trypanosomiasis	3	27.2727272727273	0.665735416775702	129-00-0, 50-32-8, 206-44-0	8	890	3849	1.62176966292135	1	1	0.665735416775702
CTD_CHEMICALS_DISEASES	Acute Kidney Injury	3	27.2727272727273	0.675999919190567	129-00-0, 53-70-3, 206-44-0	10	1579	8530	1.62064597846738	1	1	0.675999919190567
HTS_ACTIVE	cytotoxicity_RXR/agonism	4	36.3636363636364	0.698422986144893	85-01-8, 129-00-0, 50-32-8, 206-44-0	9	1213	4173	1.52899148117615	1	1	0.698422986144893
TOXCAST_ACTIVE	BSK_SAg_Proliferation_down	2	18.1818181818182	1	129-00-0, 206-44-0	7	415	1723	1.18623063683305	1	1	1
PHARMACTIONLIST	Chemical Actions and Uses	3	27.2727272727273	1	129-00-0, 53-70-3, 206-44-0	3	2720	2720	1	1	1	1
CTD_CHEMICALS_DISEASES	Infertility, Female	2	18.1818181818182	1	129-00-0, 206-44-0	10	1197	8530	1.42522974101921	1	1	1
TOXCAST_ACTIVE	BSK_SAg_CD38_down	2	18.1818181818182	1	129-00-0, 206-44-0	7	292	1723	1.68590998043053	1	1	1
TOXCAST_ACTIVE	BSK_SAg_CD40_down	2	18.1818181818182	1	129-00-0, 206-44-0	7	313	1723	1.57279780921953	1	1	1
TOXCAST_ACTIVE	BSK_hDFCGF_Proliferation_down	2	18.1818181818182	1	129-00-0, 206-44-0	7	433	1723	1.13691850874299	1	1	1
CTD_CHEMICALS_DISEASES	Ischemia	2	18.1818181818182	1	53-70-3, 206-44-0	10	882	8530	1.93424036281179	1	1	1
TOXCAST_ACTIVE	BSK_4H_VCAM1_down	2	18.1818181818182	1	129-00-0, 206-44-0	7	255	1723	1.93053221288515	1	1	1
CTD_CHEMICALS_DISEASES	Kidney Neoplasms	2	18.1818181818182	1	129-00-0, 53-70-3	10	1060	8530	1.60943396226415	1	1	1

Annotation Cluster 53	Enrichment Score: 0.71307608306827
Category	Term	Count	%	PValue	CASRNs	List Total	Pop Hits	Pop Total	Fold Enrichment	Bonferroni	Benjamini	FDR
CTD_CHEMICALS_DISEASES	Neurodevelopmental Disorders	4	36.3636363636364	0.0016295343407518	50-32-8, 206-44-0, 191-24-2, 218-01-9	10	240	8530	14.2166666666667	1	0.659961408004478	0.0016295343407518
CTD_CHEMICALS_DISEASES	Uterine Cervical Neoplasms	4	36.3636363636364	0.0176261147308594	56-55-3, 85-01-8, 206-44-0, 218-01-9	10	561	8530	6.08199643493761	1	1	0.0176261147308594
CTD_CHEMICALS_DISEASES	MIGRAINE WITH OR WITHOUT AURA, SUSCEPTIBILITY TO, 1	4	36.3636363636364	0.0429178509269492	56-55-3, 129-00-0, 206-44-0, 218-01-9	10	786	8530	4.34096692111959	1	1	0.0429178509269492
CTD_CHEMICALS_DISEASES	Spinal Cord Injuries	4	36.3636363636364	0.0460657166304461	53-70-3, 206-44-0, 191-24-2, 218-01-9	10	808	8530	4.22277227722772	1	1	0.0460657166304461
CTD_CHEMICALS_DISEASES	Primary Graft Dysfunction	2	18.1818181818182	0.0939942704090523	206-44-0, 218-01-9	10	93	8530	18.3440860215054	1	1	0.0939942704090523
CTD_CHEMICALS_DISEASES	Psoriasis	4	36.3636363636364	0.0991187969560934	85-01-8, 129-00-0, 206-44-0, 218-01-9	10	1101	8530	3.09900090826521	1	1	0.0991187969560934
CTD_CHEMICALS_DISEASES	Shock, Hemorrhagic	3	27.2727272727273	0.166441966912268	129-00-0, 206-44-0, 218-01-9	10	704	8530	3.63494318181818	1	1	0.166441966912268
CTD_CHEMICALS_DISEASES	Respiratory Hypersensitivity	3	27.2727272727273	0.192014313684733	56-55-3, 206-44-0, 218-01-9	10	770	8530	3.32337662337662	1	1	0.192014313684733
CTD_CHEMICALS_DISEASES	Liver Neoplasms	4	36.3636363636364	0.223786456970162	56-55-3, 83-32-9, 206-44-0, 218-01-9	10	1581	8530	2.15812776723593	1	1	0.223786456970162
CTD_CHEMICALS_DISEASES	Esophageal Neoplasms	3	27.2727272727273	0.299001685160361	53-70-3, 206-44-0, 218-01-9	10	1033	8530	2.47725072604066	1	1	0.299001685160361
CTD_CHEMICALS_DISEASES	Parkinson Disease	4	36.3636363636364	0.382515735612742	129-00-0, 53-70-3, 206-44-0, 218-01-9	10	1590	8530	2.14591194968554	1	1	0.382515735612742
CTD_CHEMICALS_DISEASES	Brain Injuries, Traumatic	2	18.1818181818182	0.474355809600804	206-44-0, 218-01-9	10	588	8530	2.90136054421769	1	1	0.474355809600804
CTD_CHEMICALS_DISEASES	Arthritis, Juvenile	2	18.1818181818182	0.50454642145833	206-44-0, 218-01-9	10	640	8530	2.665625	1	1	0.50454642145833
CTD_CHEMICALS_DISEASES	Trigeminal Neuralgia	2	18.1818181818182	0.5267106337797	206-44-0, 218-01-9	10	680	8530	2.50882352941176	1	1	0.5267106337797
CTD_CHEMICALS_DISEASES	Liver Cirrhosis, Experimental	4	36.3636363636364	0.719828606893784	56-55-3, 120-12-7, 206-44-0, 218-01-9	10	2423	8530	1.40817168799009	1	1	0.719828606893784
CTD_CHEMICALS_DISEASES	Carcinoma, Hepatocellular	4	36.3636363636364	0.720280042241255	85-01-8, 83-32-9, 206-44-0, 218-01-9	10	2428	8530	1.40527182866557	1	1	0.720280042241255
CTD_CHEMICALS_DISEASES	Glomerulonephritis	2	18.1818181818182	1	206-44-0, 218-01-9	10	1032	8530	1.6531007751938	1	1	1
CTD_PATHWAY	KEGG:05210|Colorectal cancer	3	27.2727272727273	1	50-32-8, 206-44-0, 218-01-9	8	1345	3849	1.07314126394052	1	1	1
CTD_CHEMICALS_DISEASES	Myocardial Infarction	2	18.1818181818182	1	206-44-0, 218-01-9	10	1476	8530	1.15582655826558	1	1	1

Annotation Cluster 54	Enrichment Score: 0.671754794859414
Category	Term	Count	%	PValue	CASRNs	List Total	Pop Hits	Pop Total	Fold Enrichment	Bonferroni	Benjamini	FDR
HTS_ACTIVE	activation_EndoRS	4	36.3636363636364	0.000328932112757107	53-70-3, 120-12-7, 206-44-0, 191-24-2	9	78	4173	23.7777777777778	1	0.136835758906957	0.000328932112757107
CTD_CHEMICALS_DISEASES	Glaucoma 3, primary infantile, B	3	27.2727272727273	0.0111321969088127	83-32-9, 53-70-3, 120-12-7	10	157	8530	16.2993630573248	1	1	0.0111321969088127
CTD_CHEMICALS_DISEASES	Mouth Neoplasms	4	36.3636363636364	0.0608609592342952	83-32-9, 53-70-3, 120-12-7, 191-24-2	10	902	8530	3.78270509977827	1	1	0.0608609592342952
CTD_CHEMICALS_DISEASES	Birth Weight	3	27.2727272727273	0.0643195376919312	83-32-9, 120-12-7, 191-24-2	10	403	8530	6.34987593052109	1	1	0.0643195376919312
CTD_CHEMICALS_DISEASES	Arthritis, Rheumatoid	4	36.3636363636364	0.134912068564149	56-55-3, 83-32-9, 53-70-3, 50-32-8	10	1256	8530	2.71656050955414	1	1	0.134912068564149
CTD_CHEMICALS_DISEASES	Glaucoma 3, Primary Congenital, A	2	18.1818181818182	0.13751445260415	83-32-9, 120-12-7	10	139	8530	12.273381294964	1	1	0.13751445260415
CTD_CHEMICALS_DISEASES	Insulin Resistance	4	36.3636363636364	0.140878430714406	83-32-9, 53-70-3, 120-12-7, 206-44-0	10	1280	8530	2.665625	1	1	0.140878430714406
CTD_CHEMICALS_DISEASES	Growth Disorders	3	27.2727272727273	0.180294747163775	83-32-9, 53-70-3, 120-12-7	10	740	8530	3.45810810810811	1	1	0.180294747163775
CTD_CHEMICALS_DISEASES	Hyperventilation	2	18.1818181818182	0.201044920926842	83-32-9, 120-12-7	10	210	8530	8.12380952380953	1	1	0.201044920926842
CTD_CHEMICALS_DISEASES	Ureteral Neoplasms	2	18.1818181818182	0.212215599537122	83-32-9, 120-12-7	10	223	8530	7.65022421524664	1	1	0.212215599537122
CTD_CHEMICALS_DISEASES	Peanut Hypersensitivity	2	18.1818181818182	0.22493216116227	83-32-9, 120-12-7	10	238	8530	7.16806722689076	1	1	0.22493216116227
CTD_CHEMICALS_DISEASES	Pancreatic cancer, adult	2	18.1818181818182	0.230803859941091	83-32-9, 120-12-7	10	245	8530	6.96326530612245	1	1	0.230803859941091
CTD_CHEMICALS_DISEASES	Mouth Diseases	2	18.1818181818182	0.237465929474481	53-70-3, 191-24-2	10	253	8530	6.74308300395257	1	1	0.237465929474481
CTD_CHEMICALS_DISEASES	Nystagmus, Congenital	2	18.1818181818182	0.249819207724245	83-32-9, 120-12-7	10	268	8530	6.36567164179104	1	1	0.249819207724245
CTD_CHEMICALS_DISEASES	Weight Gain	3	27.2727272727273	0.313507567321241	83-32-9, 53-70-3, 120-12-7	10	1068	8530	2.39606741573034	1	1	0.313507567321241
CTD_CHEMICALS_DISEASES	Glucose Intolerance	2	18.1818181818182	0.356105227249033	83-32-9, 120-12-7	10	407	8530	4.19164619164619	1	1	0.356105227249033
CTD_CHEMICALS_DISEASES	Pulmonary Fibrosis	3	27.2727272727273	0.370943760703869	83-32-9, 53-70-3, 120-12-7	10	1207	8530	2.12013256006628	1	1	0.370943760703869
CTD_CHEMICALS_DISEASES	Tachycardia	2	18.1818181818182	0.481464339303244	83-32-9, 120-12-7	10	600	8530	2.84333333333333	1	1	0.481464339303244
HTS_ACTIVE	activation_p53	2	18.1818181818182	0.543204307132219	53-70-3, 191-24-2	9	389	4173	2.38389031705227	1	1	0.543204307132219
CTD_CHEMICALS_DISEASES	Splenomegaly	2	18.1818181818182	0.560852163935467	83-32-9, 120-12-7	10	745	8530	2.28993288590604	1	1	0.560852163935467
CTD_CHEMICALS_DISEASES	Pulmonary Disease, Chronic Obstructive	3	27.2727272727273	0.634859175577902	83-32-9, 53-70-3, 50-32-8	10	1303	8530	1.96392939370683	1	1	0.634859175577902
CTD_CHEMICALS_DISEASES	Adenocarcinoma	2	18.1818181818182	1	83-32-9, 53-70-3	10	1419	8530	1.20225510923185	1	1	1
CTD_CHEMICALS_DISEASES	Breast Neoplasms	3	27.2727272727273	1	85-01-8, 83-32-9, 53-70-3	10	2515	8530	1.01749502982107	1	1	1
CTD_CHEMICALS_DISEASES	Ovarian Neoplasms	2	18.1818181818182	1	83-32-9, 191-24-2	10	1135	8530	1.50308370044053	1	1	1
TOXCAST_ACTIVE	Tox21_Aromatase_Inhibition	2	18.1818181818182	1	83-32-9, 53-70-3	7	382	1723	1.28870605833957	1	1	1
CTD_CHEMICALS_DISEASES	Reperfusion Injury	3	27.2727272727273	1	83-32-9, 53-70-3, 191-24-2	10	1799	8530	1.4224569205114	1	1	1

Annotation Cluster 55	Enrichment Score: 0.661848456782115
Category	Term	Count	%	PValue	CASRNs	List Total	Pop Hits	Pop Total	Fold Enrichment	Bonferroni	Benjamini	FDR
CTD_CHEMICALS_DISEASES	Atrophy	3	27.2727272727273	0.0612216929665671	83-32-9, 120-12-7, 50-32-8	10	392	8530	6.52806122448979	1	1	0.0612216929665671
CTD_CHEMICALS_DISEASES	Arthritis, Rheumatoid	4	36.3636363636364	0.134912068564149	56-55-3, 83-32-9, 53-70-3, 50-32-8	10	1256	8530	2.71656050955414	1	1	0.134912068564149
CTD_CHEMICALS_DISEASES	Melanoma	4	36.3636363636364	0.135405138270814	83-32-9, 50-32-8, 191-24-2, 218-01-9	10	1258	8530	2.71224165341812	1	1	0.135405138270814
CTD_CHEMICALS_DISEASES	Staphylococcal Infections	2	18.1818181818182	0.161281835266818	83-32-9, 50-32-8	10	165	8530	10.3393939393939	1	1	0.161281835266818
CTD_CHEMICALS_DISEASES	Adenocarcinoma of Lung	3	27.2727272727273	0.171032253904042	83-32-9, 50-32-8, 191-24-2	10	716	8530	3.57402234636872	1	1	0.171032253904042
CTD_CHEMICALS_DISEASES	Inflammation	4	36.3636363636364	0.388050053679453	83-32-9, 120-12-7, 50-32-8, 206-44-0	10	1643	8530	2.07668898356665	1	1	0.388050053679453
CTD_CHEMICALS_DISEASES	Pulmonary Disease, Chronic Obstructive	3	27.2727272727273	0.634859175577902	83-32-9, 53-70-3, 50-32-8	10	1303	8530	1.96392939370683	1	1	0.634859175577902
CTD_CHEMICALS_DISEASES	Neoplasms	3	27.2727272727273	0.667409585981077	83-32-9, 120-12-7, 50-32-8	10	1527	8530	1.67583497053045	1	1	0.667409585981077

Annotation Cluster 56	Enrichment Score: 0.656275973499107
Category	Term	Count	%	PValue	CASRNs	List Total	Pop Hits	Pop Total	Fold Enrichment	Bonferroni	Benjamini	FDR
CTD_CHEMICALS_DISEASES	Heart Valve Diseases	3	27.2727272727273	0.15697318292029	85-01-8, 53-70-3, 191-24-2	10	679	8530	3.76877761413844	1	1	0.15697318292029
CTD_CHEMICALS_DISEASES	Cholangitis	2	18.1818181818182	0.158569489698567	85-01-8, 191-24-2	10	162	8530	10.5308641975309	1	1	0.158569489698567
CTD_CHEMICALS_DISEASES	Lymphoma, Mantle-Cell	2	18.1818181818182	0.238295071269181	85-01-8, 191-24-2	10	254	8530	6.71653543307087	1	1	0.238295071269181
CTD_CHEMICALS_DISEASES	Ophthalmoplegia, Chronic Progressive External	2	18.1818181818182	0.399701661133414	85-01-8, 191-24-2	10	470	8530	3.62978723404255	1	1	0.399701661133414

Annotation Cluster 57	Enrichment Score: 0.653556605105774
Category	Term	Count	%	PValue	CASRNs	List Total	Pop Hits	Pop Total	Fold Enrichment	Bonferroni	Benjamini	FDR
CTD_CHEM2DISEASE	Hypertrophy	3	27.2727272727273	0.00470341717948041	56-55-3, 50-32-8, 206-44-0	8	84	5441	24.2901785714286	1	1	0.00470341717948041
CTD_CHEMICALS_DISEASES	MELAS Syndrome	4	36.3636363636364	0.0124726155525753	56-55-3, 85-01-8, 129-00-0, 206-44-0	10	494	8530	6.90688259109312	1	1	0.0124726155525753
CTD_PATHWAY	KEGG:00190|Oxidative phosphorylation	3	27.2727272727273	0.0126424328215557	129-00-0, 50-32-8, 206-44-0	8	99	3849	14.5795454545455	1	1	0.0126424328215557
CTD_CHEMICALS_DISEASES	Uterine Cervical Neoplasms	4	36.3636363636364	0.0176261147308594	56-55-3, 85-01-8, 206-44-0, 218-01-9	10	561	8530	6.08199643493761	1	1	0.0176261147308594
CTD_PATHWAY	KEGG:05323|Rheumatoid arthritis	6	54.5454545454545	0.0213970724873281	56-55-3, 129-00-0, 120-12-7, 50-32-8, 206-44-0, 218-01-9	8	1080	3849	2.67291666666667	1	1	0.0213970724873281
CTD_CHEMICALS_DISEASES	COVID-19	4	36.3636363636364	0.0228528205999287	56-55-3, 83-32-9, 120-12-7, 206-44-0	10	618	8530	5.5210355987055	1	1	0.0228528205999287
HTS_ACTIVE	antagonism_AR/full/run2	6	54.5454545454545	0.0229860025478882	56-55-3, 85-01-8, 129-00-0, 120-12-7, 50-32-8, 206-44-0	9	1003	4173	2.77367896311067	1	1	0.0229860025478882
CTD_CHEMICALS_DISEASES	Status Epilepticus	5	45.4545454545455	0.0315607300258116	56-55-3, 85-01-8, 120-12-7, 206-44-0, 218-01-9	10	1253	8530	3.40383080606544	1	1	0.0315607300258116
CTD_CHEMICALS_DISEASES	Carcinoma, Ductal, Breast	3	27.2727272727273	0.0329682879109437	56-55-3, 85-01-8, 206-44-0	10	279	8530	9.17204301075269	1	1	0.0329682879109437
CTD_CHEMICALS_DISEASES	MIGRAINE WITH OR WITHOUT AURA, SUSCEPTIBILITY TO, 1	4	36.3636363636364	0.0429178509269492	56-55-3, 129-00-0, 206-44-0, 218-01-9	10	786	8530	4.34096692111959	1	1	0.0429178509269492
CTD_PATHWAY	KEGG:05012|Parkinson's disease	3	27.2727272727273	0.0675187204673791	129-00-0, 50-32-8, 206-44-0	8	243	3849	5.93981481481481	1	1	0.0675187204673791
CTD_CHEM2DISEASE	Edema	3	27.2727272727273	0.0850043809378351	56-55-3, 129-00-0, 50-32-8	8	391	5441	5.21835038363171	1	1	0.0850043809378351
HTS_ACTIVE	inhibition_MMP	5	45.4545454545455	0.0898736098692622	56-55-3, 129-00-0, 120-12-7, 50-32-8, 206-44-0	9	967	4173	2.39744915546363	1	1	0.0898736098692622
TOXCAST_ACTIVE	OT_ER_ERbERb_1440	3	27.2727272727273	0.129974102328696	56-55-3, 129-00-0, 206-44-0	7	186	1723	3.97004608294931	1	1	0.129974102328696
CTD_CHEMICALS_DISEASES	Arthritis, Psoriatic	3	27.2727272727273	0.136276999402798	83-32-9, 120-12-7, 206-44-0	10	623	8530	4.10754414125201	1	1	0.136276999402798
TOXCAST_ACTIVE	BSK_3C_Proliferation_down	4	36.3636363636364	0.144440962418179	56-55-3, 85-01-8, 129-00-0, 206-44-0	7	403	1723	2.44310528181496	1	1	0.144440962418179
CTD_CHEMICALS_DISEASES	Cardiotoxicity	3	27.2727272727273	0.148753429443634	83-32-9, 120-12-7, 206-44-0	10	657	8530	3.89497716894977	1	1	0.148753429443634
CTD_CHEMICALS_DISEASES	Leishmaniasis, Cutaneous	3	27.2727272727273	0.150984227321103	56-55-3, 83-32-9, 120-12-7	10	663	8530	3.85972850678733	1	1	0.150984227321103
TOXCAST_ACTIVE	BSK_3C_TissueFactor_down	3	27.2727272727273	0.154424933343467	85-01-8, 120-12-7, 206-44-0	7	206	1723	3.58460471567268	1	1	0.154424933343467
CTD_CHEMICALS_DISEASES	Papilloma	3	27.2727272727273	0.15697318292029	56-55-3, 120-12-7, 206-44-0	10	679	8530	3.76877761413844	1	1	0.15697318292029
HTS_ACTIVE	cytotoxicity_MMP/inhibition	4	36.3636363636364	0.162512486661459	56-55-3, 129-00-0, 50-32-8, 206-44-0	9	755	4173	2.45651214128035	1	1	0.162512486661459
TOXCAST_ACTIVE	APR_HepG2_OxidativeStress_72h_up	3	27.2727272727273	0.189166768409049	129-00-0, 120-12-7, 206-44-0	7	233	1723	3.16922133660331	1	1	0.189166768409049
CTD_CHEMICALS_DISEASES	Respiratory Hypersensitivity	3	27.2727272727273	0.192014313684733	56-55-3, 206-44-0, 218-01-9	10	770	8530	3.32337662337662	1	1	0.192014313684733
TOXCAST_ACTIVE	APR_HepG2_CellCycleArrest_72h_dn	3	27.2727272727273	0.194456910104031	56-55-3, 120-12-7, 206-44-0	7	237	1723	3.11573236889693	1	1	0.194456910104031
CTD_PATHWAY	KEGG:05146|Amoebiasis	5	45.4545454545455	0.210981893745681	56-55-3, 129-00-0, 120-12-7, 50-32-8, 206-44-0	8	1177	3849	2.04386151231946	1	1	0.210981893745681
CTD_CHEMICALS_DISEASES	Hypertension, Pulmonary	3	27.2727272727273	0.216259316457712	56-55-3, 120-12-7, 206-44-0	10	831	8530	3.07942238267148	1	1	0.216259316457712
CTD_CHEMICALS_DISEASES	Liver Neoplasms	4	36.3636363636364	0.223786456970162	56-55-3, 83-32-9, 206-44-0, 218-01-9	10	1581	8530	2.15812776723593	1	1	0.223786456970162
CTD_CHEMICALS_DISEASES	Tobacco Use Disorder	3	27.2727272727273	0.228353107168394	85-01-8, 120-12-7, 206-44-0	10	861	8530	2.97212543554007	1	1	0.228353107168394
CTD_CHEMICALS_DISEASES	Breast Neoplasms, Male	2	18.1818181818182	0.242428771439614	120-12-7, 206-44-0	10	259	8530	6.58687258687259	1	1	0.242428771439614
TOXCAST_ACTIVE	Tox21_ERa_LUC_BG1_Agonist	3	27.2727272727273	0.25588015414235	56-55-3, 120-12-7, 206-44-0	7	282	1723	2.61854103343465	1	1	0.25588015414235
CTD_CHEMICALS_DISEASES	Brain Injuries	3	27.2727272727273	0.261006183998182	56-55-3, 129-00-0, 120-12-7	10	941	8530	2.71944739638682	1	1	0.261006183998182
TOXCAST_ACTIVE	APR_HepG2_CellLoss_24h_dn	3	27.2727272727273	0.261472967484519	56-55-3, 120-12-7, 206-44-0	7	286	1723	2.58191808191808	1	1	0.261472967484519
TOXCAST_ACTIVE	Tox21_ESRE_BLA_ratio	2	18.1818181818182	0.304403341271129	120-12-7, 206-44-0	7	101	1723	4.87411598302687	1	1	0.304403341271129
CTD_CHEMICALS_DISEASES	Sepsis	3	27.2727272727273	0.313507567321241	129-00-0, 120-12-7, 206-44-0	10	1068	8530	2.39606741573034	1	1	0.313507567321241
CTD_CHEMICALS_DISEASES	Burns	2	18.1818181818182	0.324755053252284	56-55-3, 120-12-7	10	364	8530	4.68681318681319	1	1	0.324755053252284
TOXCAST_ACTIVE	NVS_ADME_hCYP1A2	2	18.1818181818182	0.380566012218892	56-55-3, 206-44-0	7	132	1723	3.72943722943723	1	1	0.380566012218892
CTD_PATHWAY	KEGG:05144|Malaria	4	36.3636363636364	0.387133481369952	129-00-0, 120-12-7, 50-32-8, 206-44-0	8	1006	3849	1.91302186878728	1	1	0.387133481369952
TOXCAST_ACTIVE	NVS_TR_hNET	2	18.1818181818182	0.428104113967335	56-55-3, 120-12-7	7	153	1723	3.21755368814192	1	1	0.428104113967335
TOXCAST_ACTIVE	APR_HepG2_CellCycleArrest_24h_dn	2	18.1818181818182	0.451765447370769	56-55-3, 120-12-7	7	164	1723	3.00174216027875	1	1	0.451765447370769
TOXCAST_ACTIVE	APR_HepG2_MitoticArrest_24h_up	2	18.1818181818182	0.519807480287105	56-55-3, 206-44-0	7	198	1723	2.48629148629149	1	1	0.519807480287105
TOXCAST_ACTIVE	APR_HepG2_OxidativeStress_24h_up	2	18.1818181818182	0.568689503775063	56-55-3, 120-12-7	7	225	1723	2.18793650793651	1	1	0.568689503775063
TOXCAST_ACTIVE	Tox21_MitochondrialToxicity_ratio	3	27.2727272727273	0.613276243968899	56-55-3, 129-00-0, 206-44-0	7	366	1723	2.0175644028103	1	1	0.613276243968899
TOXCAST_ACTIVE	APR_HepG2_CellLoss_72h_dn	3	27.2727272727273	0.643283797131192	56-55-3, 120-12-7, 206-44-0	7	430	1723	1.71727574750831	1	1	0.643283797131192
CTD_PATHWAY	KEGG:05143|African trypanosomiasis	3	27.2727272727273	0.665735416775702	129-00-0, 50-32-8, 206-44-0	8	890	3849	1.62176966292135	1	1	0.665735416775702
CTD_PATHWAY	KEGG:05214|Glioma	3	27.2727272727273	0.674665603494797	56-55-3, 50-32-8, 206-44-0	8	919	3849	1.5705930359086	1	1	0.674665603494797
CTD_PATHWAY	KEGG:05215|Prostate cancer	4	36.3636363636364	0.69359369890391	56-55-3, 53-70-3, 50-32-8, 206-44-0	8	1292	3849	1.48955108359133	1	1	0.69359369890391
CTD_PATHWAY	KEGG:04620|Toll-like receptor signaling pathway	4	36.3636363636364	0.699174155964701	56-55-3, 120-12-7, 50-32-8, 206-44-0	8	1333	3849	1.4437359339835	1	1	0.699174155964701
CTD_PATHWAY	KEGG:05152|Tuberculosis	3	27.2727272727273	0.709344124047658	56-55-3, 50-32-8, 206-44-0	8	1541	3849	0.936648280337443	1	1	0.709344124047658
CTD_CHEMICALS_DISEASES	Liver Cirrhosis, Experimental	4	36.3636363636364	0.719828606893784	56-55-3, 120-12-7, 206-44-0, 218-01-9	10	2423	8530	1.40817168799009	1	1	0.719828606893784
CTD_PATHWAY	KEGG:05142|Chagas disease (American trypanosomiasis)	4	36.3636363636364	1	56-55-3, 120-12-7, 50-32-8, 206-44-0	8	1545	3849	1.24563106796117	1	1	1
CTD_CHEMICALS_DISEASES	Fibrosis	2	18.1818181818182	1	56-55-3, 120-12-7	10	1046	8530	1.63097514340344	1	1	1
TOXCAST_ACTIVE	ATG_ERa_TRANS_up	2	18.1818181818182	1	56-55-3, 120-12-7	7	470	1723	1.04741641337386	1	1	1
CTD_PATHWAY	KEGG:05140|Leishmaniasis	3	27.2727272727273	1	56-55-3, 120-12-7, 50-32-8	8	1374	3849	1.05049126637555	1	1	1
CTD_PATHWAY	KEGG:05020|Prion diseases	3	27.2727272727273	1	56-55-3, 50-32-8, 206-44-0	8	994	3849	1.45208752515091	1	1	1
CTD_PATHWAY	KEGG:05219|Bladder cancer	3	27.2727272727273	1	56-55-3, 50-32-8, 206-44-0	8	1098	3849	1.31454918032787	1	1	1
CTD_CHEMICALS_DISEASES	Prostatic Neoplasms	4	36.3636363636364	1	56-55-3, 85-01-8, 53-70-3, 206-44-0	10	2979	8530	1.14535078885532	1	1	1
CTD_CHEMICALS_DISEASES	Stroke	2	18.1818181818182	1	120-12-7, 206-44-0	10	1044	8530	1.63409961685824	1	1	1
CTD_CHEMICALS_DISEASES	Skin Diseases	2	18.1818181818182	1	120-12-7, 206-44-0	10	934	8530	1.82655246252677	1	1	1
TOXCAST_ACTIVE	APR_HepG2_MitoticArrest_72h_up	2	18.1818181818182	1	56-55-3, 206-44-0	7	265	1723	1.85768194070081	1	1	1
CTD_PATHWAY	KEGG:04621|NOD-like receptor signaling pathway	3	27.2727272727273	1	56-55-3, 120-12-7, 50-32-8	8	1293	3849	1.11629930394432	1	1	1

Annotation Cluster 58	Enrichment Score: 0.608559848777755
Category	Term	Count	%	PValue	CASRNs	List Total	Pop Hits	Pop Total	Fold Enrichment	Bonferroni	Benjamini	FDR
CTD_CHEMICALS_DISEASES	Mouth Neoplasms	4	36.3636363636364	0.0608609592342952	83-32-9, 53-70-3, 120-12-7, 191-24-2	10	902	8530	3.78270509977827	1	1	0.0608609592342952
CTD_CHEMICALS_DISEASES	Birth Weight	3	27.2727272727273	0.0643195376919312	83-32-9, 120-12-7, 191-24-2	10	403	8530	6.34987593052109	1	1	0.0643195376919312
CTD_CHEMICALS_DISEASES	Melanoma	4	36.3636363636364	0.135405138270814	83-32-9, 50-32-8, 191-24-2, 218-01-9	10	1258	8530	2.71224165341812	1	1	0.135405138270814
CTD_CHEMICALS_DISEASES	Adenocarcinoma of Lung	3	27.2727272727273	0.171032253904042	83-32-9, 50-32-8, 191-24-2	10	716	8530	3.57402234636872	1	1	0.171032253904042
CTD_CHEMICALS_DISEASES	Dermatitis, Contact	3	27.2727272727273	0.371765050144617	83-32-9, 191-24-2, 218-01-9	10	1209	8530	2.1166253101737	1	1	0.371765050144617
CTD_CHEMICALS_DISEASES	Urinary Bladder Neoplasms	4	36.3636363636364	0.401659256023774	56-55-3, 83-32-9, 191-24-2, 218-01-9	10	1748	8530	1.95194508009153	1	1	0.401659256023774
CTD_CHEMICALS_DISEASES	Ovarian Neoplasms	2	18.1818181818182	1	83-32-9, 191-24-2	10	1135	8530	1.50308370044053	1	1	1
CTD_CHEMICALS_DISEASES	Reperfusion Injury	3	27.2727272727273	1	83-32-9, 53-70-3, 191-24-2	10	1799	8530	1.4224569205114	1	1	1

Annotation Cluster 59	Enrichment Score: 0.532789581490645
Category	Term	Count	%	PValue	CASRNs	List Total	Pop Hits	Pop Total	Fold Enrichment	Bonferroni	Benjamini	FDR
CTD_CHEMICALS_DISEASES	COVID-19	4	36.3636363636364	0.0228528205999287	56-55-3, 83-32-9, 120-12-7, 206-44-0	10	618	8530	5.5210355987055	1	1	0.0228528205999287
CTD_CHEMICALS_DISEASES	Inflammatory Bowel Diseases	4	36.3636363636364	0.0365965470545591	56-55-3, 129-00-0, 120-12-7, 218-01-9	10	739	8530	4.617050067659	1	1	0.0365965470545591
CTD_CHEMICALS_DISEASES	Hypersensitivity	4	36.3636363636364	0.0560654991308512	56-55-3, 129-00-0, 53-70-3, 120-12-7	10	873	8530	3.90836197021764	1	1	0.0560654991308512
CTD_CHEMICALS_DISEASES	Polycystic Ovary Syndrome	4	36.3636363636364	0.0590179253583112	56-55-3, 120-12-7, 191-24-2, 218-01-9	10	891	8530	3.8294051627385	1	1	0.0590179253583112
CTD_CHEMICALS_DISEASES	Leishmaniasis, Cutaneous	3	27.2727272727273	0.150984227321103	56-55-3, 83-32-9, 120-12-7	10	663	8530	3.85972850678733	1	1	0.150984227321103
CTD_CHEMICALS_DISEASES	Papilloma	3	27.2727272727273	0.15697318292029	56-55-3, 120-12-7, 206-44-0	10	679	8530	3.76877761413844	1	1	0.15697318292029
TOXCAST_ACTIVE	APR_HepG2_CellCycleArrest_72h_dn	3	27.2727272727273	0.194456910104031	56-55-3, 120-12-7, 206-44-0	7	237	1723	3.11573236889693	1	1	0.194456910104031
CTD_CHEMICALS_DISEASES	Hypertension, Pulmonary	3	27.2727272727273	0.216259316457712	56-55-3, 120-12-7, 206-44-0	10	831	8530	3.07942238267148	1	1	0.216259316457712
TOXCAST_ACTIVE	Tox21_ERa_LUC_BG1_Agonist	3	27.2727272727273	0.25588015414235	56-55-3, 120-12-7, 206-44-0	7	282	1723	2.61854103343465	1	1	0.25588015414235
CTD_CHEMICALS_DISEASES	Brain Injuries	3	27.2727272727273	0.261006183998182	56-55-3, 129-00-0, 120-12-7	10	941	8530	2.71944739638682	1	1	0.261006183998182
TOXCAST_ACTIVE	APR_HepG2_CellLoss_24h_dn	3	27.2727272727273	0.261472967484519	56-55-3, 120-12-7, 206-44-0	7	286	1723	2.58191808191808	1	1	0.261472967484519
CTD_CHEMICALS_DISEASES	Burns	2	18.1818181818182	0.324755053252284	56-55-3, 120-12-7	10	364	8530	4.68681318681319	1	1	0.324755053252284
TOXCAST_ACTIVE	NVS_TR_hNET	2	18.1818181818182	0.428104113967335	56-55-3, 120-12-7	7	153	1723	3.21755368814192	1	1	0.428104113967335
TOXCAST_ACTIVE	APR_HepG2_CellCycleArrest_24h_dn	2	18.1818181818182	0.451765447370769	56-55-3, 120-12-7	7	164	1723	3.00174216027875	1	1	0.451765447370769
TOXCAST_ACTIVE	APR_HepG2_OxidativeStress_24h_up	2	18.1818181818182	0.568689503775063	56-55-3, 120-12-7	7	225	1723	2.18793650793651	1	1	0.568689503775063
TOXCAST_ACTIVE	APR_HepG2_CellLoss_72h_dn	3	27.2727272727273	0.643283797131192	56-55-3, 120-12-7, 206-44-0	7	430	1723	1.71727574750831	1	1	0.643283797131192
CTD_PATHWAY	KEGG:04620|Toll-like receptor signaling pathway	4	36.3636363636364	0.699174155964701	56-55-3, 120-12-7, 50-32-8, 206-44-0	8	1333	3849	1.4437359339835	1	1	0.699174155964701
CTD_CHEMICALS_DISEASES	Liver Cirrhosis, Experimental	4	36.3636363636364	0.719828606893784	56-55-3, 120-12-7, 206-44-0, 218-01-9	10	2423	8530	1.40817168799009	1	1	0.719828606893784
CTD_PATHWAY	KEGG:05142|Chagas disease (American trypanosomiasis)	4	36.3636363636364	1	56-55-3, 120-12-7, 50-32-8, 206-44-0	8	1545	3849	1.24563106796117	1	1	1
CTD_CHEMICALS_DISEASES	Fibrosis	2	18.1818181818182	1	56-55-3, 120-12-7	10	1046	8530	1.63097514340344	1	1	1
TOXCAST_ACTIVE	ATG_ERa_TRANS_up	2	18.1818181818182	1	56-55-3, 120-12-7	7	470	1723	1.04741641337386	1	1	1
CTD_PATHWAY	KEGG:05140|Leishmaniasis	3	27.2727272727273	1	56-55-3, 120-12-7, 50-32-8	8	1374	3849	1.05049126637555	1	1	1
CTD_PATHWAY	KEGG:04621|NOD-like receptor signaling pathway	3	27.2727272727273	1	56-55-3, 120-12-7, 50-32-8	8	1293	3849	1.11629930394432	1	1	1

Annotation Cluster 60	Enrichment Score: 0.523693829527764
Category	Term	Count	%	PValue	CASRNs	List Total	Pop Hits	Pop Total	Fold Enrichment	Bonferroni	Benjamini	FDR
CTD_CHEMICALS_DISEASES	Neurodevelopmental Disorders	4	36.3636363636364	0.0016295343407518	50-32-8, 206-44-0, 191-24-2, 218-01-9	10	240	8530	14.2166666666667	1	0.659961408004478	0.0016295343407518
CTD_CHEM2DISEASE	Hypertrophy	3	27.2727272727273	0.00470341717948041	56-55-3, 50-32-8, 206-44-0	8	84	5441	24.2901785714286	1	1	0.00470341717948041
CTD_PATHWAY	KEGG:00190|Oxidative phosphorylation	3	27.2727272727273	0.0126424328215557	129-00-0, 50-32-8, 206-44-0	8	99	3849	14.5795454545455	1	1	0.0126424328215557
CTD_CHEMICALS_DISEASES	Meier-Gorlin syndrome	2	18.1818181818182	0.0434713512095554	50-32-8, 206-44-0	10	42	8530	40.6190476190476	1	1	0.0434713512095554
CTD_PATHWAY	KEGG:05012|Parkinson's disease	3	27.2727272727273	0.0675187204673791	129-00-0, 50-32-8, 206-44-0	8	243	3849	5.93981481481481	1	1	0.0675187204673791
CTD_PATHWAY	KEGG:00051|Fructose and mannose metabolism	2	18.1818181818182	0.115753663048287	50-32-8, 206-44-0	8	67	3849	14.3619402985075	1	1	0.115753663048287
CTD_PATHWAY	KEGG:03320|PPAR signaling pathway	3	27.2727272727273	0.125702003437735	53-70-3, 50-32-8, 206-44-0	8	347	3849	4.15958213256484	1	1	0.125702003437735
HTS_ACTIVE	cytotoxicity_MMP/inhibition	4	36.3636363636364	0.162512486661459	56-55-3, 129-00-0, 50-32-8, 206-44-0	9	755	4173	2.45651214128035	1	1	0.162512486661459
CTD_CHEMICALS_DISEASES	Respiratory Distress Syndrome, Adult	3	27.2727272727273	0.164918237164603	85-01-8, 50-32-8, 206-44-0	10	700	8530	3.65571428571429	1	1	0.164918237164603
CTD_PATHWAY	KEGG:05144|Malaria	4	36.3636363636364	0.387133481369952	129-00-0, 120-12-7, 50-32-8, 206-44-0	8	1006	3849	1.91302186878728	1	1	0.387133481369952
CTD_CHEMICALS_DISEASES	Inflammation	4	36.3636363636364	0.388050053679453	83-32-9, 120-12-7, 50-32-8, 206-44-0	10	1643	8530	2.07668898356665	1	1	0.388050053679453
CTD_CHEMICALS_DISEASES	Cardiovascular Diseases	2	18.1818181818182	0.491388476092041	50-32-8, 206-44-0	10	617	8530	2.76499189627229	1	1	0.491388476092041
CTD_PATHWAY	KEGG:00480|Glutathione metabolism	2	18.1818181818182	0.564819039386756	50-32-8, 206-44-0	8	431	3849	2.23259860788863	1	1	0.564819039386756
CTD_PATHWAY	KEGG:05410|Hypertrophic cardiomyopathy (HCM)	2	18.1818181818182	0.589189724243756	50-32-8, 206-44-0	8	459	3849	2.09640522875817	1	1	0.589189724243756
CTD_PATHWAY	KEGG:04350|TGF-beta signaling pathway	3	27.2727272727273	0.62140532293499	53-70-3, 50-32-8, 206-44-0	8	718	3849	2.01027158774373	1	1	0.62140532293499
CTD_PATHWAY	KEGG:05143|African trypanosomiasis	3	27.2727272727273	0.665735416775702	129-00-0, 50-32-8, 206-44-0	8	890	3849	1.62176966292135	1	1	0.665735416775702
CTD_PATHWAY	KEGG:05214|Glioma	3	27.2727272727273	0.674665603494797	56-55-3, 50-32-8, 206-44-0	8	919	3849	1.5705930359086	1	1	0.674665603494797
CTD_PATHWAY	KEGG:04660|T cell receptor signaling pathway	2	18.1818181818182	0.681327689964851	50-32-8, 206-44-0	8	1131	3849	0.85079575596817	1	1	0.681327689964851
CTD_PATHWAY	KEGG:05220|Chronic myeloid leukemia	2	18.1818181818182	0.681336096842893	50-32-8, 206-44-0	8	1068	3849	0.900983146067416	1	1	0.681336096842893
CTD_PATHWAY	KEGG:04115|p53 signaling pathway	2	18.1818181818182	0.687127488943986	50-32-8, 206-44-0	8	973	3849	0.988951695786228	1	1	0.687127488943986
CTD_PATHWAY	KEGG:05215|Prostate cancer	4	36.3636363636364	0.69359369890391	56-55-3, 53-70-3, 50-32-8, 206-44-0	8	1292	3849	1.48955108359133	1	1	0.69359369890391
HTS_ACTIVE	cytotoxicity_RXR/agonism	4	36.3636363636364	0.698422986144893	85-01-8, 129-00-0, 50-32-8, 206-44-0	9	1213	4173	1.52899148117615	1	1	0.698422986144893
CTD_PATHWAY	KEGG:04620|Toll-like receptor signaling pathway	4	36.3636363636364	0.699174155964701	56-55-3, 120-12-7, 50-32-8, 206-44-0	8	1333	3849	1.4437359339835	1	1	0.699174155964701
CTD_PATHWAY	KEGG:05152|Tuberculosis	3	27.2727272727273	0.709344124047658	56-55-3, 50-32-8, 206-44-0	8	1541	3849	0.936648280337443	1	1	0.709344124047658
CTD_PATHWAY	KEGG:04110|Cell cycle	2	18.1818181818182	1	50-32-8, 206-44-0	8	619	3849	1.55452342487884	1	1	1
CTD_CHEMICALS_DISEASES	Liver Cirrhosis, Alcoholic	2	18.1818181818182	1	50-32-8, 206-44-0	10	966	8530	1.76604554865424	1	1	1
CTD_PATHWAY	KEGG:05218|Melanoma	2	18.1818181818182	1	50-32-8, 206-44-0	8	915	3849	1.0516393442623	1	1	1
CTD_PATHWAY	KEGG:05219|Bladder cancer	3	27.2727272727273	1	56-55-3, 50-32-8, 206-44-0	8	1098	3849	1.31454918032787	1	1	1
CTD_PATHWAY	KEGG:05210|Colorectal cancer	3	27.2727272727273	1	50-32-8, 206-44-0, 218-01-9	8	1345	3849	1.07314126394052	1	1	1
CTD_PATHWAY	KEGG:05020|Prion diseases	3	27.2727272727273	1	56-55-3, 50-32-8, 206-44-0	8	994	3849	1.45208752515091	1	1	1
CTD_PATHWAY	KEGG:05142|Chagas disease (American trypanosomiasis)	4	36.3636363636364	1	56-55-3, 120-12-7, 50-32-8, 206-44-0	8	1545	3849	1.24563106796117	1	1	1

Annotation Cluster 61	Enrichment Score: 0.3683488549014
Category	Term	Count	%	PValue	CASRNs	List Total	Pop Hits	Pop Total	Fold Enrichment	Bonferroni	Benjamini	FDR
CTD_CHEM2DISEASE	Kidney Diseases	4	36.3636363636364	0.0236141489826933	85-01-8, 120-12-7, 50-32-8, 218-01-9	8	528	5441	5.15246212121212	1	1	0.0236141489826933
CTD_CHEMICALS_DISEASES	Atrophy	3	27.2727272727273	0.0612216929665671	83-32-9, 120-12-7, 50-32-8	10	392	8530	6.52806122448979	1	1	0.0612216929665671
CTD_CHEM2DISEASE	Breast Neoplasms	2	18.1818181818182	0.301757357955877	120-12-7, 50-32-8	8	272	5441	5.00091911764706	1	1	0.301757357955877
CTD_PATHWAY	KEGG:05144|Malaria	4	36.3636363636364	0.387133481369952	129-00-0, 120-12-7, 50-32-8, 206-44-0	8	1006	3849	1.91302186878728	1	1	0.387133481369952
CTD_CHEMICALS_DISEASES	Inflammation	4	36.3636363636364	0.388050053679453	83-32-9, 120-12-7, 50-32-8, 206-44-0	10	1643	8530	2.07668898356665	1	1	0.388050053679453
CTD_CHEMICALS_DISEASES	Behcet Syndrome	2	18.1818181818182	0.532112052535401	120-12-7, 50-32-8	10	690	8530	2.47246376811594	1	1	0.532112052535401
CTD_CHEMICALS_DISEASES	Neoplasms	3	27.2727272727273	0.667409585981077	83-32-9, 120-12-7, 50-32-8	10	1527	8530	1.67583497053045	1	1	0.667409585981077
CTD_PATHWAY	KEGG:04620|Toll-like receptor signaling pathway	4	36.3636363636364	0.699174155964701	56-55-3, 120-12-7, 50-32-8, 206-44-0	8	1333	3849	1.4437359339835	1	1	0.699174155964701
CTD_PATHWAY	KEGG:04622|RIG-I-like receptor signaling pathway	2	18.1818181818182	1	120-12-7, 50-32-8	8	658	3849	1.46238601823708	1	1	1
CTD_PATHWAY	KEGG:04621|NOD-like receptor signaling pathway	3	27.2727272727273	1	56-55-3, 120-12-7, 50-32-8	8	1293	3849	1.11629930394432	1	1	1
CTD_PATHWAY	KEGG:05140|Leishmaniasis	3	27.2727272727273	1	56-55-3, 120-12-7, 50-32-8	8	1374	3849	1.05049126637555	1	1	1
CTD_CHEMICALS_DISEASES	Nervous System Diseases	2	18.1818181818182	1	120-12-7, 50-32-8	10	1505	8530	1.13355481727575	1	1	1
CTD_PATHWAY	KEGG:05142|Chagas disease (American trypanosomiasis)	4	36.3636363636364	1	56-55-3, 120-12-7, 50-32-8, 206-44-0	8	1545	3849	1.24563106796117	1	1	1

Annotation Cluster 62	Enrichment Score: 0.314849000515962
Category	Term	Count	%	PValue	CASRNs	List Total	Pop Hits	Pop Total	Fold Enrichment	Bonferroni	Benjamini	FDR
CTD_CHEMICALS_DISEASES	Melanoma	4	36.3636363636364	0.135405138270814	83-32-9, 50-32-8, 191-24-2, 218-01-9	10	1258	8530	2.71224165341812	1	1	0.135405138270814
CTD_CHEMICALS_DISEASES	Heart Failure	4	36.3636363636364	0.188817685894531	83-32-9, 129-00-0, 120-12-7, 218-01-9	10	1460	8530	2.33698630136986	1	1	0.188817685894531
CTD_CHEMICALS_DISEASES	Liver Neoplasms	4	36.3636363636364	0.223786456970162	56-55-3, 83-32-9, 206-44-0, 218-01-9	10	1581	8530	2.15812776723593	1	1	0.223786456970162
CTD_CHEMICALS_DISEASES	Dermatitis, Contact	3	27.2727272727273	0.371765050144617	83-32-9, 191-24-2, 218-01-9	10	1209	8530	2.1166253101737	1	1	0.371765050144617
CTD_CHEMICALS_DISEASES	Urinary Bladder Neoplasms	4	36.3636363636364	0.401659256023774	56-55-3, 83-32-9, 191-24-2, 218-01-9	10	1748	8530	1.95194508009153	1	1	0.401659256023774
CTD_CHEMICALS_DISEASES	Cardiomegaly	3	27.2727272727273	0.630082022029842	83-32-9, 129-00-0, 218-01-9	10	1263	8530	2.02612826603325	1	1	0.630082022029842
CTD_CHEMICALS_DISEASES	Fatty Liver	3	27.2727272727273	0.654837368186469	83-32-9, 129-00-0, 218-01-9	10	1447	8530	1.76848652384243	1	1	0.654837368186469
CTD_CHEMICALS_DISEASES	Liver Neoplasms, Experimental	3	27.2727272727273	0.656360013201798	56-55-3, 83-32-9, 218-01-9	10	1457	8530	1.75634866163349	1	1	0.656360013201798
CTD_CHEMICALS_DISEASES	Carcinoma, Hepatocellular	4	36.3636363636364	0.720280042241255	85-01-8, 83-32-9, 206-44-0, 218-01-9	10	2428	8530	1.40527182866557	1	1	0.720280042241255
CTD_CHEMICALS_DISEASES	Atherosclerosis	2	18.1818181818182	1	83-32-9, 218-01-9	10	1260	8530	1.35396825396825	1	1	1
CTD_CHEMICALS_DISEASES	Pancreatic Neoplasms	2	18.1818181818182	1	83-32-9, 218-01-9	10	1256	8530	1.35828025477707	1	1	1
CTD_CHEMICALS_DISEASES	Precursor Cell Lymphoblastic Leukemia-Lymphoma	2	18.1818181818182	1	83-32-9, 218-01-9	10	1128	8530	1.51241134751773	1	1	1

